HEXO (HEXO) 40-F/A 2 Jan 20 2019 FY Annual report (Canada) (amended) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jul. 31, 2019shares
Document And Entity Information [Abstract]
Entity Registrant Name	HEXO Corp.
Entity Central Index Key	0001690947
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--07-31
Entity Common Stock, Shares Outstanding	256,981,753
Document Type	40-F/A
Document Period End Date	Jul. 31, 2019
Amendment Flag	true
Amendment Description	This Amendment No. 4 (this “Amendment”) to the Annual Report on Form 40-F of HEXO Corp. (the “Company”) for the year ended July 31, 2019 (the “Form 40-F”) is being filed solely to include the interactive data filing exhibits, which were omitted from Amendment No. 3 to the Form 40-F pursuant to the temporary hardship exemption provided by Rule 201(c) of Regulation S-T.
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Amended and Restated Consolidat

Amended and Restated Consolidated Statements of Financial Position - CAD ($) $ in Thousands		Jul. 31, 2019		Jul. 31, 2018
Current assets
Cash and cash equivalents		$ 113,568	[1]	$ 99,042
Restricted cash	[1]	22,350
Short-term investments		25,937	[1]	145,747
Trade receivables		19,693	[1]	644
Commodity taxes recoverable and other receivables		15,247	[1]	4,237
Convertible debenture receivable		13,354	[1]	10,000
Prepaid expenses		10,762	[1]	4,204
Inventory		83,854	[1]	10,415
Biological assets		7,371	[1]	2,332
Total current assets		312,136	[1]	276,621
Property, plant and equipment		258,793	[1]	54,333
Intangible assets and other longer term assets		127,282	[1]	4,044
Investment in associate and joint ventures	[1]	52,849
License and prepaid royalty - HIP	[1]	1,409
Long term investments	[1]	14,277
Goodwill	[1]	111,877
Total assets		878,623	[1]	334,998
Current liabilities
Accounts payable and accrued liabilities		45,581	[1]	8,995
Excise taxes payable	[1]	3,494
Warrant liability		493	[1]	3,130
Term loan - current	[1]	3,117
Total current liabilities		52,685	[1]	12,125
Term loan	[1]	30,257
Deferred rent liability	[1]	946
Deferred tax liability	[1]	6,023
Total liabilities		89,911	[1]	12,125
Shareholders' equity
Share capital		799,706	[1]	347,233
Share-based payment reserve		40,315	[1]	6,139
Warrants		60,433	[1]	12,635
Deficit		(112,742)	[1]	(43,134)
Non-controlling interest	[1]	1,000
Total Shareholders' equity		788,712	[1]	322,873
Total equity and liabilities		$ 878,623	[1]	$ 334,998
[1]	Restated

Amended and Restated Consolid_2

Amended and Restated Consolidated Statements of Loss and Comprehensive Loss - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019		Jul. 31, 2018
Profit (loss) [abstract]
Gross revenue from sale of goods		$ 59,256	[1]	$ 4,934
Excise taxes	[1]	(11,914)
Net revenue from sale of goods		47,342	[1]	4,934
Ancillary revenue		199	[1]
Net revenue		47,541	[1]	4,934
Cost of goods sold		26,197	[1]	2,093
Gross margin before fair value adjustments		21,344	[1]	2,841
Fair value loss adjustment on sale of inventory		16,357	[1]	2,289
Fair value gain adjustment on biological assets		(38,856)	[1]	(7,340)
Adjustment to net realizable value of inventory				1,491
Impairment loss on inventory	[1]	19,335
Gross margin		24,508	[1]	6,400
Operating Expenses
General and administrative		45,947	[1]	9,374
Marketing and promotion		31,191	[1]	8,335
Stock-based compensation		28,008	[1]	4,997
Research and development		2,822	[1]
Depreciation of property, plant and equipment		1,747	[1]	896
Amortization of intangible assets		1,767	[1]	765
Total		111,482	[1]	24,367
Loss from operations		(86,974)	[1]	(17,966)
Revaluation of financial instruments loss		(3,730)	[1]	(5,091)
Share of loss from investment in associate and joint ventures	[1]	(2,964)
Loss on investment				(650)
Unrealized gain on convertible debenture receivable	[1]	1,737
Unrealized loss on investments	[1]	(315)
Realized loss on investments	[1]	(215)
Foreign exchange loss		(78)	[1]	(229)
Interest and financing expenses		(469)	[1]	(1,529)
Interest income		5,187	[1]	2,115
Net loss and comprehensive loss attributable to shareholders before tax recovery		(87,821)	[1]	(23,350)
Tax recovery	[1]	18,213
Total net loss		$ (69,608)	[1]	$ (23,350)
Total net loss per share, basic and diluted (in dollars per share)		$ (0.33)	[1]	$ (0.17)
Weighted average number of outstanding shares
Basic and diluted (in shares)		212,740,552	[1]	134,171,509
[1]	Restated

Amended and Restated Consolid_3

Amended and Restated Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands		Share capital		Share-based payment reserve	Warrants	Contributed surplus	Non-controlling Interest	Deficit	Total
Balance at Jul. 31, 2017		$ 45,159		$ 1,562	$ 3,728	$ 1,775		$ (19,785)	$ 32,439
Balance (shares) at Jul. 31, 2017		76,192,990
Issuance of 7% unsecured convertible debentures					3,530	7,283			10,813
Issuance of units		$ 139,029			10,471				149,500
Issuance of units (shares)		37,375,000
Issuance fees/costs		$ (5,870)			(768)	(506)			(7,144)
Issuance of Broker/Finder warrants		(1,472)			2,352				880
Conversion of 8% unsecured convertible debentures		$ 23,462				(1,743)			21,719
Conversion of 8% unsecured convertible debentures (shares)		15,853,887
Conversion of 7% unsecured convertible debentures		$ 61,555				$ (6,809)			54,746
Conversion of 7% unsecured convertible debentures (shares)		31,384,081
Exercise of stock options		$ 1,009		(419)					590
Exercise of stock options (shares)		907,273
Exercise of warrants		$ 75,254			(5,029)				70,225
Exercise of warrants (shares)		27,897,087
Exercise of Broker/Finder warrants		$ 9,106			(1,647)				7,458
Exercise of Broker/Finder warrants (shares)		4,018,798
Stock-based compensation				4,997					4,997
Total net loss								(23,350)	(23,350)
Balance at Jul. 31, 2018		$ 347,233		6,139	12,635			(43,134)	322,873
Balance (shares) at Jul. 31, 2018		193,629,116
Share issuance - January offering		$ 57,558							57,558
Share issuance - January offering (shares)		8,855,000
Share issuance - Newstrike acquisition		$ 322,439							322,439
Share issuance - Newstrike acquisition (shares)		35,394,041
Issuance fees/costs		$ (3,827)							(3,827)
Replacement stock options				7,134					7,134
Replacement warrants					12,229				12,229
Issuance of warrants					42,386				42,386
Exercise of stock options		$ 7,044		(2,751)					4,293
Exercise of stock options (shares)		3,567,867
Exercise of warrants		$ 61,350			(5,204)				56,146
Exercise of warrants (shares)		13,619,202
Exercise of Broker/Finder warrants		$ 7,909			(1,613)				6,296
Exercise of Broker/Finder warrants (shares)		1,916,527
Stock-based compensation				29,793					29,793
Non-controlling interest							$ 1,000		1,000
Total net loss								(69,608)	(69,608)	[1]
Balance at Jul. 31, 2019	[1]	$ 799,706		$ 40,315	$ 60,433		$ 1,000	$ (112,742)	$ 788,712
Balance (shares) at Jul. 31, 2019		256,981,753	[1]						256,981,753
[1]	Restated

Amended and Restated Consolid_4

Amended and Restated Consolidated Statements of Cash Flows - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019		Jul. 31, 2018
Operating activities
Total net loss		$ (69,608)	[1]	$ (23,350)
Items not affecting cash
Income tax recovery	[1]	(18,213)
Depreciation of property, plant and equipment		1,747	[1]	896
Amortization of intangible assets		1,767	[1]	765
Unrealized revaluation gain on convertible debenture	[1]	(1,737)
Unrealized revaluation gain on biological assets		(38,856)	[1]	(7,340)
Unrealized fair value adjustment on investments	[1]	315
Amortization of deferred financing costs	[1]	596
Accrued interest income	[1]	(397)
License depreciation and prepaid royalty expenses - HIP	[1]	117
Impairment loss on inventory	[1]	19,335
Share of loss on investment in joint venture	[1]	2,964
Non-cash interest expense				312
Fair value adjustment on inventory sold		16,357	[1]	2,289
Stock-based compensation		28,008	[1]	4,997
Stock-based compensation expensed through cost of sales	[1]	936
Accretion of convertible debt				1,368
Revaluation of financial instruments loss		3,730	[1]	5,091
Changes in non-cash operating working capital items
Trade receivables		(17,845)	[1]	(292)
Commodity taxes recoverable		(6,425)	[1]	(3,742)
Prepaid expenses		(4,927)	[1]	(4,003)
Inventory		(90,748)	[1]	(2,503)
Biological assets	[1]	37,108
Accounts payable and accrued liabilities		6,630	[1]	3,399
Interest payable				(72)
Excise taxes payable	[1]	3,494
Deferred rent liability	[1]	946
Cash and cash equivalents used in operating activities		(124,706)	[1]	(22,185)
Financing activities
Share issuance - January offering	[1]	57,558
Issuance fees		(3,827)	[1]	(10,306)
Issuance of units				149,500
Issuance of secured convertible debentures				69,000
Exercise of stock options		4,293	[1]	590
Exercise of warrants		56,075	[1]	74,366
Proceeds from term loan, net of financing costs	[1]	32,778
Cash provided by financing activities		146,877	[1]	283,150
Investing activities
Disposal/(Acquisition) of short-term investments		119,810	[1]	(142,874)
Restricted cash	[1]	(22,350)
Acquisition of property, plant and equipment		(138,034)	[1]	(45,722)
Purchase of intangible assets		(3,010)	[1]	(1,780)
Investment in associate and joint ventures	[1]	(13,427)
Net cash acquired on business acquisition	[1]	49,366
Acquired convertible debenture				(10,000)
Cash used in investing activities		(7,645)	[1]	(200,376)
Increase in cash and cash equivalents		14,526	[1]	60,589
Cash and cash equivalents, beginning of year		99,042		38,453
Cash and cash equivalents, end of year		$ 113,568	[1]	$ 99,042
[1]	Restated

Description of Business

Description of Business	12 Months Ended
	Jul. 31, 2019
Disclosure Description Of Business [Abstract]
Description of Business	1. Description of Business HEXO Corp. (formerly The Hydropothecary Corporation) (the “Company”), is a publicly traded corporation, incorporated in Canada. HEXO is a producer of cannabis and its sites are licensed by Health Canada for production and sale. Its head office is located at 240-490 Boulevard Saint-Joseph, Gatineau, Quebec, Canada. The Company’s common shares are listed on the Toronto Stock Exchange (“TSX”) and the New York Stock Exchange (“NYSE”), both under the trading symbol “HEXO”. Shareholder approval of the Company’s name change to HEXO Corp. formerly The Hydropothecary Corporation occurred August 28, 2018.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Jul. 31, 2019
Basis Of Presentation [Abstract]
Basis of Presentation	2. Basis of Presentation Statement of Compliance The consolidated financial statements have been prepared in compliance with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS"). These consolidated financial statements were approved and authorized for issue by the Board of Directors on October 23, 2019. Basis of Measurement and Consolidation The consolidated financial statements have been prepared on an historical cost basis except for cash and cash equivalents, restricted cash, short term investments, biological assets, convertible debentures receivable, long term investments, and the warrant liability, which are measured at fair value on a recurring basis and include the accounts of the Company and entities controlled by the Company and its subsidiaries. Historical cost is the fair value of the consideration given in exchange for goods and services based upon the fair value at the time of the transaction of the consideration provided. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2, Share-based payment Inventories In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows: Level 1 - inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date; Level 2 - inputs are inputs other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and Level 3 - inputs are unobservable inputs for the asset or liability. (a) INVESTMENT IN ASSOCIATES AND JOINT VENTURES When determining the appropriate basis of accounting for the Company’s interests in affiliates, the Company makes judgments about the degree of influence that it exerts directly or through an arrangement over the investees’ relevant activities. Judgment was used to determine whether the joint venture arrangements described in Note 19 should be accounted for as a joint operation or a joint venture. Given the Company has rights to the net assets of the separate legal entities, the Company has concluded they will be accounted for as joint ventures. The Company will recognize the initial investment at cost and the carrying amount is increased or decreased to recognize the Company’s share of the profit or loss of the venture after the date of acquisition. (b) FUNCTIONAL AND PRESENTATION CURRENCY These consolidated financial statements are presented in Canadian dollars, the functional currency of the Company and its subsidiaries. (c) BASIS OF CONSOLIDATION Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. MAJOR SUBSIDIARIES JURISDICTION INTEREST HELD HEXO Operations Inc. 1 Ontario, Canada 100% Newstrike Brands Ltd. 2 Ontario, Canada 100% HEXO USA Inc. Deleware, USA 100% Keystone Isolation Technologies Inc. (“KIT’’) Ontario, Canada 60% 1 2

Significant Accounting Policies

Significant Accounting Policies, Accounting Standards and Interpretations	12 Months Ended
	Jul. 31, 2019
Significant Accounting Policies [Abstract]
Significant Accounting Policies, Accounting Standards and Interpretations	3. Significant Accounting Policies, Accounting Standards and Interpretations FOREIGN CURRENCY TRANSLATION Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. CASH AND CASH EQUIVALENTS Cash and cash equivalents are comprised of cash and highly liquid investments that are readily convertibles into known amounts of cash with original maturities of three months or less. SHORT TERM INVESTMENTS Short term investments are comprised of liquid investments with maturities between 3 and 12 months. Short term investments are recognized initially at fair value and subsequently adjusted to fair value through profit or loss. BIOLOGICAL ASSETS The Company measures biological assets consisting of cannabis plants using the income approach at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs, grow consumables, materials, utilities, facilities costs, depreciation, overhead, stock-based compensation of applicable employees, quality and testing costs. The identified capitalized direct and indirect costs of biological assets are subsequently recorded within the line item ‘costs of goods sold’ on the statement of loss and comprehensive loss in the period that the related product is sold. Seeds are measured at fair value. Unrealized gains or losses arising from changes in fair value less cost to sell during the period are included in the results of operations and presented on a separate line of statement of comprehensive loss of the related period. INVENTORY Inventory is valued at the lower of cost and net realizable value. Cost is determined using the weighted average method. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost of the inventory. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Subsequent costs include materials, overhead, amortization, stock-based compensation of applicable employees and labour involved in packaging and quality assurance. The identified capitalized direct and indirect costs related to inventory are subsequently recorded within ‘cost of goods sold’ on the statement of loss and comprehensive loss at the time the product is sold, with the exclusion of realized fair value amounts included in inventory sold which are recorded as a separate line within gross margin. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Packaging and supplies are initially valued at cost and subsequently at the lower of cost and net realizable value. PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment is measured at cost less accumulated amortization and impairment losses. Amortization is provided using the following terms and method: Land Not amortized No term Buildings Straight line 5 to 20 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years Construction in progress Not amortized No term An asset’s residual value, useful life and amortization method are reviewed at each financial year and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of equipment are determined by comparing the proceeds from disposal with the carrying amount of the equipment and are recognized in profit or loss. Construction in progress is transferred to property, plant and equipment when the assets are available for use and amortization of the assets commences at that point. FINITE LIFE INTANGIBLE ASSETS Finite life intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3 to 5 years Patents Straight line 20 years The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. INDEFINITE INTANGIBLE ASSETS Indefinite intangible assets are deemed to have no foreseeable limit over which the asset is expected to generate net cash inflows. Following initial recognition, intangible assets with indefinite useful lives are carried at cost less any accumulated impairment losses and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. The Company intends to utilize the brand indefinitely. Brand Not amortized Indefinite INVESTMENT IN ASSOCIATE Associates are entities over which the Company has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence represents the power to participate in the financial and operating policy decisions of the investee but does not represent the right to exercise control or joint control over those policies. A joint venture is a contractual arrangement whereby the Company and other parties undertake an economic activity that is subject to joint control (i.e. when the strategic, financial and operating policy decisions relating to the activities of the joint venture require the unanimous consent of the parties sharing control). Investments in associates and joint ventures are accounted for using the equity method and are initially recognized at cost inclusive of transaction costs. IMPAIRMENT OF LONG-LIVED ASSETS Long-lived assets, including property, plant and equipment, goodwill and intangible assets are reviewed for impairment at the end of each financial reporting period or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs of disposal, and its value in use. If the carrying amount The Company assesses impairment of property, plant and equipment when an impairment indicator arises. When the asset does not generate cash inflows that are largely independent of those from other assets or group of assets, the asset is tested at the CGU level. In assessing an impairment, the Company compares the carrying amount of the asset or CGU to the recoverable amount, which is determined as the higher of the asset or CGU’s fair value less costs of disposal and its value-in-use. Value-in-use is assessed based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects applicable market and economic conditions, the time value of money and the risks specific to the asset. Goodwill and indefinite life intangible assets are tested annually and the end of the fiscal year for impairment by comparing the carrying value of each CGU containing the assets to its recoverable amount. Goodwill is allocated to CGUs or groups of CGU’s for impairment testing based on the level at which it is monitored by management, and not at a level higher than an operating segment. Operating segments are components of the Company that engage in business activities which generate revenues and incur expenses. Goodwill is allocated to those CGUs or groups of CGUs expected to benefit from the business combination from which the goodwill arose, which requires the use of judgment. The Company has determined that goodwill and indefinite life intangibles are tested at the adult-use cannabis level representing the primary operations of the Company as described in note 1. An impairment loss is recognized for the amount by which the CGU’s carrying amount exceeds its recoverable amount. The recoverable amounts of the CGU’s assets have been determined based on its fair value less costs of disposal. Impairment losses recognized in respect of a CGU are first allocated to the carrying value of goodwill and any excess is allocated to the carrying value of assets in the CGU. In allocating a reversal of an impairment loss, the carrying amount of an asset shall not be increased above the lower of its recoverable amount and the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior period. Impairment losses on goodwill are not subsequently reversed. Impairment losses are recognized whenever the carrying amount of the asset or CGU exceeds its recoverable amount and is recorded in the consolidated statements of comprehensive (loss) income. The Company estimated the recoverable amounts of goodwill and indefinite life intangible assets by estimating the higher of their fair value less costs of disposal and value in use, which are level 3 measurements within the fair value hierarchy. The key assumption that drove management’s determination of the recoverable amounts of the CGU’s were capacity multiples of comparable industry peers. GOODWILL Goodwill represents the excess of the purchase price paid for the acquisition of the Company’s subsidiary Newstrike over the fair value of the net tangible and intangible assets acquired. Following initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is tested for impairment annually, and whenever events or circumstances that make it more likely than not that an impairment may have occurred, such as a significant adverse change in the business climate or a decision to sell or dispose all or a portion of a reporting unit. LEASED ASSETS Leases are classified as an operating lease whenever the terms of the lease do not transfer substantially all of the risks and rewards of ownership to the lessee. Lease payments are recognized as an expense on a straight-line basis over the lease term, except where another systematic basis is more representative of the time pattern in which the economic benefits are consumed. BUSINESS ACQUISITION A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets acquired, liabilities assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date when the Company obtains control of the acquiree. The identifiable assets acquired and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where IFRS provides exceptions to recording the amounts at fair value. Goodwill represents the difference between total consideration paid and the fair value of the net-identifiable assets acquired. Acquisition costs incurred are expensed to profit or loss. Contingent consideration is measured at its acquisition date fair value and is included as part of the consideration transferred in a business combination, subject to the applicable terms and conditions. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is remeasured at subsequent reporting dates in accordance with IFRS 9 Financial Instruments with the corresponding gain or loss recognized in profit or loss. Based on the facts and circumstances that existed at the acquisition date, management will perform a valuation analysis to allocate the purchase price based on the fair values of the identifiable assets acquired and liabilities assumed on the acquisition date. Management has one year from the acquisition date to confirm and finalize the facts and circumstances that support the finalized fair value analysis and related purchase price allocation. Until such time, these values are provisionally reported and are subject to change. Changes to fair values and allocations are retrospectively adjusted in subsequent periods. REVENUE RECOGNITION The Company has effectively applied the new IFRS 15 standard to the current fiscal year and retrospectively, see ‘New IFRS Effective August 1, 2018.’ COST OF GOODS SOLD Cost of goods sold includes cost of inventory expensed, packaging costs, shipping costs and related labour. RESEARCH AND DEVELOPMENT Research costs are expensed as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized in profit and loss as incurred. INCOME TAXES The Company uses the liability method to account for income taxes. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities for accounting purposes, and the irrespective tax bases. Deferred income tax assets and liabilities are measured using tax rates that have been enacted or substantively enacted applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and are reviewed at the end of each reporting period. SHARE-BASED COMPENSATION The Company has an employee stock option plan. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Forfeitures are adjusted for on an actual basis. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For stock options granted to non-employees the compensation expense is measured at the fair value of goods and services received NON-CONTROLLING INTEREST Non-controlling interest (“NCI”) is recognized at the NCI’s proportionate share of the net assets. LOSS PER SHARE Loss per common share represents loss for the period attributable to common shareholders divided by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by dividing the applicable loss for the year by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the year. The calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive. BORROWING COSTS Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in profit or loss in the period which they are incurred. FINANCIAL INSTRUMENTS Financial assets and liabilities are recognized when the Company becomes a party to the contractual provision of the respective instrument. Fair value estimates are made at the consolidated statement of financial position date based upon the relevant market conditions and information about the financial instrument. The Company has made the following classifications: IFRS 9 Classification Financial assets Cash and cash equivalents FVTPL Restricted cash FVTPL Short-term investments FVTPL Trade receivables Amortized cost Convertible debenture receivable FVTPL Long term investment FVTPL Financial liabilities Accounts payable and accrued liabilities Amortized cost Warrant liability FVTPL Deferred rent liability Amortized cost Term loan Amortized cost Fair Value Through Profit or Loss (“FVTPL”) Financial Assets Financial assets classified and measured at FVTPL are those assets that do not meet the criteria to be classified at amortized cost or at FVTOCI. This category includes debt instruments whose cash flow characteristics are not solely payments of principal and interest (“SPPI”) or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell the financial asset. Amortized Cost Financial Assets Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. A financial asset is initially measured at fair value, including transaction costs and subsequently at amortized cost. Impairment of Financial Assets Financial assets, other than those classified at fair value through profit and loss, are assessed for indicators of impairment at the end of the reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected. Financial Liabilities and Other Financial Liabilities Financial liabilities are classified as either financial liabilities at FVTPL or other financial liabilities. Financial liabilities at FVTPL are stated at fair value, with changes being recognized through the consolidated statements of income. Other financial liabilities are initially measured at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method. Embedded Derivatives Derivatives are initially measured at fair value in conjunction with the host contract; no bifurcation is performed, and any directly attributable transaction costs are recognised in profit or loss as incurred. Subsequent to initial recognition, the entire instrument, including the embedded derivative is measured at fair value and changes therein are recognised in profit or loss. The Company has a convertible loan receivable whereby the balance can be converted into equity. See Note 15 for transaction and valuation details. Compound Instruments The component parts of compound instruments (convertible debentures) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company’s own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion or at the instrument’s maturity date. The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option. Transaction costs that relate to the issue of the convertible debentures are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the term of the convertible debentures using the effective interest method. For compound instruments with non-equity derivatives, the fair value of the embedded derivative is determined first based on the contractual terms, and the initial carrying amount of the host instrument is the residual amount after separating the embedded derivative. Transaction Costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Valuation of Biological Assets and Inventory In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis, harvesting costs, selling costs, sales price and expected yields for the cannabis plant. In calculating final inventory values, management is required to determine an estimate of spoiled or expired inventory and compares the inventory cost versus net realizable value. Estimated Useful Lives, Amortization and Impairment of Property, Plant and Equipment and Intangible Assets Amortization of property, plant and equipment and intangible assets are dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets. The impairment is amount by which the carrying amount of the asset or CGU exceeds its recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal and its value in use. Management exercises judgement in the determination of the Company’s CGUs. Share-Based Compensation In calculating the share-based compensation expense, key estimates such as the value of the common share, the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company’s stock price and the risk-free interest rate are used. Warrants In calculating the value of the warrants, key estimates such as the value of the common share, the expected life of the warrant, the volatility of the Company’s stock price and the risk free interest rate are used. All broker/compensation warrants were measured at the fair value of the equity instruments granted, as the fair value of the related services cannot be reliably measured. Provisions Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Allocation of Purchase Price In determining the allocation of the purchase price, estimates are used based on market research and appraisal values. Joint Ventures and Investments in Associates Joint ventures are joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. Investments in associates are arrangements whereby the Company exercises significant influence. Judgement is required in the assessment of these arrangements and has been determined as follows: Entity Assessment Classification (as defined in Note 19) Truss Management has determined joint control is not present due to the inability to direct the day to day operations of the entity. Investment in associate Belleville Complex Inc. Management has determined joint control is present based upon the board composition, decision making and the ability to direct the day to day operations of the entity. Joint venture HEXO MED Management has determined joint control is present based upon the board composition, decision making and the ability to direct the day to day operations of the entity. Joint venture Business Acquisitions In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates relate to private investments and intangible assets acquired. Management exercises judgment in estimating the probability and timing of when cash flows are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are fair valued using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Acquisitions that do not meet the definition of a business combination are accounted for as asset acquisitions. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values. Asset acquisitions do not give rise to goodwill. Estimation on Revenue Recognition The Company’s revenue streams include variable consideration as a result of return provisions and price concessions which require estimation based on historical results and forward looking expectations. Expected Credit Losses (“ECL”) on Trade Accounts Receivable The Company applies the simplified approach, as defined in IFRS, to measure expected credit losses, which requires the use of the lifetime expected credit loss provision for all trade receivables. To measure lifetime expected credit losses, trade receivables are first classified into groups with shared credit characteristics and the age of days past due, followed by an assessment of the Company’s historical experience of bad debts including the customers’ ability to pay and the impact of any relevant economic conditions which are expected during the life of the balance. The loss allowance is determined according to a provision matrix incorporating historical experiences adjusted for current and future conditions expected for the life of the balance. Convertible debentures The fair value of the convertible debentures is determined using the public market price. As the convertible debentures are classified as FVTPL, the subsequent interest as well as change in the fair value will flow through the consolidated statements of comprehensive income. Deferred taxes Significant estimates are required in determining the Company’s income tax provision. Some estimates are based on interpretations of existing tax laws or regulations. Various internal and external factors may have favorable or unfavorable effects on the Company’s future effective tax rate. These include, but are not limited to, changes in tax laws, regulations and/or rates, changing interpretations of existing tax laws or regulations, results of tax audits by tax authorities, changes in estimates of prior years’ items and changes in overall levels of pre-tax earnings. Going Concern Management has applied significant judgment in the assessment of the Company's ability to continue as a going concern when preparing its consolidated financial statements for the years ended July 31, 2019 and 2018. Management prepares the consolidated financial statements on a going concern basis unless management either intends to liquidate the entity or to cease trading or has no realistic alternative but to do so. The Company has considered the private placement subsequent to July 31, 2019 as disclosed in Note 33 in making this assessment. New IFRS Effective August 1, 2018 IFRS 15, REVENUE FROM CONTRACTS WITH CUSTOMERS IFRS 15 was issued by the IASB in May 2014 and specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. On April 12, 2016, the IASB published final clarifications to IFRS 15 with respect to identifying performance obligations, principal versus agent considerations, and licensing. The Company has applied IFRS 15 retrospectively and determined that there is no change to the comparative period or transitional adjustments required as a result of the adoption. The Company’s accounting policy for revenue recognition under IFRS 15 is as follows: 1. Identifying the contract with a customer; 2. Identifying the performance obligation(s) in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligation(s) in the contract; and 5. Recognizing revenue when or as the Company satisfies the performance obligation(s). Revenue from the direct sale of cannabis to customers for a fixed price is recognized when the Company transfers the control of the good(s) to the customer upon delivery and acceptance by the customer, the timing of which is consistent with the Company’s previous revenue recognition policy under IAS 18. The Company recognizes revenue in an amount that reflects the consideration which the Company expects to receive taking into account the impact which may arise from any rights of return on sales, price concessions or similar obligations. Net revenue is presented net of taxes, estimated returns, allowances and discounts. Effective October 17, 2018, Canada Revenue Agency (“CRA”) began levying an excise taxes on the sale of medical and adult-us cannabis products. The Company becomes liable for these excise duties when cannabis products are delivered to the customer. The excise taxes payable is the higher of (i) a flat-rate duty which is imposed when a cannabis product is packaged, and (ii) an advalorem duty that is imposed when a cannabis product is delivered to the customer. Effective May 1, 2019,

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-Term Investments	12 Months Ended
	Jul. 31, 2019
Categories of current financial assets [abstract]
Cash, Cash Equivalents and Short-Term Investments	4. Cash, Cash Equivalents and Short-Term Investments Cash and cash equivalents are highly liquid investments with a maturity of 3 months or less. Short term investments are comprised of liquid investments with maturities of less than 12 months. Short term investments are recognized initially at fair value and subsequently adjusted to fair value through profit or loss. July 31, 2019 July 31, 2018 Total Total Interest rate Operating cash – $ 5,993 $ 66,438 High interest savings accounts 1.45%–2.10% 107,575 32,604 Total cash and cash equivalents $ 113,568 $ 99,042 Term deposits & GIC 2.85%–4.25% maturity of 3 to 12 months $ 25,937 $ 145,747 Total short-term investments $ 25,937 $ 145,747 Interest income earned in the period amounted to $5,187 (July 31, 2018 - $2,115).

Restricted Cash

Restricted Cash	12 Months Ended
	Jul. 31, 2019
Disclosure Of Restricted Cash [Abstract]
Restricted Cash	5. Restricted Cash As at July 31, 2019, the Company had $22,350 of restricted funds. Of this, $3,433 is currently in escrow to facilitate the purchase of supply agreements with vendors. The amount of $433 shall be drawn down on a pro-rata basis based upon the delivery of goods to the Company. The remaining balance of $3,000 may be contributed to or drawn upon, in order to retain 15% of the future expected purchases. A balance of $3,141 has been restricted to secure the implementation of greenhouse infrastructure with a vendor (Note 23). Additionally, the Company had a capital contribution of $4,076 held in trust as at July 31, 2019. The remaining balance of $9,200 has been restricted due to a minimum balance to be held in a debt service reserve account as required under the Company’s term loan agreement (Note 23). A balance of $2,500 is held in trust related the Company’s joint venture Neal Brothers Inc (Note 28).

Commodity Taxes Recoverable and

Commodity Taxes Recoverable and Other Receivables	12 Months Ended
	Jul. 31, 2019
Commodity Taxes Recoverable And Other Receivables [Abstract]
Commodity Taxes Recoverable and Other Receivables	6. Commodity Taxes Recoverable and Other Receivables July 31, 2019 July 31, 2018 Commodity taxes recoverable $ 14,415 $ 4,237 Accrued interest income 570 – Other receivables (Note 20) 262 – $ 15,247 $ 4,237

Inventory

Inventory	12 Months Ended
	Jul. 31, 2019
Classes of current inventories [abstract]
Inventory	7. Inventory (Restated – see note 34 July 31, 2019 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 28,996 $ 19,349 $ 48,345 Oils 17,377 5,366 22,743 Hemp derived distillate 1,523 – 1,523 Purchased dried cannabis 8,087 – 8,087 Packaging and supplies 3,156 – 3,156 $ 59,139 $ 24,715 $ 83,854 The inventory expensed to cost of goods sold in the year ended July 31, 2019, was $18,565 (July 31, 2018 – $965). Total stock-based compensation expensed to costs of sales in the period as $936. The fair value adjustment on the sale of inventory during the period was $16,357 (July 31, 2018 – $2,289). The Company recorded an impairment loss on inventory of $19,335, realized on cannabis trim and milled inventory in which the cost exceeds its net realizable value. During the year ended July 31, 2018, the Company recorded an adjustment to the net realizable value of inventories of $1,491. This was due to the decrease in the estimated market selling price input of the inventory valuation which was caused by the onset of the adult-use market and is reflective of competitive market prices. July 31, 2018 Capitalized Biological asset fair Cost value adjustment Total Dried cannabis $ 2,115 $ 4,440 $ 6,555 Oils 2,281 882 3,163 Packaging and supplies 697 – 697 $ 5,093 $ 5,322 $ 10,415

Biological Assets

Biological Assets	12 Months Ended
	Jul. 31, 2019
Disclosure of detailed information about biological assets [abstract]
Biological Assets	8. Biological Assets The Company’s biological assets consist of cannabis plants from seeds all the way through to mature plants. The changes in the carrying value of biological assets are as follows: July 31, 2019 July 31, 2018 Carrying amount, beginning of period $ 2,332 $ 1,504 Acquired through acquisition 1 3,291 – Production costs capitalized 19,215 993 Net increase in fair value due to biological transformation less cost to sell 38,856 7,340 Transferred to inventory upon harvest (56,323 ) (7,505 ) Carrying amount, end of period $ 7,371 $ 2,332 1 As at July 31, 2019, the fair value of biological assets included $2 in seeds and $7,369 in cannabis plants ($6 in seeds and $2,326 in cannabis plants as at July 31, 2018). The significant estimates used in determining the fair value of cannabis plants are as follows: • yield by plant; • stage of growth estimated as the percentage of costs incurred as a percentage of total cost as applied to the estimated total fair value per gram (less fulfilment costs) to arrive at an in-process fair value for estimated biological assets, which have not yet been harvested; • percentage of costs incurred for each stage of plant growth. • fair value selling price per gram less cost to complete and cost to sell. • destruction/wastage of plants during the harvesting and processing process. All biological assets are classified as current assets in the statement of financial position and are considered Level 3 fair value estimates. As at July 31, 2019, it is expected that the Company’s biological assets will yield approximately 17,571 kilograms of cannabis (July 31, 2018 – 4,374 kilograms of cannabis). The Company’s estimates are, by their nature, subject to change. Changes in the anticipated yield will be reflected in future changes in the fair values of biological assets. The valuation of biological assets is based on an income approach in which the fair value at the point of harvesting is estimated based on selling prices less the costs to sell. For in process biological assets, the fair value at point of harvest is adjusted based on the stage of growth at period end. Stage of growth is determined by reference to the cost incurred as a percentage of total cost as applied to estimated total fair value per gram (less fulfilment costs) to arrive at an in-process fair value for estimated biological assets, which have not yet been harvested. Management’s identified significant unobservable inputs, their range of values and sensitivity analysis are presented in the tables below. The following table summarizes the unobservable inputs for the period ended July 31, 2019: Unobservable inputs Input values Sensitivity analysis Average selling price An increase or decrease of 5% applied to the average Obtained through actual retail prices on a per $4.23 – $5.01 per dried gram. selling price would result in a change of approximately $480 strain basis. to the valuation. Yield per plant An increase or decrease of 5% applied to the average yield Obtained through historical harvest cycle results 15 – 123 grams per plant. per plant would result in a change up to approximately $344 on a per strain basis. in valuation. Stage of growth An increase or decrease of 5% applied to the average stage Obtained through the estimates of stage of Average of 29% completion. of growth per plant would result in a change of completion within the harvest cycle. approximately $1,148 in valuation. Wastage An increase or decrease of 5% applied to the wastage Obtained through the estimates of wastage 0%–30% dependent upon the expectation would result in a change of approximately $302 within the cultivation and production cycle. stage within the harvest cycle. in valuation. The following table summarizes the unobservable inputs for the period ended July 31, 2018: Unobservable inputs Input values Sensitivity analysis Average selling price An increase or decrease of 5% applied to the average Obtained through actual retail prices on a per $4.66 per dried gram. selling price would result in a change of approximately $329 strain basis. to the valuation. Yield per plant Obtained through historical harvest cycle results 50–235 grams per plant. An increase of decrease of 5% applied to the average yield on a per strain basis. per plant would not result in a material change in valuation. Stage of growth Obtained through the estimates of stage of Average of 32% completion. An increase or decrease of 5% applied to the average stage completion within the harvest cycle. of growth per plant would result in a change of approximately $320 in valuation. Wastage Obtained through the estimates of wastage 0%–30% dependent upon the An increase of decrease of 5% applied to the average yield within the cultivation and production cycle. stage within the harvest cycle. per plant would not result in a material change in valuation.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Jul. 31, 2019
Property, plant and equipment [abstract]
Property, Plant and Equipment	9. Property, Plant and Equipment Balance at Additions from Balance at business Cost July 31, 2018 acquisitions Additions Adjustments July 31, 2019 Land $ 1,038 $ 4,301 $ – $ – $ 5,339 Buildings 32,536 18,855 11,365 88,078 150,834 Leasehold Improvements 206 – 421 – 627 Furniture and equipment 1,661 119 4,576 – 6,356 Cultivation and production equipment 4,031 9,913 28,085 – 42,029 Vehicles 151 – 880 – 1,031 Computers 659 529 1,793 – 2,981 Construction in progress 15,433 12,286 117,909 (88,078 ) 57,550 $ 55,715 $ 46,003 $ 165,029 $ – $ 266,747 Balance at Additions from Balance at business Accumulated depreciation July 31, 2018 acquisitions Depreciation Adjustments July 31, 2019 Land $ – $ – $ – $ – $ – Buildings 533 – 3,859 – 4,392 Leasehold Improvements 9 – 121 – 130 Furniture and equipment 527 – 585 (650 ) 462 Cultivation and production equipment 69 – 1,497 650 2,216 Vehicles 56 – 77 – 133 Computers 188 – 433 – 621 $ 1,382 $ – $ 6,572 $ – $ 7,954 Balance at Additions from Balance at business Net Additions / Net Carrying Value July 31, 2018 acquisitions (Deductions) Adjustments July 31, 2019 Land $ 1,038 $ 4,301 $ – $ – $ 5,339 Buildings 32,003 18,855 7,506 88,078 146,442 Leasehold Improvements 197 – 300 – 497 Furniture and equipment 1,134 119 3,991 650 5,894 Cultivation and production equipment 3,962 9,913 26,588 (650 ) 39,813 Vehicles 95 – 803 – 898 Computers 471 529 1,360 – 2,360 Construction in progress 15,433 12,286 117,909 (88,078 ) 57,550 $ 54,333 $ 46,003 $ 158,457 $ – $ 258,793 As at July 31, 2019, there was $21,265 (July 31, 2018 – $3,920) of property, plant and equipment in accounts payable and accrued liabilities. During the year ended July 31, 2019, the Company capitalized $4,825 of depreciation to inventory and capitalized borrowing costs to buildings in the amount of $511 (July 31, 2018 – $994) at an average annual interest rate of 3.2% . During the period depreciation expensed to the statement of loss was $1,474 (July 31, 2018 - $876). Adjustments during the period, reflect the activation of an asset’s useful life, transitioning from construction in progress to the appropriate property, plant and equipment classification. The Company has contractual commitments for remaining leasehold improvements of $33,455 payable in fiscal year 2020 as at July 31, 2019 (July 31, 2018 - $40,471). Balance at Balance at Cost July 31, 2017 Additions Adjustments July 31, 2018 Land $ 358 $ 680 $ – $ 1,038 Buildings 3,745 3,930 24,861 32,536 Leasehold Improvements – 206 – 206 Furniture and equipment 900 1,233 (472 ) 1,661 Cultivation and production equipment 380 3,165 486 4,031 Vehicles 114 33 4 151 Computers 234 425 – 659 Construction in progress 605 39,707 (24,879 ) 15,433 $ 6,336 $ 49,379 $ – $ 55,715 Balance at Balance at Accumulated depreciation July 31, 2017 Depreciation Adjustments July 31, 2018 Land $ – $ – $ – $ – Buildings 194 339 – 533 Leasehold Improvements – 9 – 9 Furniture and equipment 165 195 167 527 Cultivation and production equipment 23 213 (167 ) 69 Vehicles 26 30 – 56 Computers 78 110 – 188 $ 486 $ 896 $ – $ 1,382 Balance at Net Additions / Balance at Net Carrying Value Adjustments July 31, 2017 (Deductions) July 31, 2018 Land $ 358 $ 680 $ – $ 1,038 Buildings 3,551 3,591 24,861 32,003 Leasehold Improvements – 197 – 197 Furniture and equipment 735 1,038 (639 ) 1,134 Cultivation and production equipment 357 2,952 653 3,962 Vehicles 88 3 4 95 Computers 156 315 – 471 Construction in progress 605 39,707 (24,879 ) 15,433 $ 5,850 $ 48,483 $ – $ 54,333

Intangible Assets and Other Lon

Intangible Assets and Other Longer Term Assets	12 Months Ended
	Jul. 31, 2019
Changes in intangible assets other than goodwill [abstract]
Intangible Assets and Other Longer Term Assets	10. Intangible Assets and Other Longer Term Assets Balance at Additions from Balance at business Cost July 31, 2018 acquisitions Additions Adjustments July 31, 2019 Cultivating and processing license $ 2,545 $ 113,888 $ – $ – $ 116,433 Brand – 8,440 – – 8,440 Software 1,800 12 1,746 – 3,558 Domain names 585 – – – 585 Patents – – 1,231 – 1,231 Other longer term assets and capitalized 312 – – (312 ) – transaction costs $ 5,242 $ 122,340 $ 2,977 $ (312 ) $ 130,247 Balance at Additions from Balance at business Accumulated amortization July 31, 2018 acquisitions Amortization Adjustments July 31, 2019 Cultivating and processing license $ 403 $ – $ 1,198 $ – $ 1,601 Software 786 – 483 – 1,269 Domain name 9 – 57 – 66 Patents – – 29 – 29 $ 1,198 $ – $ 1,767 $ – $ 2,965 Balance at Additions from Balance at business Net Additions / Net Carrying Value July 31, 2018 acquisitions (Deductions) Adjustments July 31, 2019 Cultivating and processing license $ 2,142 $ 113,888 $ (1,198 ) $ – $ 114,832 Brand – 8,440 – – 8,440 Software 1,014 12 1,263 – 2,289 Domain names 576 – (57 ) – 519 Patents – – 1,202 – 1,202 Other longer term assets and capitalized 312 – – (312 ) – transaction costs $ 4,044 $ 122,340 $ 1,210 $ (312 ) $ 127,282 Software includes $121 relating to managerial software (July 31, 2018 - $258) not yet available for use. Accordingly, no amortization has been taken during the year ended July 31, 2019 on these inactive assets. As at July 31, 2019, there was $422 (July 31, 2018 – $266) of intangible assets in accounts payable and accrued liabilities. The adjustment represents $212 of capitalized transaction costs being allocated to the Truss investment in associate (Note 19a) and $100 other longer term investment has been reclassified to long term investments. Research and development expenses in the period amounted to $2,822 (July 31, 2018 - $Nil). Balance at Disposals/ Balance at Cost July 31, 2017 Additions adjustments July 31, 2018 Cultivating and processing license $ 2,545 $ – $ – $ 2,545 Software 651 1,149 – 1,800 Domain names – 585 – 585 Other longer term assets and capitalized – 312 – 312 transaction costs $ 3,196 $ 2,046 $ – $ 5,242 Balance at Disposals/ Balance at Accumulated amortization July 31, 2017 Amortization adjustments July 31, 2018 Cultivating and processing license $ 277 $ 126 $ – $ 403 Software 156 630 – 786 Domain name – 9 – 9 $ 433 $ 765 $ – $ 1,198 Net Carrying Value Balance at July 31, 2017 Net Additions / (Deductions) Disposals/ adjustments Balance at July 31, 2018 Cultivating and processing license $ 2,268 $ (126 ) $ – $ 2,142 Software 495 519 – 1,014 Domain names – 576 – 576 Other longer term assets and capitalized – 312 – 312 transaction costs $ 2,763 $ 1,281 $ – $ 4,044 During the fiscal year ended July 31, 2018, the Company conducted a review of its intangible assets, which resulted in changes in the expected usage of its software. Certain assets, which management previously intended to use for 5 years from the date of purchase were replaced during the fiscal year as well as September 2018. As a result, the expected useful lives of these assets decreased. The effect of these changes on actual and expected depreciation expense, in current and future years respectively is as follows. 2019 2020 2021 2022 Later (Decrease) increase in amortization expense $ (87 ) $ (119 ) $ (100 ) $ (3 ) $ Nil

Business Acquisition

Business Acquisition	12 Months Ended
	Jul. 31, 2019
Disclosure of detailed information about business combination [abstract]
Business Acquisition	11. Business Acquisition Acquisition of Newstrike Brands Limited. On May 24, 2019, the Company acquired 100% of the issued and outstanding common shares of Newstrike Brands Limited (“Newstrike”) pursuant to an arrangement agreement entered into on March 13, 2019. Newstrike is a licensed producer of cannabis operating in Ontario, Canada and was acquired for additional production capacity, established sales relationships and its brand. Under the arrangement, each former Newstrike common share was exchanged for 0.06332 of a HEXO common share (the “Exchange Ratio”), subject to certain exceptions. In addition, all issued and outstanding stock options of Newstrike were replaced with stock options of HEXO having the same terms but adjusted for the Exchange Ratio, and all issued and outstanding common share purchase warrants of Newstrike became exercisable for HEXO common shares adjusted for the Exchange Ratio. The following table summarizes the preliminary values of the net assets acquired from Newstrike on the acquisition date. The fair values of the acquired property, plant and equipment, deferred tax liability, private investments and intangible assets are preliminary are subject to change within the one-year measurement. Note Number of Shares, Share Price Amount Warrants and Options ($) ($) Consideration Shares issued (i) 35,394,041 9.11 322,439 Warrants outstanding (ii) 7,196,164 12,229 Replacement options issued (iii) 2,002,365 7,134 Total fair value of consideration 341,802 Net assets acquired Current assets Cash and cash equivalents 49,366 Accounts receivable 1,204 Other receivables 4,585 Inventory 22,359 Biological assets 3,291 Long-term assets Property, Plant and Equipment 46,003 Investments (iv) 14,492 Convertible debenture receivable 1,220 Prepaid expenses 1,631 Prepaid expense and license 1,526 Software 10 Cultivation and processing license 113,888 Brand 8,440 Goodwill 111,877 Total assets 379,892 Current liabilities Accounts payable and accrued liabilities 12,849 Payment received in advance 5 Long-term liabilities Deferred tax liabilities 24,236 Total liabilities 37,090 Non-controlling interest 1,000 Total net assets acquired 341,802 Net accounts receivables acquired Total accounts receivable 5,789 Expected uncollectible receivables – Net accounts receivables acquired 5,789 (i) Share price based upon the TSX market price of common shares as at May 24, 2019. (ii) Warrants were valued using the Black-Scholes option pricing model as at the acquisition date May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 0.73 – 4.07 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $11.84 – $27.64 • Stock price of $9.11 (iii) All replacement options were valued using the Black-Scholes option pricing model as at the acquisition date of May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 1.2 – 4.7 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $6.00 – $17.37 • Stock price of $9.11 The fair value of the vested options as at the acquisition date was deemed consideration paid in the transaction. The fair value of those options not yet vested at the acquisition date was added to the Company’s share-based payment reserve to be expensed over the remaining vesting period of the options as permitted under IFRS 3 – Business Combinations (iv) Included in total investments were two level 3 private company investments (see ‘ Greentank Technologies Neal Brothers Inc The above acquisition contributed net revenue of $2,770 and a net loss of $13,699 to the Company’s consolidated results since the date of acquisition. If each acquisition had occurred on August 1, 2018, management estimates that the Company’s consolidated net revenue would have increased by $9,287 and the net loss would have increased by $19,096 for the year ended July 31, 2019. Goodwill arising from the acquisition represents the expected synergies, future income and growth, and other intangibles that do not qualify for separate recognition. None of the goodwill arising on these acquisitions are expected to be deductible for tax purposes. The NCI acquired at the acquisition date arises from Newstrike holding a 60% interest in Neal Brothers Inc. The net assets of Neal Brothers consist of cash only and the NCI was measured at its fair value (Note 28). The NCI acquired at the acquisition date arises from Newstrike holding a 60% interest in Neal Brothers Inc. as the NCI relates to the joint venture Neal Up Brands Inc. Total non-capitalized transaction expenses amounted to $3,958 in the period.

Convertible Debentures

Convertible Debentures	12 Months Ended
	Jul. 31, 2019
Debt instruments held [abstract]
Convertible Debentures	12. Convertible Debentures 2017 unsecured 2018 unsecured convertible convertible debentures 8% debentures 7% Total Balance at July 31, 2017 20,639 – 20,639 Gross proceeds – 69,000 69,000 Issuance costs – (4,792 ) (4,792 ) Warrants, net of issuance costs – (3,285 ) (3,285 ) Conversion feature, net of issuance costs – (6,777 ) (6,777 ) Accretion 814 554 1,368 Conversion of debenture (21,453 ) (54,700 ) (76,153 ) Balance at July 31, 2018 – – – 2017 Secured Convertible Debentures During the year ended July 31, 2019, 863,693, warrants were exercised for total proceeds of $863 (US$656, based on an exercise price of US$0.76) . On the various dates of exercise, the warrant liability was revalued using the Black-Scholes-Merton option pricing model. Overall, the liability value of the warrants exercised was $6,367 (US$4,819); using the following variables: • stock prices ranging from $5.90 to $10.36; • expected life of 12 months; • $Nil dividends; • 75% volatility based upon comparative market indicators and historical data; • risk free interest rates of 1.55% to 2.35%; • USD/CAD exchange rate of various. The exercise of these warrants resulted in an increase to share capital of $6,367. The remaining warrant liability was revalued on July 31, 2019 using the Black-Scholes-Merton option pricing model (Level 2). The warrant liability was revalued to $493 (US$375); with a stock price of US$4.24; expected life of 12 months; $Nil dividends; 74% volatility based upon historical data; risk free interest rate of 1.61%; and USD/CAD exchange rate of 1.3148. The loss on the revaluation of the warrant liability for the year ended July 31, 2019 was ($3,730) (July 31, 2018 – ($5,091)), which is recorded in the revaluation of financial instruments account on the statement of loss and comprehensive loss. The following table summarizes warrant liability activity during the fiscal year ended July 31, 2019 and fiscal year ended July 31, 2018. July 31, 2019 July 31, 2018 Opening balance $ 3,130 $ 1,356 Granted – – Expired – – Exercised (6,367 ) (3,317 ) Revaluation due to foreign exchange 3,730 5,091 Closing balance $ 493 $ 3,130 2017 Unsecured Convertible Debentures 8% Interest related to the 2017 8% unsecured convertible debentures (which were converted during fiscal 2017) expensed to the statement of loss and comprehensive loss amounted to $Nil and interest capitalized to property, plant, and equipment was $Nil for the year ended July 31, 2019 (July 31, 2018 –$922 respectively). Accretion for the year ended July 31, 2019 was $Nil (July 31, 2018 – $814). 2018 Unsecured Convertible Debentures 7% On November 24, 2017, the Company issued $69,000 principal amount of unsecured debentures through a brokered private placement. The debentures bear interest at 7% per annum and mature on November 24, 2020. Interest will be accrued and paid semi-annually in arrears. The debentures were convertible into common shares of the Company at $2.20 at the option of the holder. The Company may force the conversion of the debentures on 30 days prior written notice should the daily weighted average trading price of the common shares of the Company be greater than $3.15 for any 10 consecutive trading days. The debenture holders received 15,663,000 warrants, 227 for every $1,000 unit. The warrants have a two-year term, expiring November 24, 2019, and have an exercise price of $3.00. The Company has the right to accelerate the expiry of the warrants should the closing trading price of the common shares of the Company be greater than $4.50 for any 10 consecutive trading days. On initial recognition, the residual method was used to allocate the fair value of the warrants and conversion option. The fair value of the liability component was calculated as $58,187 using a discount rate of 14%. The residual proceeds of $10,813 were allocated between the warrants and conversion option on a pro-rata basis relative to their fair values. The fair values of the warrants and conversion option were determined using the Black-Scholes-Merton option pricing model. The warrants were valued with a fair value $8,648 using the following assumptions: stock price of $2.62; expected life of one year; $Nil dividends; 65% volatility; based upon comparative market indicators and historical data risk free interest rate of 1.25%. The conversion option was valued with a fair value of $17,843 using the following assumptions: stock price of $2.62; expected life of three months; $Nil dividends; 65% volatility; based upon comparative market indicators and historical data risk free interest rate of 1.25%. Based on the fair value of the warrants and conversion option, the residual proceeds of $10,813 were allocated as $3,530 to the warrants and $7,283 to the conversion option, less allocation of issuance costs. In connection with the closing of the debentures, the Company paid a placement fee of $3,450 from the gross proceeds of the financing and incurred an additional $476 of issuance costs. The Company also issued broker warrants exercisable to acquire 1,568 common shares at an exercise price of $3.00 per share. The broker warrants were attributed a fair value of $866 based on the Black-Scholes-Merton option pricing model with the following assumptions: stock price of $2.62; expected life of 1 year; $Nil dividends; 65% volatility; based upon comparative market indicators and historical data risk free interest rate of 1.25%. The total issuance costs amounted to $4,792 and were allocated on pro-rata basis as follows: Debt – $4,041, Conversion option – $506, and the Warrants – $245. On December 15, 2017 the Company announced that it had elected to exercise its right to convert all of the outstanding principal amount of the Company’s 7.0% Debentures and unpaid accrued interest thereon into Common Shares. The Company became entitled to force the conversion of the 7.0% Debentures on December 13, 2017 on the basis that the VWAP of the Common Shares on the TSXV for 10 consecutive trading days was equal to or exceeded $3.15. For the 10 consecutive trading days preceding December 13, 2017, the VWAP of the Common Shares was $3.32. The Company provided the holders of the 7.0% Debentures with the required 30 days advance written notice of the conversion, and the effective date for the conversion was January 15, 2018. Pursuant to the conversion of the 7.0% Debentures, holders of the 7.0% Debentures received 454.54 Common Shares for each $1,000 principal amount of 7.0% Debentures held. In addition, the accrued and unpaid interest on each $1,000 principal amount of the 7.0% Debentures for the period from December 31, 2017 (the interest payment scheduled for December 31, 2017 was paid in cash) up to, but excluding the conversion date, was $2.92 and 7.0% Debenture holders received an additional 1.33 Common Shares for each $1,000 principal amount of 7.0% Debentures held on account of accrued and unpaid interest, for a total of 455.87 Common Shares for each $1,000 principal amount of 7.0% Debentures held. Accordingly, at the date of conversion the carrying value of the debentures of $54,700, interest payable paid through shares of $46 and the conversion feature of $6,809 resulted in the cumulative increase to share capital of $61,555. There exists no convertible debt as at July 31, 2019.

Share Capital

Share Capital	12 Months Ended
	Jul. 31, 2019
Share Capital [Abstract]
Share Capital	13. Share Capital (a) Authorized An unlimited number of common shares and an unlimited number of special shares, issuable in series. (b) Issued and Outstanding During the first quarter of fiscal 2018, 481,896 warrants with exercise prices of $0.75 and US$0.70 were exercised for proceeds of $406, resulting in the issuance of 481,896 common shares. During the second quarter of fiscal 2018, the Company issued 15,687,500 common shares from the conversion of the 8% unsecured convertible debentures and 166,387 common shares in lieu of accrued interest, as described Note 10 Convertible debentures. On January 2, 2018, the Company announced that it had elected to exercise its right to accelerate the expiry date of the common share purchase warrants issued under the 8% convertible debentures. The Company became entitled to accelerate the expiry date of the warrants on December 27, 2017 on the basis that the closing trading price of the Common Shares on the TSXV exceeded $3.00 for 15 consecutive trading days. The expiry date for the warrants was accelerated from July 18, 2019 to February 1, 2018. During the second quarter of fiscal 2018, the Company issued 7,799,960 common shares related to the exercise of warrants associated with the 8% convertible debentures. During the second quarter of fiscal 2018, the Company issued 31,363,252 common shares from the conversion of the 7% unsecured convertible debentures and 20,829 common shares in lieu of accrued interest, as described Note 10 Convertible debentures. The Company issued 2,922,393 common shares related to the exercise of warrants from the 7% unsecured convertible debentures. During the second quarter of fiscal 2018, in addition to common shares issued related to the exercise of warrants associated with the convertible debentures, 5,025,627 warrants with exercise prices of $0.75 and US$0.70 were exercised, resulting in the issuance of 5,021,940 common shares. Total proceeds from the exercise of warrants were $30,937. On January 30, 2018 the Company closed a bought deal public offering of 37,375,000 units at a price of $4.00 per unit for gross proceeds of $149,500. Each unit consisted one common share and one-half of one share purchase warrant of the Company. Each warrant is exercisable into one common share at a price of $5.60 per share for a period of two years. The fair value of the warrants at the date of grant was estimated at $0.56 per warrants based on the following weighted average assumptions: • stock price of $3.93; • expected life of 1 year; • $Nil dividends; • 65% volatility based upon comparative market indicators and historical data; • risk free interest rate of 1.25%. Total cash share issue costs amounted to $6,380 which consisted of underwriters’ commissions of $5,980, underwriters’ expenses of $10, underwriters’ legal fees of $97 and incurred $311 of additional cash issuance costs. In addition, the Company issued an aggregate of 1,495 compensation warrants to the underwriters at a fair value of $1,486. The compensation warrants have an exercise price of $4.00 and expire January 30, 2020. The fair value of the compensation warrants at the date of grant was estimated at $0.99 per warrant based on the following weighted average assumptions: • stock price of $3.93; • expected life of 1 year; • $Nil dividends; • 65% volatility based upon comparative market indicators and historical data; • risk free interest rate of 1.25%. The Company allocated $7,342 of the issuance costs to the common shares and $523 to the warrants. During the third quarter of fiscal 2018, 2,475 warrants with exercise prices ranging from $0.75 to $5.60 and US$0.76 were exercised for proceeds of $4,423, resulting in the issuance of 2,475 common shares. On May 24, 2018, the Company announced that it had elected to exercise its right to accelerate the expiry date governing the common share purchase warrants issued November 24, 2017. Pursuant to the terms of the warrant indenture the Company elected its right to accelerate the expiry date of the remaining 5,261,043 warrants from November 24, 2019 to June 25, 2018. As at the date of expiry all warrants were exercised. The accelerated expiry date also applied to the remaining 1,568,181 compensation warrants originally issued to certain investment banks on November 24, 2017. As at the date of expiry 1,505,453 compensation warrants were exercised and 62,728 warrants expired. During the fourth quarter of fiscal 2018, 13,214,883 warrants with exercise prices ranging from $0.75 to $5.60 and US$0.76 were exercised for proceeds of $38,601, resulting in the issuance of 13,214,883 common shares. On October 4, 2018 the Company closed its transaction with joint venture partner Molson Coors in which the Company granted 11,500,000 warrants at a price of $6.00 per warrant. Each warrant is exercisable into one common share at a price of $6.00 per share for a period of three years. The fair value of the warrants at the date of grant was estimated at $3.69 per warrant based on the following weighted average assumptions: • stock price of $8.45; • expected life of 1.5 years; • $Nil dividends; • 65% volatility based upon comparative market indicators and historical data; • risk free interest rate of 0.75%. During the first quarter of fiscal 2019, 3,137,746 warrants with exercise prices ranging from $0.75 to $5.60 and US$0.76 were exercised for proceeds of $5,589, resulting in the issuance of 3,137,746 common shares. On January 30, 2019, the Company closed its offering of 7,700,000 common shares at a price of $6.50 per share for gross proceeds of $50,050. Included in the offering was an 1,155,000 over-allotment option pool with a price of $6.50 per share which was exercised in full on the closing date for $7,508 and total gross proceeds of $57,558 for total common shares issued of 8,855,000. Underwriting and legal fees accumulated to $3,827 for total net proceeds of $53,731. During the second quarter of fiscal 2019, 682,678 warrants with exercise prices ranging from $0.75 to $5.60 and US$0.76 were exercised for proceeds of $1,307, which resulted in the issuance of 682,678 common shares. During the third quarter of fiscal 2019, 3,661,761 warrants with exercise prices ranging from $0.75 to $5.60 and US$0.76 were exercised for proceeds of $8,425, resulting in the issuance of 3,661,761 common shares. On May 24, 2019, the Company completed the acquisition of Newstrike Brands Ltd. (Note 11), resulting in the issuance of 35,394,041 common shares. During the fourth quarter of fiscal 2019, 8,053,544 warrants with exercise prices ranging from $0.75 to $5.60 and US$0.76 were exercised for proceeds of $47,396, resulting in the issuance of 8,053,544 common shares. In fiscal 2019 a total of 15,535,729 warrants with exercise prices ranging from $0.75 to $5.60 and US$0.76 were exercised for total proceeds of $69,259, resulting in the issuance of 15,535,729 common shares. As at July 31, 2019, there were 256,981,753 common shares outstanding and 29,585,408 warrants outstanding. The following is a consolidated summary of warrants on July 31, 2019. Number outstanding Book value Classified as Equity 2018 Equity financing Exercise price of $5.60 expiring January 30, 2020 10,512,208 $ 5,673 February 2018 financing warrants Exercise price of $27.64 expiring February 16, 2020 4,413,498 1,331 June 2019 financing warrants Exercise price of $15.79 expiring June 19, 2023 2,184,540 9,998 Broker / Consultant warrants Exercise price of $20.85 expiring February 16, 2020 264,809 160 Exercise price of $11.84 expiring June 19, 2020 262,021 610 Exercise price of $0.75 expiring November 3, 2021 175,618 78 Exercise price of $0.75 expiring March 14, 2022 94,282 66 Exercise price of $15.79 expiring June 19, 2023 61 1 Inner Spirit warrants Exercise price of $15.63 expiring July 21, 2020 71,235 129 Joint Venture Molson warrants Exercise price of $6.00 expiring October 4, 2021 11,500,000 42,386 Classified as Liability 29,478,272 60,432 2017 secured convertible debenture warrants Exercise price of USD$0.76 expiring November 14, 2019 107,136 493 29,585,408 $ 60,925 The following table summarizes warrant activity during the years ended July 31, 2019 and 2018. July 31, 2019 July 31, 2018 Number of Weighted average Number of Weighted average warrants exercise price warrants exercise price Outstanding, beginning of period 26,425,504 $ 4.35 20,994,123 $ 1.31 Expired during the period (531 ) – (62,728 ) 3.00 Acquired and reissued through acquisition 1 7,196,164 23.10 – – Issued during the period 11,500,000 6.00 37,413,681 4.34 Exercised during the period (15,535,729 ) 3.61 (31,919,572 ) 2.33 Outstanding, end of the period 29,585,408 $ 9.95 26,425,504 $ 4.35 1 Exercised during the period were 1,916,527 broker compensation warrants. Stock Option Plan The Company has a share option plan (the “Plan”) adopted in July 2018, that is administered by the Board of Directors who establish exercise prices and expiry dates, which are up to 10 years from issuance as determined by the Board at the time of issuance. Unless otherwise determined by the Board, options issued under the Plan vest over a three-year period except for options granted to consultants or persons employed in investor relations activities (as defined in the policies of the TSX) which vest in stages over 12 months with no more than ¼ of the options vesting in any three-month period. The maximum number of common shares reserved for issuance for options that may be granted under the Plan is 25,698,175 common shares as at July 31, 2019. Options issued prior to July 2018 under the outgoing plan and the options assumed through the acquisition of Newstrike do not contribute to the available option pool reserved for issuance. As of July 31, 2019, the Company had 17,376,615 issued and outstanding under the Plan. The following table summarizes the stock option grants during the years ended July 31, 2019 and 2018. Options granted Executive and Non-executive Grant date Exercise price directors employees Vesting terms Vesting period September 8, 2017 $ 1.37 650,000 1,000 Terms A 10 years November 6, 2017 $ 2.48 125,000 3,000 Terms A 10 years December 4, 2017 $ 2.69 1,750,000 20,000 Terms B 10 years January 29, 2018 $ 4.24 – 261,000 Terms A, C 10 years March 12, 2018 $ 3.89 325,000 – Terms A 10 years April 16, 2018 $ 4.27 845,000 61,500 Terms A 10 years June 8, 2018 $ 5.14 – 441,000 Terms A 10 years July 11, 2018 $ 4.89 4,325,000 1,366,500 Terms A 10 years September 17, 2018 $ 7.93 650,000 523,500 Terms A 10 years November 22, 2018 $ 5.92 – 440,000 Terms A 10 years December 17, 2018 $ 5.09 74,000 227,500 Terms A, D 10 years February 19, 2019 $ 7.13 615,000 626,000 Terms A 10 years February 21, 2019 $ 7.46 3,333,333 – Terms E 10 years March 20, 2019 $ 8.50 325,000 1,077,500 Terms A 10 years April 17, 2019 $ 8.24 – 1,132,500 Terms A 10 years July 18, 2019 $ 6.54 650,000 2,768,785 Terms A 10 years July 26, 2019 $ 5.88 250,000 – Terms A 10 years Vesting terms A – One-third of the options will vest on the one-year anniversary of the date of grant and the balance will vest quarterly over two years thereafter. Vesting terms B – Half of the options will vest immediately, and the balance will vest annually over three years thereafter. Vesting terms C – Based upon organizational milestones. Vesting terms D – 54,000 of the options granted to a director will fully vest 6-months from the grant date. Vesting terms E – In addition to the standard vesting terms A, the grant defines an achievement condition in which vesting may only occur once a volume weighted average trading price of $10 or greater is achieved for a 20- day period prior to a vesting date. All unvested options will carry over and vest if the condition is met at a future vesting date. The following table summarizes stock option activity during the fiscal years ended July 31, 2019 and 2018. July 31, 2019 July 31, 2018 Options Weighted average Options Weighted average issued exercise price issued exercise price Opening balance 14,388,066 $ 3.02 5,748,169 $ 0.68 Granted 12,693,118 7.27 10,174,000 4.16 Acquired and reissued through acquisition 1 2,002,365 9.49 – – Forfeited (1,226,763 ) 6.33 (626,830 ) 3.44 Exercised (3,567,867 ) 1.20 (907,273 ) 0.65 Closing balance 24,288,919 $ 5.87 14,388,066 $ 3.02 1 The following table summarizes information concerning stock options outstanding as at July 31, 2019. Weighted average Weighted average remaining contractual remaining contractual Exercise price Number outstanding life (years) Number exercisable life (years) $ 0.58 372,900 0.08 363,000 0.30 0.75 1,228,750 0.34 1,013,750 1.07 1.27 522,620 0.16 322,053 0.37 3.15 4,748 0.00 4,748 0.00 6.00 891,833 0.04 891,833 0.14 1.37 352,866 0.12 82,304 0.10 2.48 86,332 0.03 22,342 0.03 2.69 853,333 0.29 313,335 0.41 4.24 258,000 0.09 122,519 0.16 17.37 253,270 0.04 253,270 0.14 3.89 325,000 0.12 135,418 0.18 16.58 31,659 0.00 15,828 0.00 16.74 56,985 0.00 28,488 0.01 4.27 879,002 0.32 366,852 0.50 16.10 63,319 0.00 63,319 0.00 4.89 5,513,497 2.03 2,046,567 2.87 5.14 107,666 0.04 35,680 0.05 10.42 162,295 0.01 138,549 0.04 10.42 142,467 0.01 71,230 0.02 11.84 44,322 0.00 11,079 0.00 7.93 1,058,500 0.40 – – 8.21 94,979 0.01 23,744 0.01 5.92 310,000 0.12 – – 5.09 276,500 0.11 54,000 0.08 6.94 94,979 0.02 – – 8.84 94,979 0.02 – – 7.13 1,136,000 0.45 – – 7.46 3,333,333 1.31 – – 8.50 1,222,500 0.49 – – 8.24 857,500 0.34 – – 6.54 3,408,785 1.40 – – $ 5.88 250,000 0.10 – – 24,288,919 8.49 6,379,908 6.48 Stock-based Compensation For the year ended July 31, 2019, the Company recorded $28,008 (July 31, 2018 – $4,997) in stock-based compensation expense related to employee options, which are measured at fair value at the date of grant and are expensed over the vesting period (See Note 18 for stock based compensation allocation by expense group). In determining the amount of stock-based compensation, the Company used the Black-Scholes-Merton option pricing model to establish the fair value of options granted by applying the following assumptions: July 31, 2019 July 31, 2018 Exercise price $0.75–$8.95 $1.37–$5.14 Stock price $5.09–$8.50 $1.37–$5.14 Risk-free interest rate 1.54%–2.42% 2.06%-2.37% Expected life of options (years) 5-7 7 Expected annualized volatility 64%–76% 65% Volatility was estimated using the average historical volatility of the Company and comparable companies in the industry that have trading history and volatility history. For the year ended July 31, 2019, the Company allocated to inventory $1,724 (July 31, 2018 – $Nil) of stock-based compensation applicable to direct and indirect labour in the selling and production process.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Jul. 31, 2019
Earnings per share [abstract]
Net Loss per Share	14. Net Loss per Share The following securities could potentially dilute basic net loss per share in the future but have not been included in diluted loss per share because their effect was anti-dilutive: July 31, 2019 July 31, 2018 Options 24,288,919 14,388,066 Warrants issued with $0.75 units – 3,234,960 2015 Secured convertible debentures warrants – 1,318,332 2016 Unsecured convertible debenture warrants – 100,002 2017 Secured convertible debenture warrants 107,136 928,542 2018 Equity warrants 10,512,208 18,570,500 2018 February 2018 financing warrants 4,413,498 – 2019 June financing warrants 2,184,540 – Joint venture and Inner Spirit issued warrants 11,571,235 – Convertible debenture broker/finder warrants 796,791 2,273,168 53,874,327 40,813,570

Convertible Debentures Receivab

Convertible Debentures Receivable	12 Months Ended
	Jul. 31, 2019
Disclosure Of Convertible Note Receivable [Abstract]
Convertible Debentures Receivable	15. Convertible Debentures Receivable 12% CONTERIBLE DEBENTURE On July 26, 2018, the Company purchased $10,000 in the form of unsecured and subordinated convertible debentures to an unrelated entity, Fire and Flower (“F&F”). The convertible debenture bears interest at 8%, paid semi-annually, matures July 31, 2020 and includes a conversion feature to convert the debenture into common shares of F&F at the lower of $1.15 and the share price as defined within the agreement. The Company obtained the debenture as a part of a strategic investment into the private retail cannabis market. The debentures may be converted into common shares or a loan on July 31, 2020, which bears interest at 12%, at the holders option. For the year ended July 31, 2019, the Company’s debenture increased by $1,627 (July 31, 2018 – $Nil) due to fair value adjustments. At period end, the level 2 instrument convertible debenture receivable was fair valued using the F&F July 31, 2019 public market rate of $1.33 and totalled $12,024 (July 31, 2018 – $10,000). Accrued unpaid interest and the unrealized gain amounted to $397 and $1,627 respectively. ZERO INTEREST CONTERIBLE DEBENTURE On February 13, 2019, the Company purchased $800 in the form of unsecured and subordinated convertible debentures to F&F. The convertible debenture bears zero interest and matures November 30, 2019 and includes a conversion feature to convert the debenture into common shares of F&F at $0.80 as defined within the agreement. The debentures may be partially or converted in-full into common shares at the maturity date at the holder’s option. The Company acquired the zero interest convertible debenture through the acquisition of Newstrike on May 24, 2019 which carried a fair value of $1,220. Since acquisition, for the stub period ended July 31, 2019, the Company’s zero interest debenture increased by $110 (July 31, 2018 – $Nil) due to fair value adjustments. At period end, the level 2 instrument convertible debenture receivable was fair valued using the F&F July 31, 2019 public market rate of $1.33 and totalled $1,330 (July 31, 2018 – $Nil).

Term Loan

Term Loan	12 Months Ended
	Jul. 31, 2019
Borrowings [abstract]
Term Loan	16. Term Loan Term Loan On February 15, 2019, the Company entered into a syndicated credit facility with Canadian Imperial Bank of Commerce (“CIBC”) as Sole Bookrunner, Co-Lead Arranger and Administrative Agent and Bank of Montreal as Co-Lead Arranger and Syndication Agent (together “the Lenders”). The Lenders will provide the Company up to $65 million in secured debt financing at a rate of interest that is expected to average in the mid-to-high 5% per annum range. The credit facility consists of a $50 million term loan and a $15 million revolving loan with an uncommitted option to increase the facility up to $135 million. Both loans mature in 2022. The Company may repay the loan without penalty, at any time and contains customary financial and restrictive covenants. The Company shall repay at minimum 2.5% of the outstanding balance each quarter per the terms of the credit facility agreement. The term loan possess several covenants which the Company has met as of July 31, 2019, including maintaining a minimum cash balance of $15,000 up to and including January 31, 2020. On February 14, 2019, the Company received $35,000 and incurred financing costs to secure the loan of $1,347. As of July 31, 2019, the Company has drawn a total of $35,000 on the term loan, of which $3,500 is due within 12 months in according with the terms of the credit facility. Carrying value net of deferred financing costs of total term loan is $33,374. The total interest expense and total interest capitalized was $252 and $511, respectively. The total accretion of deferred financing costs was $387 for the year ended July 31, 2019. The following table illustrates the continuity schedule of the term loan: Term Loan Current Long term July 31, 2018 $ – $ – Term loan Additions – 35,000 Adjustments 3,500 (3,500 ) Repayments (87 ) (788 ) $ 3,413 $ 30,712 Deferred financing costs Additions (296 ) (1,347 ) Adjustments – 296 Realized expense – 596 July 31, 2019 $ 3,117 $ 30,257

Financial Instruments

Financial Instruments	12 Months Ended
	Jul. 31, 2019
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	17. Financial Instruments Market Risk Interest Risk The Company has exposure to interest rate risk related to any investments of surplus cash. The Company may invest surplus cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. The Company also has exposure to interest rate risk related to the outstanding balance of the term loan. The fluctuation of the interest rate may result in a material increase to the associated interest. As at July 31, 2019, the Company had short term investments and a convertible debenture of $517 and a long term loan of $33,374. All interest rates are fixed. An increase or decrease of 5% to the applicable interest rates would not result in a material variance to net loss. Price Risk Price risk is the risk of variability in fair value due to movements in equity or market prices. The Company’s level 1 and 2 investments are susceptible to price risk arising from uncertainties about their future outlook, future values and the impact of market conditions. The fair value of marketable securities and derivatives held in publicly traded entities are based on quoted market prices which the shares of the investments can be exchanged for. If the fair value of these financial assets were to increase or decrease by 10% as of July 31, 2019, the Company would incur an associated increase or decrease in comprehensive loss of approximately $340 (2018 - $Nil). The price risk exposure as at July 31, 2019 is presented in the table below. $ Financial assets 16,756 Financial liabilities (493 ) Total exposure 16,263 Credit Risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company’s trade receivables, promissory note receivable and convertible debenture receivable. As at July 31, 2019, the Company was exposed to credit related losses in the event of non-performance by the counterparties. The Company provides credit to its customers in the normal course of business and has established credit evaluation and monitoring processes to mitigate credit risk. Since the majority of the medical sales are transacted with clients that are covered under various insurance programs, the Company has limited credit risk. Cash, cash equivalents and short-term investments are held by some of the largest cooperative financial groups in Canada. Since the inception of the Company, no losses have been incurred in relation to cash held by the financial institution. The majority of the trade receivables balance are held with crown corporations of Quebec, Ontario and Alberta as well as one of the largest medical insurance companies in Canada. Credit worthiness of a counterparty is evaluated prior to the granting of credit. The Company has estimated the expected credit loss using a lifetime credit loss approach. The current expected credit loss for the year ended July 31, 2019 is $37 (July 31, 2018 - $94). In measuring the expected credit losses, the adult-use cannabis trade receivables have been assessed on a per customer basis as they consist of a low number of material contracts. Medical trade receivables have been assessed collectively as they possess share credit risk characteristics. They have been grouped based on the days past due. Credit risk from the convertible debenture receivable arises from the possibility that principal and/or interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationship. The carrying amount of cash and cash equivalents, restricted cash, short-term investments, trade receivables and convertible debentures receivable represents the maximum exposure to credit risk and as at July 31, 2019; this amounted to $194,902. The following table summarizes the Company’s aging of trade receivables as at July 31, 2019 and 2018: July 31, July 31, 2019 2018 $ $ 0–30 days 14,102 262 31– 60 days 1,826 188 61– 90 days 166 91 Over 90 days 3,599 103 Total 19,693 644 The following table summarizes the Company’s ECL by aging group as at July 31, 2019 and 2018: July 31, July 31, 2019 2018 $ $ 0–30 days 3 - 31– 60 days 7 - 61– 90 days 3 - Over 90 days 24 94 Total 37 94 Economic Dependence Risk Economic dependence risk is the risk of reliance upon a select number of customers which significantly impact the financial performance of the Company. The Company recorded sales from three crown corporations representing 81% (July 31, 2018 – Nil%) of total sales in the year ended July 31, 2019. The Company holds trade receivables from three crown corporations representing 79% of total trade receivables as of July 31, 2019 (July 31, 2018 – Nil%). Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by reviewing on an ongoing basis its capital requirements. As at July 31, 2019, the Company had $139,505 of cash and cash equivalents and short-term investments. The Company is obligated to pay accounts payable and accrued liabilities, excise taxes payable and current portions of the term loan with total carrying amounts and contractual cash flows amounting to $52,685 due in the next 12 months. The carrying values of cash, trade receivable, accounts payable and accrued liabilities approximate their fair values due to their short term to maturity. The carrying value of the term loan approximates its fair value as there has been no change the Company’s risk profile and no changes to the market interest rate.

Operating Expenses by Nature

Operating Expenses by Nature	12 Months Ended
	Jul. 31, 2019
Expenses by nature [abstract]
Operating Expenses by Nature	18. Operating Expenses by Nature For the years ended July 31, 2019 July 31, 2018 Stock based compensation $ 28,008 $ 4,997 Marketing and promotion 22,308 2,447 Salaries and benefits 25,349 6,992 Consulting 11,176 3,659 Professional fees 8,258 1,761 Facilities 5,697 919 General and administrative 4,462 1,442 Travel 2,710 488 Amortization of intangible assets 1,767 765 Depreciation of property, plant and equipment 1,747 896 Total $ 111,482 $ 24,367 The following table summarizes the nature of stock based compensation in the period: For the year ended July 31, 2019 General and administrative related stock -based compensation $ 26,322 Marketing and promotion related stock -based compensation 1,686 Total operating expense related stock-based compensation 28,008 Stock based compensation capitalized to inventory 1,724 Total stock-based compensation $ 29,732 The following table summarizes the total payroll related wages and benefits by nature in the period: For the year ended July 31, 2019 General and administrative related wages and benefits $ 17,975 Marketing and promotion related wages and benefits 6,162 Research and development related wages and benefits 1,212 Total operating expense related wages and benefits 25,349 Wages and benefits capitalized through cost of sales 10,905 Total wages and benefits in the period $ 36,254

Investment in Associate and Joi

Investment in Associate and Joint Ventures	12 Months Ended
	Jul. 31, 2019
Disclosure Of Associate And Joint Ventures [Abstract]
Investment in Associate and Joint Ventures	19. Investment in Associate and Joint Ventures The following is a summary of financial information for the Company’s joint ventures for the periods presented based on the latest publicly available information. Note that the numbers have not been pro-rated for the Company’s ownership interest. Truss Belleville Complex Inc HEXO MED Period July 31, 2019 July 31, 2019 July 31, 2019 Statement of Financial Position $ $ $ Cash and cash equivalents 14,318 278 542 Current assets 5,701 2,604 59 Non- current assets 7,880 19,906 22 Current liabilities 7,477 1,155 26 Non-current labilities – 21,909 – Period 11 months ended July 31, 2019 August 21, 2018 to July 31, 2019 December 22, 2018 to July 31, 2019 Statement of Comprehensive Loss Revenue – 4,018 – Operating expenses excluding depreciation and amortization (6,579 ) (3,716 ) – Depreciation and amortization – (578 ) – Other expenses – – (503 ) Loss from operations (6,579 ) (276 ) (503 ) Income tax expenses – – – Total comprehensive loss (6,579 ) (276 ) (503 ) (a) Truss – Investment in Associate July 31, 2019 July 31, 2018 Opening Balance $ – $ – Cash consideration of investment 11,476 – Fair value of warrant consideration 42,386 – Capitalized transaction costs 721 – Share of net loss (2,796 ) – Ending Balance $ 51,786 $ – On October 4, 2018, the formation of the entity Truss between the Company and Molson Coors Canada (the “Partner”) was finalized. Truss is a standalone start-up company with its own board of directors and an independent management team and is incorporated in Canada. Truss is private company and its principle activities consist of pursuing opportunities to develop non-alcoholic, cannabis-infused beverages and is currently operating in Gatineau, Quebec. The Partner holds 57,500 common shares representing 57.5% controlling interest in Truss with the Company holding 42,500 common shares and controlling the remaining 42.5% . In connection with the transaction the Company has granted the Partner 11,500,000 common share warrants at an exercise price of $6.00 for a period of 3 years. Included in the initial investment cost is the capitalized fair value $42,386 of warrant consideration (see Note 11 for fair value inputs and assumptions). Transaction costs of $721 in respect to the definitive agreement to form the joint venture were capitalized. The joint venture is accounted for using the equity method. During the year ended July 31, 2019, the Company’s share in the net loss of Truss was ($2,796) (July 31, 2018 – $Nil). (b) Belleville Complex Inc - Joint Venture On October 31, 2018, the Company acquired a 25% interest in the joint venture Belleville Complex Inc. (“BCI”) with a related party Olegna Holdings Inc., owned and controlled by a director of the Company, holding the remaining 75% in BCI. The joint venture purchased a configured 1.5 million sq. ft. facility through a $20,279 loan issued by the Company on September 7, 2018, bearing an annual 4% interest rate and interest payable monthly. The loan and all remaining accrued interest were repaid in full during the period and interest income of $454 was realized. As a part of the agreement, the Company will be the anchor tenant for a period of 20 years. Consideration for the 25% interest on the joint venture is deemed $Nil. The carrying value of BCI as at July 31, 2019 is $Nil (July 31, 2018 - $Nil). (c) HEXO MED - Joint Venture July 31, 2019 July 31, 2018 Opening Balance $ – $ – Cash consideration of investment 1,106 – Capitalized transaction costs 125 Share of net loss (168 ) – Ending Balance $ 1,063 $ – HEXO MED is a Greece based joint venture established with partner QNBS P.C. (formerly Qannabos) and will serve as the Company’s entry point into the European medical cannabis markets. During the fiscal year 2019, the Company contributed a total of EUR$250 for a 33.34% interest in HEXO MED in cash. As of July 31, 2019, the Company has also accrued an additional EUR$500 per the terms of the shareholders agreement. Once remitted, the Company’s interest will increase to 51% (see Note 32). The carrying value of HEXO MED as at July 31, 2019 is $1,063 (July 31, 2018 - $Nil).

Long-term Investments

Long-term Investments	12 Months Ended
	Jul. 31, 2019
Disclosure Of Long Term Investment Abstract
Long-term Investments	20. Long-term Investments Cost July 31, 2018 Fair value July 31, 2018 Investment Divesture/ Transfer Subtotal July 31, 2019 Change in fair value Fair value July 31, 2019 $ $ $ $ $ $ $ Level 1 Investments Fire & Flower Inc. common shares – – 2,970 (2,493 ) 477 (477 ) – Fire & Flower Inc. common share purchase warrants 1 – – 505 (262 ) 243 (243 ) – Inner Spirit common shares 1 – – 2,850 – 2,850 150 3,000 Level 2 Investments Inner Spirit common share purchase warrants 1 – – 414 – 414 (11 ) 403 Level 3 Investments Greentank Technologies 1 – – 6,723 – 6,723 (149 ) 6,574 Neal Brothers Inc. 1 – – 4,000 – 4,000 – 4,000 Segra International Corp. – 100 – – 100 200 300 Total – 100 17,462 2,755 14,807 (530 ) 14,277 1 Fire & Flower Inc. Common Shares On November 1, 2018, the Company obtained 1,980,000 subscription receipts in the entity F&F for proceeds of $2,970. The subscription receipts converted to common shares of F&F at a 1:1 ratio on February 19, 2019 upon the commencement of trading on the TSX Venture and held an initial fair value of $2,970. On July 25, 2019, the Company liquidated the investment in full resulting in a cash injection net of fees of $2,493. The Level 1 long term investment and associated realized loss as at July 30, 2019, were $Nil and ($477), respectively. Common Share Purchase Warrants On May 24, 2019, through the acquisition of Newstrike, the Company obtained 1,000,000 common share purchase warrants in the entity F&F. Each warrant entitles the Company to a common share at a ratio of 1:1. The warrants held an initial fair value of $505. The investment was fair valued through the Black Scholes-Merton model at $243 and disposed of as at July 30, 2019. The Company realized a loss of ($243) as at July 30, 2019 based upon the following assumptions and inputs: • market price of $1.33; • expected life of 0.70 year; • $Nil dividends; • 100% volatility based upon comparative market indicators and historical data; • risk free interest rate of 1.46%. Inner Spirit Holding Inc. Common Shares On May 24, 2019, through the acquisition of Newstrike, the Company obtained 15,000,000 common shares in the entity Inner Spirit Holdings Inc. which held a fair value of $2,850. The investment held an unrealized gain of $150 as at July 31, 2019 based upon the market price of $0.20 per common share. Common Share Purchase Warrants On May 24, 2019, through the acquisition of Newstrike, the Company obtained 7,500,000 common share purchase warrants in the entity Inner Spirit Holdings Inc. Each warrant entitles the Company to a common share at a ratio of 1:1. The warrants held an initial fair value of $414. The investment was fair valued through the Black Scholes-Merton model and held an unrealized loss of ($11) as at July 31, 2019 based upon the following assumptions and inputs: • market price of $0.20; • expected life of 1.00 year; • $Nil dividends; • 100% volatility based upon comparative market indicators and historical data; • risk free interest rate of 1.48%. Greentank Technologies. On February 22, 2019, Newstrike acquired 1,953,125 preferred shares of Greentank Technologies for cash consideration of $6,622 (USD$5,000). The investment is strategic and long term in nature. The investments initial fair value upon the acquisition of Newstrike was $6,723 and is measured through fair value through profit and loss. The fair value was established using the information from a recent financing which demonstrates the same underlying preferred share value as the original investment consideration. During the stub period ended July 31, 2019, there was a decrease in fair value of $149 due to a reduction of CAD/USD rate (July 31, 2018 - $Nil). A variance of 5% to the underlying preferred share price would result in a change of $331 to the investments fair value. Neal Brothers Inc. The Company also acquired 19.9% of the shares of Neal Brothers Inc. through the acquisition of Newstrike on May 24, 2019. The Company holds no board seat. The initial investment was for cash consideration of $5,604. The Company has measured these investments at fair value upon the date of acquisition which was determined to be $4,000. During the stub period ended July 31, 2019, there was no change in fair value (July 31, 2018 - $Nil). A variance of 5% to the underlying investment would result in a change of $200 to the investments fair value. Segra International Corp. The Company holds 400,000 shares in the private entity Segra International Corp. The investment represents a strategic long term investment in the cannabis micropropogation entity. The initial investment was made for $0.25 per share. The Company has measured this investment to its fair value of $0.75 per share which totalled $300 as at July 31, 2019 (July 31, 2018 – $100). The fair value measurement was based upon the most recent financing information and the associated unrealized gain of $200 (July 31, 2018 - $Nil) was recorded through profit and loss. A variance of 5% to the underlying share price would result in a nominal change to the investments fair value.

Related Party Disclosure

Related Party Disclosure	12 Months Ended
	Jul. 31, 2019
Disclosure of transactions between related parties [abstract]
Related Party Disclosure	21. Related Party Disclosure Key Management Personnel Compensation Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the Company’s operations, directly or indirectly. The key management personnel of the Company are the members of the executive management team and Board of Directors, and they control approximately 6.15% of the outstanding shares of the Company as at July 31, 2019 (July 31, 2018 – 8.77%) . Compensation provided to key management during the period was as follows: For the years ended July 31, 2019 July 31, 2018 Salary and/or consulting fees $ 3,550 $ 1,969 Bonus compensation 481 275 Stock-based compensation 16,235 3,836 Total $ 20,266 $ 6,080 These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed by the related parties. Unless otherwise stated the below granted stock options will vest on the one-year anniversary of the date of grant and the balance will vest quarterly over two years thereafter. On July 26, 2019, the Company granted certain of its executives a total 250,000 stock options with an exercise price of $5.88 On July 18, 2019, the Company granted certain of its executives a total 650,000 stock options with an exercise price of $6.54. On March 20, 2019, the Company granted certain of its executives a total 325,000 stock options with an exercise price of $8.50. On February 21, 2019, the Company granted the CEO 3,333,333 stock options with an exercise price of $7.46. Additional to the standard vesting terms as defined in Note 11, is an achievement condition in which vesting may only occur once a volume weighted average trading price of $10 or greater is achieved for a 20-day period prior to a vesting date. All unvested options will carry over and vest if the condition is met at a future vesting date. On February 19, 2019, the Company granted certain of its executives a total 615,000 stock options with an exercise price of $7.13. On December 17, 2018, the Company granted certain of its executives a total 74,000 stock options with an exercise price of $5.09. Of which, 54,000 stock options will fully vest at the 6-month anniversary of the grant date. On September 17, 2018, the Company granted certain executives of the Company a total of 650,000 stock options with an exercise price of $7.93. On July 11, 2018, the Company granted certain directors and executives of the Company a total of 4,325,000 stock options with an exercise price of $4.89. Within the grant there exist 350,000 stock option which fully vest on April 30, 2019. On April 16, 2018, the Company granted certain directors and executives of the Company a total of 845,000 stock options with an exercise price of $4.27. On March 12, 2018, the Company granted certain directors and executives of the Company a total of 325,000 stock options with an exercise price of $3.89. On December 4, 2017, the Company granted certain directors and executives of the Company a total of 1,750,000 stock options with an exercise price of $2.69, of which half of the options will vest immediately, and the balance will vest annually over three years thereafter with the exception of 75,000 stock options which vest in full by April 30, 2019. On November 6, 2017, the Company granted certain directors of the Company a total of 125,000 stock options with an exercise price of $2.48. On September 8, 2017, the Company granted certain executives of the Company a total of 650,000 stock options with an exercise price of $1.37. The Company loaned $20,279 on September 7, 2018, to the related party BCI to be used in the purchase of a facility in Belleville, Ontario and was repaid in full during the third quarter of fiscal 2019.

Capital Management (Restated -

Capital Management (Restated - see note 34)	12 Months Ended
	Jul. 31, 2019
Disclosure Of Capital Management [Abstract]
Capital Management	22. Capital Management (Restated – see note 34 The Company’s objective is to maintain sufficient capital so as to maintain investor, creditor and customer confidence and to sustain future development of the business and provide the ability to continue as a going concern. Management defines capital as the Company’s shareholders’ equity. The Board of Directors does not establish quantitative return on capital criteria for management. The Company has not paid any dividends to its shareholders. The Company is not subject to any externally imposed capital requirements. As at July 31, 2019 total managed capital was comprised of shareholders’ equity of $788,712 (July 31, 2018 – $322,873). There were no changes in the Company’s approach to capital management during the period.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jul. 31, 2019
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and Contingencies	23. Commitments and Contingencies COMMITMENTS The Company has certain contractual financial obligations related to service agreements, purchase agreements, rental agreements and construction contracts. Some of these contracts have optional renewal terms that the Company may exercise at its option. The annual minimum payments payable under these obligations over the next five years is as follows: 2020 $ 93,647 2021 7,332 2022 5,804 2023 5,259 2024 4,970 Thereafter 75,218 $ 192,230 Inclusive of the commitments balance is $99,652 related to the Belleville Complex Inc 20-year anchor tenant agreement ending September 7, 2038 (Note 17) and additional lease commitments amounting to $2,089. The following table summarizes the Company’s proportionate share of the annual minimum payments and commitments held by its investment in associate and joint ventures. 2020 $ 26,962 2021 1,794 2022 26 2023 26 2024 27 $ 28,835 Letter of Credit On June 28, 2018, the Company executed a letter of credit with a Canadian credit union as required under an agreement with a public utility provider entitling the Company up to a maximum limit of $3,141 subject to certain operational requirements. The letter of credit has a one-year expiry from the date of issuance with an autorenewal feature and was still in effect as at July 31, 2019. The credit facility is secured by a guaranteed investment certificate (“GIC”). As at July 31, 2019, the letter of credit has not been drawn upon (July 31, 2018 – $Nil) and is in compliance with the specified requirements. Surety Bond On June 28, 2018, the Company entered into an indemnity agreement to obtain a commercial surety bond with a North American insurance provider entitling the Company up to a maximum of $2,000. The bond bears a premium at 0.1% annually. The Company obtained the surety bond as required under the Canada Revenue Agency’s excise tax laws for the transporting of commercial goods throughout Canada. CONTINGENCIES The Company may be, from time to time, subject to various administrative and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Jul. 31, 2019
Disclosure Of Fair Value Of Financial Instruments Explanatory [Abstract]
Fair Value of Financial Instruments	24. Fair Value of Financial Instruments The carrying values of the financial instruments as at July 31, 2019 are summarized in the following table: Financial assets Financial liabilities Amortized designated as designated Note costs FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 4 – 113,568 – 113,568 Restricted cash 5 – 22,350 – 22,350 Short-term investments 4 – 25,937 – 25,937 Trade receivables 19,693 – – 19,693 Commodity taxes recoverable and other receivables 6 15,247 – – 15,247 Convertible debenture receivable 15 – 13,354 – 13,354 Long term investments 20 – 14,277 – 14,277 Liabilities $ $ $ $ Accounts payable and accrued liabilities 45,581 – – 45,581 Warrant liability 12 – – 493 493 Deferred rent liability 946 – – 946 Term loan 16 33,374 – – 33,374 The carrying values of trade receivables, accounts payable, accrued liabilities and the term loan approximate their fair values due to their relatively short periods to maturity. The carrying values of the financial instruments as at July 31, 2018 are summarized in the following table: Financial assets Financial liabilities Amortized designated as designated Note costs FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 4, 26 – 99,042 – 99,042 Short-term investments 4, 26 – 145,747 – 145,747 Trade receivables 644 – – 644 Commodity taxes recoverable and 6 4,237 – – 4,237 other receivables Convertible debenture receivable 15 – 10,000 – 10,000 Liabilities $ $ $ $ Accounts payable and accrued liabilities 8,995 – – 8,995 Warrant liability 12 – – 3,130 3,130

Ancillary Revenue

Ancillary Revenue	12 Months Ended
	Jul. 31, 2019
Disclosure Of Ancillary Revenue [Abstract]
Ancillary Revenue	25. Ancillary Revenue Ancillary revenues are those sales outside of the primary business of the Company as outlined in Note 1. During the year ended July 31, 2019 the Company realized net revenues of $199 (July 31, 2018 – $Nil) related to management fees.

Comparative Amounts

Comparative Amounts	12 Months Ended
	Jul. 31, 2019
Disclosure Of Comparative Amounts [Abstract]
Comparative Amounts	26. Comparative Amounts The Company has identified no errors or required changes to the comparative period’s information.

License and Prepaid Royalty - H

License and Prepaid Royalty - HIP	12 Months Ended
	Jul. 31, 2019
License And Prepaid Royalty [Abstract]
License and Prepaid Royalty - HIP	27. License and Prepaid Royalty – HIP On May 24, 2019, through the acquisition of Newstrike, the Company inherited a royalty agreement with the Tragically Hip (the “Hip Agreement”) with an effective date of January 12, 2017, expiring after five years with an option of renewal for a two-year period. Newstrike’s initial consideration was 3,000,000 common shares with an initial fair value of $2,655 and an ongoing royalty of 2.5% of revenues of cannabis products sold by the Company inspired by the Tragically Hip. The issuance of the 3,000,000 common shares includes a payment of 1,000,000 common shares that will be applied against future royalties’ payable. The fair value of the license and prepaid asset as at the acquisition date of May 24, 2019 was $926 and $600, respectively. During the stub period ended July 31, 2019, the Company recorded amortization of $59 using the straight-line method over a five-year term from the effective date of the License, and $58 was drawn down on the prepaid royalty. July 31, 2019 July 31, 2018 License – HIP, net of amortization $ 867 $ – Prepaid Royalty – HIP 542 – License and prepaid royalty – HIP $ 1,409 $ –

Non-Controlling Interest

Non-Controlling Interest	12 Months Ended
	Jul. 31, 2019
Non Controlling Interest [Abstract]
Non-Controlling Interest	28. Non-Controlling Interest The following table summarizes the information relating to the Company’s subsidiary Neal Up Brands Inc., before intercompany eliminations. July 31, 2019 July 31, 2018 Current assets $ 2,500 $ – Non-current assets – – Current liabilities – – Non-current liabilities – – Net assets 2,500 – Non-controlling interest (%) 40% Non-controlling interest $ 1,000 $ –

Income Taxes (Restated)

Income Taxes (Restated)	12 Months Ended
	Jul. 31, 2019
Income taxes paid (refund) [abstract]
Income Taxes	29. Income Taxes (Restated) Income tax expense recognized in comprehensive loss consists of the following components: July 31, 2019 July 31, 2018 Current tax for the year $ – $ – Adjustments of previous years – – Total $ – $ – Components of deferred income tax expense (recovery): July 31, 2019 July 31, 2018 Origination and reversal of temporary differences $ (13,007 ) $ (6,780 ) Difference between statutory tax rate and deferred tax rate 172 (7 ) Change in temporary difference for which no deferred tax assets are recorded (5,377 ) 6,787 Deferred income tax recovery $ (18,213 ) $ – The Company's expected tax rate is different from the combined federal and provincial income tax rate in Canada. These differences result from the following elements: July 31, 2019 July 31, 2018 Expected tax rate 26.64% 26.9% Earnings before income taxes $ (87,281 ) $ (23,350 ) Expected tax benefit resulting from loss (23,252 ) (6,281 ) Adjustments for the following items: Tax rate differences 172 (7 ) Permanent differences 9,973 3,095 Change in temporary differences for which no tax assets are recorded (5,770 ) 2,401 True up and other 664 792 $ (18,213 ) $ – The following is a reconciliation of the deferred tax assets and liabilities recognized by the Company: Opening Recognized in Recognized in Ending August 1, 2018 income goodwill July 31, 2019 $ $ $ $ Taxable temporary differences (117 ) 7,195 (200 ) 6,858 Biological assets (458 ) (764 ) (292 ) (1,514 ) Inventory (1,432 ) (930 ) (559 ) (2,920 ) Loss carryforward 2,007 14,058 7,304 23,369 Share issue costs – (1,003 ) 1,724 721 Intangible assets – (344 ) (32,193 ) (32,537 ) Net deferred tax asset (liability) – 18,212 (24,236 ) (6,023 ) Opening Recognized in Recognized in Ending August Income Equity/OCI July 31, 2018 $ $ $ $ Deferred tax assets 813 – (813 ) – Taxable temporary differences – (117 ) – (117 ) Biological assets – (458 ) – (458 ) Inventory – (1,432 ) – (1,432 ) Loss carryforward – 2,007 – 2,007 Revaluation of financial instruments - Equity (813 ) – 813 – Net deferred tax asset (liability) – – – – Deferred income taxes reflect the impact of loss carryforwards and of temporary differences between amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws. At July 31, 2019 deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized are attributable to the following: July 31, 2019 July 31, 2018 $ $ Losses carried forward 5,898 20,672 Research and development expenditures 266 266 Fixed Assets - – Share issue costs 8,612 13,352 14,776 34,289 The Company has approximated non-capital losses available to reduce future years' federal and provincial taxable income which expires as follows: $ 2024 187 2025 199 2026 279 2027 236 2028 257 2029 205 2030 172 2031 338 2032 726 2033 384 2034 1,495 2035 3,774 2036 6,165 2037 10,836 2038 30,812 2039 52,910 108,975

Loss on Investment

Loss on Investment	12 Months Ended
	Jul. 31, 2019
Disclosure Of Loss On Investment [Abstract]
Loss on Investment	30. Loss on Investment During the fiscal year ended July 31, 2018, the Company realized a loss on investment activities in the amount of $650. The Company continues to take legal action to recover the loss.

Gross Revenue

Gross Revenue	12 Months Ended
	Jul. 31, 2019
Revenue [abstract]
Gross Revenue	31. Gross Revenue Year ended July 31, 2019 July 31, 2018 Gross Cannabis Revenue $ $ Retail 53,590 – Medical 5,288 4,934 Wholesale 378 – Total gross revenue from sale of goods 59,256 4,934 Gross revenue is inclusive of sales returns and recoveries. During the fiscal year ended July 31, 2019, the Company incurred $6,718 (July 31, 2018 - $Nil) of sales provisions.

Segmented Information

Segmented Information	12 Months Ended
	Jul. 31, 2019
Disclosure of operating segments [abstract]
Segmented Information	32. Segmented Information The Company operates in one operating segment. All property, plant and equipment and intangible assets are located in Canada.

Subsequent Events

Subsequent Events	12 Months Ended
	Jul. 31, 2019
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent Events	33. Subsequent Events Amalgamation of Subsidiaries On August 1, 2019, the Company completed the amalgamation of the subsidiaries 8980268 Canada Inc and Newstrike Brands Ltd into HEXO Operations Inc. The resulting entity retained the name HEXO Corp. Letter of Credit On August 2, 2019, the Company amendedthe letter of credit (Note 23) that was issued in favor of a public utility provider. The amount of the letter was reduced to $2,581 from $3,142. This amended letter is secured against the company’s revolving loan and no longer secured by a GIC. Increased Ownership in HEXO MED On September 24, 2019, the Company increased its ownership in its European based joint venture HEXO MED from 33.3% to 51% which an additional capital injection of $729. $70 Million Private Placement On October 23, 2019, the Company announced it has entered into subscription agreements with a group of investors pursuant to which the investors have agreed to purchase, on a private placement basis, $70,001 principal amount of 8.0% unsecured debentures of the Company (the “Debentures”). The Debentures will bear interest from the date of closing at 8.0% per annum payable quarterly and will mature on the date which is three years from issuance. Following the date, which is one year from issuance, the Debentures will be convertible at the option of the holder into common shares of the Company at any time prior to maturity at a conversion price of $3.16 per share (the “Conversion Price”), subject to adjustment in certain events. Beginning on the date which is one year from issuance, the Company may force the conversion of all of the principal amount of the then outstanding Debentures at the Conversion Price on not less than 30 days’ notice should the daily volume weighted average trading price of the common shares of the Company be greater than $7.50 for any 15 consecutive trading days. At any time on or before the date which is one year from issuance, the Company may repay all, but not less than all, of the principal amount of the Debentures, plus accrued and unpaid interest. Upon any repayment of the principal amount of the Debentures, the Company shall have the right to satisfy the repayment of the principal amount, together with all accrued and unpaid interest thereon, through the conversion of such amounts into common shares of the Company at the Conversion Price. Upon a change of control of the Company, holders of the Debentures will have the right to require the Company to repurchase their Debentures, in whole or in part, on the date that is 30 days following the giving of notice of the change of control, at a price equal to 115% of the principal amount of the Convertible Debentures then outstanding plus accrued and unpaid interest thereon (the “Offer Price”). If 90% or more of the principal amount of the Convertible Debentures outstanding on the date of the notice of the change of control have been tendered for redemption, the Company will have the right to redeem all of the remaining Debentures at the Offer Price. The Debentures and any common shares of the Company issuable upon conversion thereof will be subject to a statutory hold period lasting four months and one day following the closing date. The Company intends to use the net proceeds of the private placement for working capital and general corporate purposes. Closing of the Offering is expected to occur on or about November 15, 2019. The private placement is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approvals of the Toronto Stock Exchange and the New York Stock Exchange.

Correction of Errors

Correction of Errors	12 Months Ended
	Jul. 31, 2019
Correction Of Errors [Abstract]
Correction of Errors	34. Correction of Errors Subsequent to the original issuance of these consolidated financial statements, management determined that the Company determined that the deferred tax liability was overstated as at July 31, 2019, as it was not offset by a deferred tax asset relating to a tax loss generated in one subsidiary against a deferred tax liability generated by a separate subsidiary. Due to the two tax positions existing in two separate entities, the Company’s original position was that they could not be offset or reduce one another. The applicable subsidiaries were amalgamated on August 1, 2019. The correction of this error resulted in a reduction of the deferred tax liability and deficit, by $14,373, as at July 31, 2019. Additionally, net loss for the year ended July 31, 2019 was overstated by $14,373. These corrections are noted in the ‘Corrections’ column in the following tables. As guided under IAS 12.67, the Company has netted the applicable portion of the deferred tax liability against the deferred tax asset resulting in the stated correction of this error in the following tables. In assessing the financial impact of subsequent events, the Company also determined additional write-down of its cannabis trim based inventory based on the estimated fair market value due to new and available third party information resulting in an increased impairment loss on inventory of $2,417. These corrections are noted in the ‘Adjustments’ column in the following tables. Line items on the restated consolidated statement of financial position at: July 31, 2019 Previously reported Correction Adjustments As restated ASSETS $ $ $ $ Inventory 86,271 - (2,417 ) 83,854 Current assets 314,553 - (2,417 ) 312,136 Total Assets 881,040 - (2,417 ) 878,623 LIABILITIES Deferred tax liability 20,396 (14,373 ) - 6,023 Total Liabilities 104,284 (14,373 ) - 89,911 SHAREHOLDER'S EQUITY Deficit (124,698 ) 14,373 (2,417 ) (112,742 ) Total shareholder's equity 776,756 14,373 (2,417 ) 788,712 Line items on the restated consolidated statement of loss and comprehensive loss at: Fiscal year ended July 31, 2019 Previously reported Correction Adjustments As restated $ $ $ $ Impairment loss on inventory 16,918 - 2,417 19,335 Gross margin 26,925 - (2,417 ) 24,508 Loss from operations (84,557 ) - (2,417 ) (86,974 ) Net loss and comprehensive loss attributable to shareholders before tax recovery (85,404 ) - (2,417 ) (87,821 ) Tax recovery 3,840 14,373 - 18,213 Total net loss (81,564 ) 14,373 (2,417 ) (69,608 ) Total net loss per share, basic and diluted (0.38 ) 0.06 (0.01 ) (0.33 ) Line items on the restated consolidated statement of changes in shareholder's equity at: July 31, 2019 Previously reported Correction Adjustments As restated $ $ $ $ Total net loss (81,564 ) 14,373 (2,417 ) (69,608 ) Deficit as at July 31, 2019 (124,698 ) 14,373 (2,417 ) (112,742 ) Shareholder's equity as at July 31, 2019 776,756 14,373 (2,417 ) 788,712 Line items on the restated consolidated statements of cash flows at: July 31, 2019 Previously reported Correction Adjustments As restated $ $ $ $ OPERATING ACTIVITIES Total net loss (81,564 ) 14,373 (2,417 ) (69,608 ) Tax recoveries (3,840 ) (14,373 ) - (18,213 ) Impairment loss on inventory 16,918 - 2,417 19,335 Total operating activities (124,706 ) - - (124,706 ) There has been no impact to the July 31, 2018 consolidated financial statements or any other financial statements and as such no opening balance sheet has been presented.

Significant Accounting Polici_2

Significant Accounting Policies, Accounting Standards and Interpretations (Policies)	12 Months Ended
	Jul. 31, 2019
Significant Accounting Policies [Abstract]
FOREIGN CURRENCY TRANSLATION	FOREIGN CURRENCY TRANSLATION Foreign currency transactions are translated into Canadian dollars at exchange rates in effect on the date of the transactions. Monetary assets and liabilities denominated in foreign currencies at the consolidated statement of financial position date are translated to Canadian dollars at the foreign exchange rate applicable at that date. Realized and unrealized exchange gains and losses are recognized through profit or loss. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.
CASH AND CASH EQUIVALENTS	CASH AND CASH EQUIVALENTS Cash and cash equivalents are comprised of cash and highly liquid investments that are readily convertibles into known amounts of cash with original maturities of three months or less.
SHORT TERM INVESTMENTS	SHORT TERM INVESTMENTS Short term investments are comprised of liquid investments with maturities between 3 and 12 months. Short term investments are recognized initially at fair value and subsequently adjusted to fair value through profit or loss.
BIOLOGICAL ASSETS	BIOLOGICAL ASSETS The Company measures biological assets consisting of cannabis plants using the income approach at fair value less costs to sell up to the point of harvest, which becomes the basis for the cost of finished goods inventories after harvest. The Company capitalizes all the direct and indirect costs as incurred related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest including labour related costs, grow consumables, materials, utilities, facilities costs, depreciation, overhead, stock-based compensation of applicable employees, quality and testing costs. The identified capitalized direct and indirect costs of biological assets are subsequently recorded within the line item ‘costs of goods sold’ on the statement of loss and comprehensive loss in the period that the related product is sold. Seeds are measured at fair value. Unrealized gains or losses arising from changes in fair value less cost to sell during the period are included in the results of operations and presented on a separate line of statement of comprehensive loss of the related period.
INVENTORY	INVENTORY Inventory is valued at the lower of cost and net realizable value. Cost is determined using the weighted average method. Inventories of harvested cannabis are transferred from biological assets at their fair value at harvest, which becomes the initial deemed cost of the inventory. Any subsequent post-harvest costs are capitalized to inventory to the extent that cost is less than net realizable value. Subsequent costs include materials, overhead, amortization, stock-based compensation of applicable employees and labour involved in packaging and quality assurance. The identified capitalized direct and indirect costs related to inventory are subsequently recorded within ‘cost of goods sold’ on the statement of loss and comprehensive loss at the time the product is sold, with the exclusion of realized fair value amounts included in inventory sold which are recorded as a separate line within gross margin. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Packaging and supplies are initially valued at cost and subsequently at the lower of cost and net realizable value.
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment is measured at cost less accumulated amortization and impairment losses. Amortization is provided using the following terms and method: Land Not amortized No term Buildings Straight line 5 to 20 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years Construction in progress Not amortized No term An asset’s residual value, useful life and amortization method are reviewed at each financial year and adjusted if appropriate. When parts of an item of equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of equipment are determined by comparing the proceeds from disposal with the carrying amount of the equipment and are recognized in profit or loss. Construction in progress is transferred to property, plant and equipment when the assets are available for use and amortization of the assets commences at that point.
FINITE LIFE INTANGIBLE ASSETS	FINITE LIFE INTANGIBLE ASSETS Finite life intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over the following terms: Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3 to 5 years Patents Straight line 20 years The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.
INDEFINITE INTANGIBLE ASSETS	INDEFINITE INTANGIBLE ASSETS Indefinite intangible assets are deemed to have no foreseeable limit over which the asset is expected to generate net cash inflows. Following initial recognition, intangible assets with indefinite useful lives are carried at cost less any accumulated impairment losses and are tested annually for impairment, or more frequently if events or changes in circumstances indicate that they might be impaired. Brand Not amortized Indefinite
INVESTMENT IN ASSOCIATE	INVESTMENT IN ASSOCIATE Associates are entities over which the Company has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence represents the power to participate in the financial and operating policy decisions of the investee but does not represent the right to exercise control or joint control over those policies. A joint venture is a contractual arrangement whereby the Company and other parties undertake an economic activity that is subject to joint control (i.e. when the strategic, financial and operating policy decisions relating to the activities of the joint venture require the unanimous consent of the parties sharing control). Investments in associates and joint ventures are accounted for using the equity method and are initially recognized at cost inclusive of transaction costs.
IMPAIRMENT OF LONG-LIVED ASSETS	IMPAIRMENT OF LONG-LIVED ASSETS Long-lived assets, including property, plant and equipment, goodwill and intangible assets are reviewed for impairment at the end of each financial reporting period or whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds its recoverable amount. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the cash-generating unit, or "CGU"). The recoverable amount of an asset or a CGU is the higher of its fair value, less costs of disposal, and its value in use. If the carrying amount The Company assesses impairment of property, plant and equipment when an impairment indicator arises. When the asset does not generate cash inflows that are largely independent of those from other assets or group of assets, the asset is tested at the CGU level. In assessing an impairment, the Company compares the carrying amount of the asset or CGU to the recoverable amount, which is determined as the higher of the asset or CGU’s fair value less costs of disposal and its value-in-use. Value-in-use is assessed based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects applicable market and economic conditions, the time value of money and the risks specific to the asset. Goodwill and indefinite life intangible assets are tested annually and the end of the fiscal year for impairment by comparing the carrying value of each CGU containing the assets to its recoverable amount. Goodwill is allocated to CGUs or groups of CGU’s for impairment testing based on the level at which it is monitored by management, and not at a level higher than an operating segment. Operating segments are components of the Company that engage in business activities which generate revenues and incur expenses. Goodwill is allocated to those CGUs or groups of CGUs expected to benefit from the business combination from which the goodwill arose, which requires the use of judgment. An impairment loss is recognized for the amount by which the CGU’s carrying amount exceeds its recoverable amount. The recoverable amounts of the CGU’s assets have been determined based on its fair value less costs of disposal. Impairment losses recognized in respect of a CGU are first allocated to the carrying value of goodwill and any excess is allocated to the carrying value of assets in the CGU. In allocating a reversal of an impairment loss, the carrying amount of an asset shall not be increased above the lower of its recoverable amount and the carrying amount that would have been determined had no impairment loss been recognized for the asset in prior period. Impairment losses on goodwill are not subsequently reversed. Impairment losses are recognized whenever the carrying amount of the asset or CGU exceeds its recoverable amount and is recorded in the consolidated statements of comprehensive (loss) income.
GOODWILL	GOODWILL Goodwill represents the excess of the purchase price paid for the acquisition of the Company’s subsidiary Newstrike over the fair value of the net tangible and intangible assets acquired. Following initial recognition, goodwill is measured at cost less any accumulated impairment losses. Goodwill is tested for impairment annually, and whenever events or circumstances that make it more likely than not that an impairment may have occurred, such as a significant adverse change in the business climate or a decision to sell or dispose all or a portion of a reporting unit.
LEASED ASSETS	LEASED ASSETS Leases are classified as an operating lease whenever the terms of the lease do not transfer substantially all of the risks and rewards of ownership to the lessee. Lease payments are recognized as an expense on a straight-line basis over the lease term, except where another systematic basis is more representative of the time pattern in which the economic benefits are consumed.
BUSINESS ACQUISITION	BUSINESS ACQUISITION A business combination is a transaction or event in which an acquirer obtains control of one or more businesses and is accounted for using the acquisition method. The total consideration paid for the acquisition is the aggregate of the fair values of assets acquired, liabilities assumed, and equity instruments issued in exchange for control of the acquiree at the acquisition date. The acquisition date is the date when the Company obtains control of the acquiree. The identifiable assets acquired and liabilities assumed are recognized at their acquisition date fair values, except for deferred taxes and share-based payment awards where IFRS provides exceptions to recording the amounts at fair value. Goodwill represents the difference between total consideration paid and the fair value of the net-identifiable assets acquired. Acquisition costs incurred are expensed to profit or loss. Contingent consideration is measured at its acquisition date fair value and is included as part of the consideration transferred in a business combination, subject to the applicable terms and conditions. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Contingent consideration that is classified as an asset or a liability is remeasured at subsequent reporting dates in accordance with IFRS 9 Financial Instruments with the corresponding gain or loss recognized in profit or loss. Based on the facts and circumstances that existed at the acquisition date, management will perform a valuation analysis to allocate the purchase price based on the fair values of the identifiable assets acquired and liabilities assumed on the acquisition date. Management has one year from the acquisition date to confirm and finalize the facts and circumstances that support the finalized fair value analysis and related purchase price allocation. Until such time, these values are provisionally reported and are subject to change. Changes to fair values and allocations are retrospectively adjusted in subsequent periods.
REVENUE RECOGNITION	REVENUE RECOGNITION The Company has effectively applied the new IFRS 15 standard to the current fiscal year and retrospectively, see ‘New IFRS Effective August 1, 2018.’
COST OF GOODS SOLD	COST OF GOODS SOLD Cost of goods sold includes cost of inventory expensed, packaging costs, shipping costs and related labour.
RESEARCH AND DEVELOPMENT	RESEARCH AND DEVELOPMENT Research costs are expensed as incurred. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development to use or sell the asset. Other development expenditures are recognized in profit and loss as incurred.
INCOME TAXES	INCOME TAXES The Company uses the liability method to account for income taxes. Deferred income tax assets and liabilities are recognized for the future tax consequences attributable to differences between the carrying amounts of existing assets and liabilities for accounting purposes, and the irrespective tax bases. Deferred income tax assets and liabilities are measured using tax rates that have been enacted or substantively enacted applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in statutory tax rates is recognized in profit or loss in the year of change. Deferred income tax assets are recorded when their recoverability is considered probable and are reviewed at the end of each reporting period.
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION The Company has an employee stock option plan. The Company measures equity settled share-based payments based on their fair value at the grant date and recognizes compensation expense over the vesting period based on the Company’s estimate of equity instruments that will eventually vest. Forfeitures are adjusted for on an actual basis. The impact of the revision of the original estimate is recognized in profit or loss such that the cumulative expense reflects the revised estimate. For stock options granted to non-employees the compensation expense is measured at the fair value of goods and services received
NON-CONTROLLING INTEREST	NON-CONTROLLING INTEREST Non-controlling interest (“NCI”) is recognized at the NCI’s proportionate share of the net assets.
LOSS PER SHARE	LOSS PER SHARE Loss per common share represents loss for the period attributable to common shareholders divided by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by dividing the applicable loss for the year by the sum of the weighted average number of common shares outstanding and all additional common shares that would have been outstanding if potentially dilutive common shares had been issued during the year. The calculation of diluted loss per share excludes the effects of various conversions and exercise of options and warrants that would be anti-dilutive.
BORROWING COSTS	BORROWING COSTS Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. All other borrowing costs are recognized in profit or loss in the period which they are incurred.
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS Financial assets and liabilities are recognized when the Company becomes a party to the contractual provision of the respective instrument. Fair value estimates are made at the consolidated statement of financial position date based upon the relevant market conditions and information about the financial instrument. The Company has made the following classifications: IFRS 9 Classification Financial assets Cash and cash equivalents FVTPL Restricted cash FVTPL Short-term investments FVTPL Trade receivables Amortized cost Convertible debenture receivable FVTPL Long term investment FVTPL Financial liabilities Accounts payable and accrued liabilities Amortized cost Warrant liability FVTPL Term loan Amortized cost Fair Value Through Profit or Loss (“FVTPL”) Financial Assets Financial assets classified and measured at FVTPL are those assets that do not meet the criteria to be classified at amortized cost or at FVTOCI. This category includes debt instruments whose cash flow characteristics are not solely payments of principal and interest (“SPPI”) or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell the financial asset. Amortized Cost Financial Assets Financial assets at amortized cost are non-derivative financial assets which are held within a business model whose objective is to hold assets to collect contractual cash flows and its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. A financial asset is initially measured at fair value, including transaction costs and subsequently at amortized cost. Impairment of Financial Assets Financial assets, other than those classified at fair value through profit and loss, are assessed for indicators of impairment at the end of the reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected. Financial Liabilities and Other Financial Liabilities Financial liabilities are classified as either financial liabilities at FVTPL or other financial liabilities. Financial liabilities at FVTPL are stated at fair value, with changes being recognized through the consolidated statements of income. Other financial liabilities are initially measured at fair value, net of transaction costs, and are subsequently measured at amortized cost using the effective interest method. Embedded Derivatives Derivatives are initially measured at fair value in conjunction with the host contract; no bifurcation is performed, and any directly attributable transaction costs are recognised in profit or loss as incurred. Subsequent to initial recognition, the entire instrument, including the embedded derivative is measured at fair value and changes therein are recognised in profit or loss. The Company has a convertible loan receivable whereby the balance can be converted into equity. See Note 15 for transaction and valuation details. Compound Instruments The component parts of compound instruments (convertible debentures) issued by the Company are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company’s own equity instruments is an equity instrument. At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for similar non-convertible instruments. This amount is recorded as a liability on an amortized cost basis using the effective interest rate method until extinguished upon conversion or at the instrument’s maturity date. The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option. Transaction costs that relate to the issue of the convertible debentures are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the term of the convertible debentures using the effective interest method. For compound instruments with non-equity derivatives, the fair value of the embedded derivative is determined first based on the contractual terms, and the initial carrying amount of the host instrument is the residual amount after separating the embedded derivative. Transaction Costs Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss.
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Valuation of Biological Assets and Inventory In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis, harvesting costs, selling costs, sales price and expected yields for the cannabis plant. In calculating final inventory values, management is required to determine an estimate of spoiled or expired inventory and compares the inventory cost versus net realizable value. Estimated Useful Lives, Amortization and Impairment of Property, Plant and Equipment and Intangible Assets Amortization of property, plant and equipment and intangible assets are dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets. The impairment is amount by which the carrying amount of the asset or CGU exceeds its recoverable amount. The recoverable amount is the higher of the fair value less costs of disposal and its value in use. Share-Based Compensation In calculating the share-based compensation expense, key estimates such as the value of the common share, the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company’s stock price and the risk-free interest rate are used. Warrants In calculating the value of the warrants, key estimates such as the value of the common share, the expected life of the warrant, the volatility of the Company’s stock price and the risk free interest rate are used. All broker/compensation warrants were measured at the fair value of the equity instruments granted, as the fair value of the related services cannot be reliably measured. Provisions Provisions are recognized when the Company has a present obligation, legal or constructive as a result of a previous event, if it is probable that the Company will be required to settle the obligation and a reliable estimate can be made of the obligation. The amount recognized is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligations. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate of the expected future cash flows. Allocation of Purchase Price In determining the allocation of the purchase price, estimates are used based on market research and appraisal values. Joint Ventures Joint ventures are joint arrangements whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. Entity Assessment Classification Truss Management has determined joint control is not present due to the inability to direct the day to day operations of the entity. Investment in associate Belleville Complex Inc. Management has determined joint control is present based upon the board composition, decision making and the ability to direct the day to day operations of the entity. Joint venture HEXO MED Management has determined joint control is present based upon the board composition, decision making and the ability to direct the day to day operations of the entity. Joint venture Business Acquisitions In determining the fair value of all identifiable assets acquired and liabilities assumed, the most significant estimates relate to private investments and intangible assets acquired. Management exercises judgment in estimating the probability and timing of when earn-outs are expected to be achieved, which is used as the basis for estimating fair value. Identified intangible assets are fair valued using appropriate valuation techniques which are generally based on a forecast of the total expected future net cash flows of the acquiree. Valuations are highly dependent on the inputs used and assumptions made by management regarding the future performance of these assets and any changes in the discount rate applied. Acquisitions that do not meet the definition of a business combination are accounted for as asset acquisitions. Consideration paid for an asset acquisition is allocated to the individual identifiable assets acquired and liabilities assumed based on their relative fair values. Asset acquisitions do not give rise to goodwill. Expected Credit Losses (“ECL”) on Trade Accounts Receivable The Company applies the simplified approach, as defined in IFRS, to measure expected credit losses, which requires the use of the lifetime expected credit loss provision for all trade receivables. To measure lifetime expected credit losses, trade receivables are first classified into groups with shared credit characteristics and the age of days past due, followed by an assessment of the Company’s historical experience of bad debts including the customers’ ability to pay and the impact of any relevant economic conditions which are expected during the life of the balance. The loss allowance is determined according to a provision matrix incorporating historical experiences adjusted for current and future conditions expected for the life of the balance. Convertible debentures The fair value of the convertible debentures is determined using the public market price. As the convertible debentures are classified as FVTPL, the subsequent interest as well as change in the fair value will flow through the consolidated statements of comprehensive income. Other Liability The fair value of the onerous contract is determined using the excess contract price per unit over the known sales pricing to end users. Going Concern Management has applied judgments in the assessment of the Company's ability to continue as a going concern when preparing its consolidated financial statements for the years ended July 31, 2019 and 2018. Management prepares the consolidated financial statements on a going concern basis unless management either intends to liquidate the entity or to cease trading or has no realistic alternative but to do so. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the twelve months from the end of the reporting period. Management considered a wide range of factors relating to current and expected profitability, product offerings, expansion plans, ability to liquidate investments and assets, and potential sources of financing. As a result of the assessment, management concluded the going concern basis of accounting is appropriate.
Changes to Accounting Standards and Interpretations	New IFRS Effective August 1, 2018 IFRS 15, REVENUE FROM CONTRACTS WITH CUSTOMERS IFRS 15 was issued by the IASB in May 2014 and specifies how and when revenue should be recognized based on a five-step model, which is applied to all contracts with customers. On April 12, 2016, the IASB published final clarifications to IFRS 15 with respect to identifying performance obligations, principal versus agent considerations, and licensing. The Company has applied IFRS 15 retrospectively and determined that there is no change to the comparative period or transitional adjustments required as a result of the adoption. The Company’s accounting policy for revenue recognition under IFRS 15 is as follows: 1. Identifying the contract with a customer; 2. Identifying the performance obligation(s) in the contract; 3. Determining the transaction price; 4. Allocating the transaction price to the performance obligation(s) in the contract; and 5. Recognizing revenue when or as the Company satisfies the performance obligation(s). Revenue from the direct sale of cannabis to customers for a fixed price is recognized when the Company transfers the control of the good(s) to the customer upon delivery and acceptance by the customer, the timing of which is consistent with the Company’s previous revenue recognition policy under IAS 18. The Company recognizes revenue in an amount that reflects the consideration which the Company expects to receive taking into account the impact which may arise from any rights of return on sales, price concessions or similar obligations. Revenue is presented net of taxes, estimated returns, allowances and discounts. Occasionally the Company recognizes retrospective price amendments as a cumulative catch-up adjustment when a contract modification is approved. Effective October 17, 2018, Canada Revenue Agency (“CRA”) began levying an excise taxes on the sale of medical and adult-us cannabis products. The Company becomes liable for these excise duties when cannabis products are delivered to the customer. The excise taxes payable is the higher of (i) a flat-rate duty which is imposed when a cannabis product is packaged, and (ii) an advalorem duty that is imposed when a cannabis product is delivered to the customer. Effective May 1, 2019, excise tax calculated on edible cannabis products, cannabis extracts and cannabis topicals will prospectively be calculated as a flat rate based on the quantity of total tetrahydrocannabinol (THC) contained in the final product. There were no changes in the legislation in calculating excise taxes for fresh cannabis, dried cannabis, seeds and plants. Net revenue from sale of goods, as presented on the consolidated statements of comprehensive (loss) income, represents revenue from the sale of goods less applicable excise taxes. Given that the excise tax payable/paid to CRA cannot be reclaimed and is not always billed to customers, the Company recognizes that the excise tax is an operating cost that affects gross margin to the extent that it is not recovered from its customers. IFRS 9, FINANCIAL INSTRUMENTS The Company adopted IFRS 9 retroactively and determined that there is no change to the comparative period or transitional adjustments required as a result of the adoption. IFRS 9 was issued by the International Accounting Standards Board ("IASB") in November 2009 and October 2010 and will replace IAS 39. IFRS 9 uses a single approach to determine whether a financial asset is classified and measured at amortized cost or at fair value. The classification and measurement of financial assets is based on the Company’s business models for managing its financial assets and whether the contractual cash flows represent solely payments of principal and interest (“SPPI”). Financial assets under IFRS 9 are initially measured at fair value and are subsequently measured at either amortized cost; fair value through other comprehensive income (“FVTOCI”) or; fair value through profit or loss (“FVTPL”). Amortized Cost Financial assets classified and measured at amortized cost are those assets that are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, and the contractual terms of the financial asset give rise to cash flows that are SPPI. Financial assets classified at amortized cost are measured using the effective interest method. FVTOCI Financial assets classified and measured at FVTOCI are those assets that are held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets, and the contractual terms of the financial asset give rise to cash flows that are SPPI. This classification includes certain equity instruments where IFRS 9 allows an entity to make an irrevocable election to classify the equity instruments, on an instrument-by-instrument basis, that would otherwise be measured at FVTPL to present subsequent changes in FVTOCI. FVTPL Financial assets classified and measured at FVTPL are those assets that do not meet the criteria to be classified at amortized cost or at FVTOCI. This category includes debt instruments whose cash flow characteristics are not SPPI or are not held within a business model whose objective is either to collect contractual cash flows, or to both collect contractual cash flows and sell the financial asset. The following table summarizes the Company’s financial instruments under IAS 39 and IFRS 9: IAS 39 Classification IFRS 9 Classification Financial assets Cash and cash equivalents FVTPL FVTPL Restricted cash FVTPL FVTPL Short-term investments FVTPL FVTPL Trade receivables Loans and receivables Amortized cost Convertible debenture receivable FVTPL FVTPL Long term investment N/A FVTPL Financial liabilities Accounts payable and accrued liabilities Other financial liabilities Amortized cost Warrant liability FVTPL FVTPL Term loan N/A Amortized cost The adoption of IFRS 9 did not have a quantitative impact and did not have a material impact to the Company’s classification and measurement of financial assets and liabilities. IFRS 9 uses an expected credit loss impairment model as opposed to an incurred credit loss model under IAS 39. The impairment model is applicable to financial assets measured at amortized cost where any expected future credit losses are provided for, irrespective of whether a loss event has occurred as at the reporting date. For trade receivables, the Company has measured the expected credit losses based on lifetime expected credit losses taking into consideration historical credit loss experience and financial factors specific to the debtors and other factors. The carrying amount of trade receivables is reduced for any expected credit losses through the use of an allowance account. Changes in the carrying amount of the allowance account are recognized in the statements of loss and comprehensive loss. At the point when the Company is satisfied that no recovery of the amount owing is possible, the amount is considered not recoverable and the financial asset is written off. Evidence of impairment may include indications that a debtor or a group of debtors is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization and where observable data indicates that there is a measurable decrease in the estimated future cash flows, such as changes in arrears or economic conditions that correlate with defaults. Trade receivables are reviewed qualitatively on a case-by-case basis to determine whether they need to be written off. The adoption of the new expected credit loss impairment model had a negligible impact on the carrying amounts of financial assets at amortized cost. Classification and Measurement of Financial Liabilities Accounting for financial liabilities remains largely the same under IFRS 9 and subsequently the Company’s liabilities were not significantly impacted by the adoption. Financial liabilities are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Company designates a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortized cost using the effective interest method except for derivatives and financial liabilities designated at FVTPL, which are carried subsequently at fair value with gains or losses recognised in profit or loss (other than derivative financial instruments that are designated and effective as hedging instruments). New and Revised IFRS in Issue but Not Yet Effective IFRS 16, LEASES In January 2016, the IASB issued IFRS 16 Leases, which will replace IAS 17 Leases. This standard introduces a single lessee accounting model and requires a lessee to recognize assets and liabilities for all leases with a term greater than twelve months, unless the underlying asset’s value is insignificant. A lessee is required to recognize a right-of-use asset representing its right to use the underlying asset and a lease liability representing its obligation to make lease payments. Lessors will continue to classify leases as operating or finance, with lessor accounting remaining substantially unchanged from the preceding guidance under IAS 17, Leases. The Company is currently executing its implementation plan and has completed the initial scoping phase to identify material lease contracts. The analysis of such contracts to quantify the transitional impact is ongoing. The most significant impact of IFRS 16 will be our initial recognition of the present value of future lease payments as right-of-use assets under property, plant and equipment and the corresponding recognition of a lease liability on the consolidated statement of financial position. All material, long-term property leases, which are currently treated as operating leases, are expected to be impacted by the new standard which will result in lower rent expense, higher depreciation expense and higher finance costs related to accretion and interest expense of the lease liability. IFRS 16 will also impact the presentation of the consolidated statement of cash flows by decreasing operating cash flows and increasing financing cash flows. The standard will be effective for the Company for the fiscal year commencing August 1, 2019. The Company will be adopting the standard using the modified approach by recognizing the cumulative impact of initial adoption in opening retained earnings (i.e. the difference between the right-of-use asset and the lease liability). The Company will measure the right-of-use asset at an amount equal to the lease liability on the commencement date, apply a single discount rate to leases with similar remaining lease terms for similar classes of underlying assets and will not separate non-lease components from lease components for certain classes of underlying assets. Consistent with the guidance, the Company will not apply this standard to short-term leases and leases for which the underlying asset is of low value.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Jul. 31, 2019
Basis Of Presentation [Abstract]
Schedule of major subsidiaries	MAJOR SUBSIDIARIES JURISDICTION INTEREST HELD HEXO Operations Inc. 1 Ontario, Canada 100% Newstrike Brands Ltd. 2 Ontario, Canada 100% HEXO USA Inc. Deleware, USA 100% Keystone Isolation Technologies Inc. (“KIT’’) Ontario, Canada 60% 1 2

Significant Accounting Polici_3

Significant Accounting Policies, Accounting Standards and Interpretations (Tables)	12 Months Ended
	Jul. 31, 2019
Significant Accounting Policies [Abstract]
Schedule of terms and method use to calculate amortization of tangible assets	Land Not amortized No term Buildings Straight line 5 to 20 years Leasehold improvements Straight line lease term Furniture and equipment Straight line 5 years Cultivation and production equipment Straight line 5 to 20 years Vehicles Straight line 5 years Computers Straight line 3 years Construction in progress Not amortized No term
Schedule of terms and method use to calculate amortization of intangible assets	Domain names Straight line 10 years Health Canada licenses Straight line 20 years Software Straight line 3 to 5 years Patents Straight line 20 years

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-Term Investments (Tables)	12 Months Ended
	Jul. 31, 2019
Categories of current financial assets [abstract]
Schedule of cash, cash equivalents and short-term investments	July 31, 2019 July 31, 2018 Total Total Interest rate Operating cash – $ 5,993 $ 66,438 High interest savings accounts 1.45%–2.10% 107,575 32,604 Total cash and cash equivalents $ 113,568 $ 99,042 Term deposits & GIC 2.85%–4.25% maturity of 3 to 12 months $ 25,937 $ 145,747 Total short-term investments $ 25,937 $ 145,747

Commodity Taxes Recoverable a_2

Commodity Taxes Recoverable and Other Receivables (Tables)	12 Months Ended
	Jul. 31, 2019
Commodity Taxes Recoverable And Other Receivables [Abstract]
Schedule of commodity taxes recoverable and other receivables	July 31, 2019 July 31, 2018 Commodity taxes recoverable $ 14,415 $ 4,237 Accrued interest income 570 – Other receivables (Note 20) 262 – $ 15,247 $ 4,237

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Jul. 31, 2019
Classes of current inventories [abstract]
Schedule of inventories	July 31, 2019 Capitalized Biological asset fair cost value adjustment Total Dried cannabis $ 28,996 $ 19,349 $ 48,345 Oils 17,377 5,366 22,743 Hemp derived distillate 1,523 – 1,523 Purchased dried cannabis 8,087 – 8,087 Packaging and supplies 3,156 – 3,156 $ 59,139 $ 24,715 $ 83,854 July 31, 2018 Capitalized Biological asset fair Cost value adjustment Total Dried cannabis $ 2,115 $ 4,440 $ 6,555 Oils 2,281 882 3,163 Packaging and supplies 697 – 697 $ 5,093 $ 5,322 $ 10,415

Biological Assets (Tables)

Biological Assets (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure of detailed information about biological assets [abstract]
Schedule of changes in the carrying value of biological assets	July 31, 2019 July 31, 2018 Carrying amount, beginning of period $ 2,332 $ 1,504 Acquired through acquisition 1 3,291 – Production costs capitalized 19,215 993 Net increase in fair value due to biological transformation less cost to sell 38,856 7,340 Transferred to inventory upon harvest (56,323 ) (7,505 ) Carrying amount, end of period $ 7,371 $ 2,332 1
Schedule of significant unobservable inputs, their range of values and sensitivity analysis	Unobservable inputs Input values Sensitivity analysis Average selling price An increase or decrease of 5% applied to the average Obtained through actual retail prices on a per $4.23 – $5.01 per dried gram. selling price would result in a change of approximately $480 strain basis. to the valuation. Yield per plant An increase or decrease of 5% applied to the average yield Obtained through historical harvest cycle results 15 – 123 grams per plant. per plant would result in a change up to approximately $344 on a per strain basis. in valuation. Stage of growth An increase or decrease of 5% applied to the average stage Obtained through the estimates of stage of Average of 29% completion. of growth per plant would result in a change of completion within the harvest cycle. approximately $1,148 in valuation. Wastage An increase or decrease of 5% applied to the wastage Obtained through the estimates of wastage 0%–30% dependent upon the expectation would result in a change of approximately $302 within the cultivation and production cycle. stage within the harvest cycle. in valuation. Unobservable inputs Input values Sensitivity analysis Average selling price An increase or decrease of 5% applied to the average Obtained through actual retail prices on a per $4.66 per dried gram. selling price would result in a change of approximately $329 strain basis. to the valuation. Yield per plant Obtained through historical harvest cycle results 50–235 grams per plant. An increase of decrease of 5% applied to the average yield on a per strain basis. per plant would not result in a material change in valuation. Stage of growth Obtained through the estimates of stage of Average of 32% completion. An increase or decrease of 5% applied to the average stage completion within the harvest cycle. of growth per plant would result in a change of approximately $320 in valuation. Wastage Obtained through the estimates of wastage 0%–30% dependent upon the An increase of decrease of 5% applied to the average yield within the cultivation and production cycle. stage within the harvest cycle. per plant would not result in a material change in valuation.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Jul. 31, 2019
Property, plant and equipment [abstract]
Schedule of property, plant and equipment	Balance at Additions from Balance at business Cost July 31, 2018 acquisitions Additions Adjustments July 31, 2019 Land $ 1,038 $ 4,301 $ – $ – $ 5,339 Buildings 32,536 18,855 11,365 88,078 150,834 Leasehold Improvements 206 – 421 – 627 Furniture and equipment 1,661 119 4,576 – 6,356 Cultivation and production equipment 4,031 9,913 28,085 – 42,029 Vehicles 151 – 880 – 1,031 Computers 659 529 1,793 – 2,981 Construction in progress 15,433 12,286 117,909 (88,078 ) 57,550 $ 55,715 $ 46,003 $ 165,029 $ – $ 266,747 Balance at Additions from Balance at business Accumulated depreciation July 31, 2018 acquisitions Depreciation Adjustments July 31, 2019 Land $ – $ – $ – $ – $ – Buildings 533 – 3,859 – 4,392 Leasehold Improvements 9 – 121 – 130 Furniture and equipment 527 – 585 (650 ) 462 Cultivation and production equipment 69 – 1,497 650 2,216 Vehicles 56 – 77 – 133 Computers 188 – 433 – 621 $ 1,382 $ – $ 6,572 $ – $ 7,954 Balance at Additions from Balance at business Net Additions / Net Carrying Value July 31, 2018 acquisitions (Deductions) Adjustments July 31, 2019 Land $ 1,038 $ 4,301 $ – $ – $ 5,339 Buildings 32,003 18,855 7,506 88,078 146,442 Leasehold Improvements 197 – 300 – 497 Furniture and equipment 1,134 119 3,991 650 5,894 Cultivation and production equipment 3,962 9,913 26,588 (650 ) 39,813 Vehicles 95 – 803 – 898 Computers 471 529 1,360 – 2,360 Construction in progress 15,433 12,286 117,909 (88,078 ) 57,550 $ 54,333 $ 46,003 $ 158,457 $ – $ 258,793 Balance at Balance at Cost July 31, 2017 Additions Adjustments July 31, 2018 Land $ 358 $ 680 $ – $ 1,038 Buildings 3,745 3,930 24,861 32,536 Leasehold Improvements – 206 – 206 Furniture and equipment 900 1,233 (472 ) 1,661 Cultivation and production equipment 380 3,165 486 4,031 Vehicles 114 33 4 151 Computers 234 425 – 659 Construction in progress 605 39,707 (24,879 ) 15,433 $ 6,336 $ 49,379 $ – $ 55,715 Balance at Balance at Accumulated depreciation July 31, 2017 Depreciation Adjustments July 31, 2018 Land $ – $ – $ – $ – Buildings 194 339 – 533 Leasehold Improvements – 9 – 9 Furniture and equipment 165 195 167 527 Cultivation and production equipment 23 213 (167 ) 69 Vehicles 26 30 – 56 Computers 78 110 – 188 $ 486 $ 896 $ – $ 1,382 Balance at Net Additions / Balance at Net Carrying Value Adjustments July 31, 2017 (Deductions) July 31, 2018 Land $ 358 $ 680 $ – $ 1,038 Buildings 3,551 3,591 24,861 32,003 Leasehold Improvements – 197 – 197 Furniture and equipment 735 1,038 (639 ) 1,134 Cultivation and production equipment 357 2,952 653 3,962 Vehicles 88 3 4 95 Computers 156 315 – 471 Construction in progress 605 39,707 (24,879 ) 15,433 $ 5,850 $ 48,483 $ – $ 54,333

Intangible Assets and Other L_2

Intangible Assets and Other Longer Term Assets (Tables)	12 Months Ended
	Jul. 31, 2019
Changes in intangible assets other than goodwill [abstract]
Schedule of intangible assets and other longer-term assets	Balance at Additions from Balance at business Cost July 31, 2018 acquisitions Additions Adjustments July 31, 2019 Cultivating and processing license $ 2,545 $ 113,888 $ – $ – $ 116,433 Brand – 8,440 – – 8,440 Software 1,800 12 1,746 – 3,558 Domain names 585 – – – 585 Patents – – 1,231 – 1,231 Other longer term assets and capitalized 312 – – (312 ) – transaction costs $ 5,242 $ 122,340 $ 2,977 $ (312 ) $ 130,247 Balance at Additions from Balance at business Accumulated amortization July 31, 2018 acquisitions Amortization Adjustments July 31, 2019 Cultivating and processing license $ 403 $ – $ 1,198 $ – $ 1,601 Software 786 – 483 – 1,269 Domain name 9 – 57 – 66 Patents – – 29 – 29 $ 1,198 $ – $ 1,767 $ – $ 2,965 Balance at Additions from Balance at business Net Additions / Net Carrying Value July 31, 2018 acquisitions (Deductions) Adjustments July 31, 2019 Cultivating and processing license $ 2,142 $ 113,888 $ (1,198 ) $ – $ 114,832 Brand – 8,440 – – 8,440 Software 1,014 12 1,263 – 2,289 Domain names 576 – (57 ) – 519 Patents – – 1,202 – 1,202 Other longer term assets and capitalized 312 – – (312 ) – transaction costs $ 4,044 $ 122,340 $ 1,210 $ (312 ) $ 127,282 Balance at Disposals/ Balance at Cost July 31, 2017 Additions adjustments July 31, 2018 Cultivating and processing license $ 2,545 $ – $ – $ 2,545 Software 651 1,149 – 1,800 Domain names – 585 – 585 Other longer term assets and capitalized – 312 – 312 transaction costs $ 3,196 $ 2,046 $ – $ 5,242 Balance at Disposals/ Balance at Accumulated amortization July 31, 2017 Amortization adjustments July 31, 2018 Cultivating and processing license $ 277 $ 126 $ – $ 403 Software 156 630 – 786 Domain name – 9 – 9 $ 433 $ 765 $ – $ 1,198 Net Carrying Value Balance at July 31, 2017 Net Additions / (Deductions) Disposals/ adjustments Balance at July 31, 2018 Cultivating and processing license $ 2,268 $ (126 ) $ – $ 2,142 Software 495 519 – 1,014 Domain names – 576 – 576 Other longer term assets and capitalized – 312 – 312 transaction costs $ 2,763 $ 1,281 $ – $ 4,044
Schedule of changes in expected amortization expense	2019 2020 2021 2022 Later (Decrease) increase in amortization expense $ (87 ) $ (119 ) $ (100 ) $ (3 ) $ Nil

Business Acquisition (Tables)

Business Acquisition (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure of detailed information about business combination [abstract]
Schedule of fair value of net assets assumed as at the acquisition date	Note Number of Shares, Share Price Amount Warrants and Options ($) ($) Consideration Shares issued (i) 35,394,041 9.11 322,439 Warrants outstanding (ii) 7,196,164 12,229 Replacement options issued (iii) 2,002,365 7,134 Total fair value of consideration 341,802 Net assets acquired Current assets Cash and cash equivalents 49,366 Accounts receivable 1,204 Other receivables 4,585 Inventory 22,359 Biological assets 3,291 Long-term assets Property, Plant and Equipment 46,003 Investments (iv) 14,492 Convertible debenture receivable 1,220 Prepaid expenses 1,631 Prepaid expense and license 1,526 Software 10 Cultivation and processing license 113,888 Brand 8,440 Goodwill 111,877 Total assets 379,892 Current liabilities Accounts payable and accrued liabilities 12,849 Payment received in advance 5 Long-term liabilities Deferred tax liabilities 24,236 Total liabilities 37,090 Non-controlling interest 1,000 Total net assets acquired 341,802 Net accounts receivables acquired Total accounts receivable 5,789 Expected uncollectible receivables – Net accounts receivables acquired 5,789 (i) Share price based upon the TSX market price of common shares as at May 24, 2019. (ii) Warrants were valued using the Black-Scholes option pricing model as at the acquisition date May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 0.73 – 4.07 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $11.84 – $27.64 • Stock price of $9.11 (iii) All replacement options were valued using the Black-Scholes option pricing model as at the acquisition date of May 24, 2019, using the following assumptions and inputs; • Risk free rate of 1.48% – 1.57% • Expected life of 1.2 – 4.7 years • Volatility rate of 75%; determined using historical volatility data • Exercise prices of $6.00 – $17.37 • Stock price of $9.11 The fair value of the vested options as at the acquisition date was deemed consideration paid in the transaction. The fair value of those options not yet vested at the acquisition date was added to the Company’s share-based payment reserve to be expensed over the remaining vesting period of the options as permitted under IFRS 3 – Business Combinations (iv) Included in total investments were two level 3 private company investments (see ‘ Greentank Technologies Neal Brothers Inc

Convertible Debentures (Tables)

Convertible Debentures (Tables)	12 Months Ended
	Jul. 31, 2019
Debt instruments held [abstract]
Schedule of convertible debentures	2017 unsecured 2018 unsecured convertible convertible debentures 8% debentures 7% Total Balance at July 31, 2017 20,639 – 20,639 Gross proceeds – 69,000 69,000 Issuance costs – (4,792 ) (4,792 ) Warrants, net of issuance costs – (3,285 ) (3,285 ) Conversion feature, net of issuance costs – (6,777 ) (6,777 ) Accretion 814 554 1,368 Conversion of debenture (21,453 ) (54,700 ) (76,153 ) Balance at July 31, 2018 – – –
Schedule of warrant liability activity	July 31, 2019 July 31, 2018 Opening balance $ 3,130 $ 1,356 Granted – – Expired – – Exercised (6,367 ) (3,317 ) Revaluation due to foreign exchange 3,730 5,091 Closing balance $ 493 $ 3,130

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Jul. 31, 2019
Share Capital [Abstract]
Schedule of warrants outstanding	Number outstanding Book value Classified as Equity 2018 Equity financing Exercise price of $5.60 expiring January 30, 2020 10,512,208 $ 5,673 February 2018 financing warrants Exercise price of $27.64 expiring February 16, 2020 4,413,498 1,331 June 2019 financing warrants Exercise price of $15.79 expiring June 19, 2023 2,184,540 9,998 Broker / Consultant warrants Exercise price of $20.85 expiring February 16, 2020 264,809 160 Exercise price of $11.84 expiring June 19, 2020 262,021 610 Exercise price of $0.75 expiring November 3, 2021 175,618 78 Exercise price of $0.75 expiring March 14, 2022 94,282 66 Exercise price of $15.79 expiring June 19, 2023 61 1 Inner Spirit warrants Exercise price of $15.63 expiring July 21, 2020 71,235 129 Joint Venture Molson warrants Exercise price of $6.00 expiring October 4, 2021 11,500,000 42,386 Classified as Liability 29,478,272 60,432 2017 secured convertible debenture warrants Exercise price of USD$0.76 expiring November 14, 2019 107,136 493 29,585,408 $ 60,925
Schedule of warrant activity	July 31, 2019 July 31, 2018 Number of Weighted average Number of Weighted average warrants exercise price warrants exercise price Outstanding, beginning of period 26,425,504 $ 4.35 20,994,123 $ 1.31 Expired during the period (531 ) – (62,728 ) 3.00 Acquired and reissued through acquisition 1 7,196,164 23.10 – – Issued during the period 11,500,000 6.00 37,413,681 4.34 Exercised during the period (15,535,729 ) 3.61 (31,919,572 ) 2.33 Outstanding, end of the period 29,585,408 $ 9.95 26,425,504 $ 4.35 1
Schedule of stock option granted	Options granted Executive and Non-executive Grant date Exercise price directors employees Vesting terms Vesting period September 8, 2017 $ 1.37 650,000 1,000 Terms A 10 years November 6, 2017 $ 2.48 125,000 3,000 Terms A 10 years December 4, 2017 $ 2.69 1,750,000 20,000 Terms B 10 years January 29, 2018 $ 4.24 – 261,000 Terms A, C 10 years March 12, 2018 $ 3.89 325,000 – Terms A 10 years April 16, 2018 $ 4.27 845,000 61,500 Terms A 10 years June 8, 2018 $ 5.14 – 441,000 Terms A 10 years July 11, 2018 $ 4.89 4,325,000 1,366,500 Terms A 10 years September 17, 2018 $ 7.93 650,000 523,500 Terms A 10 years November 22, 2018 $ 5.92 – 440,000 Terms A 10 years December 17, 2018 $ 5.09 74,000 227,500 Terms A, D 10 years February 19, 2019 $ 7.13 615,000 626,000 Terms A 10 years February 21, 2019 $ 7.46 3,333,333 – Terms E 10 years March 20, 2019 $ 8.50 325,000 1,077,500 Terms A 10 years April 17, 2019 $ 8.24 – 1,132,500 Terms A 10 years July 18, 2019 $ 6.54 650,000 2,768,785 Terms A 10 years July 26, 2019 $ 5.88 250,000 – Terms A 10 years
Schedule of stock option activity	July 31, 2019 July 31, 2018 Options Weighted average Options Weighted average issued exercise price issued exercise price Opening balance 14,388,066 $ 3.02 5,748,169 $ 0.68 Granted 12,693,118 7.27 10,174,000 4.16 Acquired and reissued through acquisition 1 2,002,365 9.49 – – Forfeited (1,226,763 ) 6.33 (626,830 ) 3.44 Exercised (3,567,867 ) 1.20 (907,273 ) 0.65 Closing balance 24,288,919 $ 5.87 14,388,066 $ 3.02 1
Schedule of stock options outstanding	Weighted average Weighted average remaining contractual remaining contractual Exercise price Number outstanding life (years) Number exercisable life (years) $ 0.58 372,900 0.08 363,000 0.30 0.75 1,228,750 0.34 1,013,750 1.07 1.27 522,620 0.16 322,053 0.37 3.15 4,748 0.00 4,748 0.00 6.00 891,833 0.04 891,833 0.14 1.37 352,866 0.12 82,304 0.10 2.48 86,332 0.03 22,342 0.03 2.69 853,333 0.29 313,335 0.41 4.24 258,000 0.09 122,519 0.16 17.37 253,270 0.04 253,270 0.14 3.89 325,000 0.12 135,418 0.18 16.58 31,659 0.00 15,828 0.00 16.74 56,985 0.00 28,488 0.01 4.27 879,002 0.32 366,852 0.50 16.10 63,319 0.00 63,319 0.00 4.89 5,513,497 2.03 2,046,567 2.87 5.14 107,666 0.04 35,680 0.05 10.42 162,295 0.01 138,549 0.04 10.42 142,467 0.01 71,230 0.02 11.84 44,322 0.00 11,079 0.00 7.93 1,058,500 0.40 – – 8.21 94,979 0.01 23,744 0.01 5.92 310,000 0.12 – – 5.09 276,500 0.11 54,000 0.08 6.94 94,979 0.02 – – 8.84 94,979 0.02 – – 7.13 1,136,000 0.45 – – 7.46 3,333,333 1.31 – – 8.50 1,222,500 0.49 – – 8.24 857,500 0.34 – – 6.54 3,408,785 1.40 – – $ 5.88 250,000 0.10 – – 24,288,919 8.49 6,379,908 6.48
Schedule of fair value of stock options granted	July 31, 2019 July 31, 2018 Exercise price $0.75–$8.95 $1.37–$5.14 Stock price $5.09–$8.50 $1.37–$5.14 Risk-free interest rate 1.54%–2.42% 2.06%-2.37% Expected life of options (years) 5-7 7 Expected annualized volatility 64%–76% 65%

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Jul. 31, 2019
Earnings per share [abstract]
Schedule of anti-dilutive securities excluded from computation of diluted earnings per share	July 31, 2019 July 31, 2018 Options 24,288,919 14,388,066 Warrants issued with $0.75 units – 3,234,960 2015 Secured convertible debentures warrants – 1,318,332 2016 Unsecured convertible debenture warrants – 100,002 2017 Secured convertible debenture warrants 107,136 928,542 2018 Equity warrants 10,512,208 18,570,500 2018 February 2018 financing warrants 4,413,498 – 2019 June financing warrants 2,184,540 – Joint venture and Inner Spirit issued warrants 11,571,235 – Convertible debenture broker/finder warrants 796,791 2,273,168 53,874,327 40,813,570

Term Loan (Tables)

Term Loan (Tables)	12 Months Ended
	Jul. 31, 2019
Borrowings [abstract]
Schedule of term loan	Term Loan Current Long term July 31, 2018 $ – $ – Term loan Additions – 35,000 Adjustments 3,500 (3,500 ) Repayments (87 ) (788 ) $ 3,413 $ 30,712 Deferred financing costs Additions (296 ) (1,347 ) Adjustments – 296 Realized expense – 596 July 31, 2019 $ 3,117 $ 30,257

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure of detailed information about financial instruments [abstract]
Schedule of price risk	$ Financial assets 16,756 Financial liabilities (493 ) Total exposure 16,263
Schedule of aging of trade receivables	July 31, July 31, 2019 2018 $ $ 0–30 days 14,102 262 31– 60 days 1,826 188 61– 90 days 166 91 Over 90 days 3,599 103 Total 19,693 644
Schedule of ECL by aging group	July 31, July 31, 2019 2018 $ $ 0–30 days 3 - 31–60 days 7 - 61–90 days 3 - Over 90 days 24 94 Total 37 94

Operating Expenses by Nature (T

Operating Expenses by Nature (Tables)	12 Months Ended
	Jul. 31, 2019
Expenses by nature [abstract]
Schedule of operating expenses by nature	For the years ended July 31, 2019 July 31, 2018 Stock based compensation $ 28,008 $ 4,997 Marketing and promotion 22,308 2,447 Salaries and benefits 25,349 6,992 Consulting 11,176 3,659 Professional fees 8,258 1,761 Facilities 5,697 919 General and administrative 4,462 1,442 Travel 2,710 488 Amortization of intangible assets 1,767 765 Depreciation of property, plant and equipment 1,747 896 Total $ 111,482 $ 24,367 For the year ended July 31, 2019 General and administrative related stock -based compensation $ 26,322 Marketing and promotion related stock -based compensation 1,686 Total operating expense related stock-based compensation 28,008 Stock based compensation capitalized to inventory 1,724 Total stock-based compensation $ 29,732 For the year ended July 31, 2019 General and administrative related wages and benefits $ 17,975 Marketing and promotion related wages and benefits 6,162 Research and development related wages and benefits 1,212 Total operating expense related wages and benefits 25,349 Wages and benefits capitalized through cost of sales 10,905 Total wages and benefits in the period $ 36,254

Investment in Associate and J_2

Investment in Associate and Joint Ventures (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure Of Associate And Joint Ventures [Abstract]
Schedule of ownership interest in other entities	Truss Belleville Complex Inc HEXO MED Period July 31, 2019 July 31, 2019 July 31, 2019 Statement of Financial Position $ $ $ Cash and cash equivalents 14,318 278 542 Current assets 5,701 2,604 59 Non- current assets 7,880 19,906 22 Current liabilities 7,477 1,155 26 Non-current labilities – 21,909 – Period 11 months ended July 31, 2019 August 21, 2018 to July 31, 2019 December 22, 2018 to July 31, 2019 Statement of Comprehensive Loss Revenue – 4,018 – Operating expenses excluding depreciation and amortization (6,579 ) (3,716 ) – Depreciation and amortization – (578 ) – Other expenses – – (503 ) Loss from operations (6,579 ) (276 ) (503 ) Income tax expenses – – – Total comprehensive loss (6,579 ) (276 ) (503 )
Schedule of investment in associate	July 31, 2019 July 31, 2018 Opening Balance $ – $ – Cash consideration of investment 11,476 – Fair value of warrant consideration 42,386 – Capitalized transaction costs 721 – Share of net loss (2,796 ) – Ending Balance $ 51,786 $ –
Schedule of investment in joint venture	July 31, 2019 July 31, 2018 Opening Balance $ – $ – Cash consideration of investment 1,106 – Capitalized transaction costs 125 Share of net loss (168 ) – Ending Balance $ 1,063 $ –

Long-term Investments (Tables)

Long-term Investments (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure Of Long Term Investment Abstract
Schedule of long-term investments	Cost July 31, 2018 Fair value July 31, 2018 Investment Divesture/ Transfer Subtotal July 31, 2019 Change in fair value Fair value July 31, 2019 $ $ $ $ $ $ $ Level 1 Investments Fire & Flower Inc. common shares – – 2,970 (2,493 ) 477 (477 ) – Fire & Flower Inc. common share purchase warrants 1 – – 505 (262 ) 243 (243 ) – Inner Spirit common shares 1 – – 2,850 – 2,850 150 3,000 Level 2 Investments Inner Spirit common share purchase warrants 1 – – 414 – 414 (11 ) 403 Level 3 Investments Greentank Technologies 1 – – 6,723 – 6,723 (149 ) 6,574 Neal Brothers Inc. 1 – – 4,000 – 4,000 – 4,000 Segra International Corp. – 100 – – 100 200 300 Total – 100 17,462 2,755 14,807 (530 ) 14,277 1

Related Party Disclosure (Table

Related Party Disclosure (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure of transactions between related parties [abstract]
Schedule of compensation provided to key management	For the years ended July 31, 2019 July 31, 2018 Salary and/or consulting fees $ 3,550 $ 1,969 Bonus compensation 481 275 Stock-based compensation 16,235 3,836 Total $ 20,266 $ 6,080

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure Of Commitments And Contingencies [Abstract]
Schedule of future minimum payments under contractual financial obligations	2020 $ 93,647 2021 7,332 2022 5,804 2023 5,259 2024 4,970 Thereafter 75,218 $ 192,230 2020 $ 26,962 2021 1,794 2022 26 2023 26 2024 27 $ 28,835

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2019
Disclosure Of Fair Value Of Financial Instruments Explanatory [Abstract]
Schedule of carrying values of financial instruments	Financial assets Financial liabilities Amortized designated as designated Note costs FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 4 – 113,568 – 113,568 Restricted cash 5 – 22,350 – 22,350 Short-term investments 4 – 25,937 – 25,937 Trade receivables 19,693 – – 19,693 Commodity taxes recoverable and other receivables 6 15,247 – – 15,247 Convertible debenture receivable 15 – 13,354 – 13,354 Long term investments 20 – 14,277 – 14,277 Liabilities $ $ $ $ Accounts payable and accrued liabilities 45,581 – – 45,581 Warrant liability 12 – – 493 493 Deferred rent liability 946 – – 946 Term loan 16 33,374 – – 33,374 Financial assets Financial liabilities Amortized designated as designated Note costs FVTPL as FVTPL Total Assets $ $ $ $ Cash and cash equivalents 4, 26 – 99,042 – 99,042 Short-term investments 4, 26 – 145,747 – 145,747 Trade receivables 644 – – 644 Commodity taxes recoverable and 6 4,237 – – 4,237 other receivables Convertible debenture receivable 15 – 10,000 – 10,000 Liabilities $ $ $ $ Accounts payable and accrued liabilities 8,995 – – 8,995 Warrant liability 12 – – 3,130 3,130

License and Prepaid Royalty -_2

License and Prepaid Royalty - HIP (Tables)	12 Months Ended
	Jul. 31, 2019
License And Prepaid Royalty [Abstract]
Schedule of license and prepaid royalty - HIP	July 31, 2019 July 31, 2018 License – HIP, net of amortization $ 867 $ – Prepaid Royalty – HIP 542 – License and prepaid royalty – HIP $ 1,409 $ –

Non-Controlling Interest (Table

Non-Controlling Interest (Tables)	12 Months Ended
	Jul. 31, 2019
Non Controlling Interest [Abstract]
Schedule of information relating to subsidiary	July 31, 2019 July 31, 2018 Current assets $ 2,500 $ – Non-current assets – – Current liabilities – – Non-current liabilities – – Net assets 2,500 – Non-controlling interest (%) 40% Non-controlling interest $ 1,000 $ –

Income Taxes (Restated) (Tables

Income Taxes (Restated) (Tables)	12 Months Ended
	Jul. 31, 2019
Income taxes paid (refund) [abstract]
Schedule of components of income tax expense	July 31, 2019 July 31, 2018 Current tax for the year $ – $ – Adjustments of previous years – – Total $ – $ –
Schedule of deferred income tax expense (recovery)	July 31, 2019 July 31, 2018 Origination and reversal of temporary differences $ (13,007 ) $ (6,780 ) Difference between statutory tax rate and deferred tax rate 172 (7 ) Change in temporary difference for which no deferred tax assets are recorded (5,377 ) 6,787 Deferred income tax recovery $ (18,213 ) $ –
Schedule of income tax rate reconciliation	July 31, 2019 July 31, 2018 Expected tax rate 26.64% 26.9% Earnings before income taxes $ (87,281 ) $ (23,350 ) Expected tax benefit resulting from loss (23,252 ) (6,281 ) Adjustments for the following items: Tax rate differences 172 (7 ) Permanent differences 9,973 3,095 Change in temporary differences for which no tax assets are recorded (5,770 ) 2,401 True up and other 664 792 $ (18,213 ) $ –
Schedule of reconciliation of deferred tax assets and liabilities	Opening Recognized in Recognized in Ending August 1, 2018 income goodwill July 31, 2019 $ $ $ $ Taxable temporary differences (117 ) 7,195 (200 ) 6,858 Biological assets (458 ) (764 ) (292 ) (1,514 ) Inventory (1,432 ) (930 ) (559 ) (2,920 ) Loss carryforward 2,007 14,058 7,304 23,369 Share issue costs – (1,003 ) 1,724 721 Intangible assets – (344 ) (32,193 ) (32,537 ) Net deferred tax asset (liability) – 18,212 (24,236 ) (6,023 ) Opening Recognized in Recognized in Ending August Income Equity/OCI July 31, 2018 $ $ $ $ Deferred tax assets 813 – (813 ) – Taxable temporary differences – (117 ) – (117 ) Biological assets – (458 ) – (458 ) Inventory – (1,432 ) – (1,432 ) Loss carryforward – 2,007 – 2,007 Revaluation of financial instruments - Equity (813 ) – 813 – Net deferred tax asset (liability) – – – –
Schedule of deductible temporary differences and unused tax losses	July 31, 2019 July 31, 2018 $ $ Losses carried forward 5,898 20,672 Research and development expenditures 266 266 Fixed Assets - – Share issue costs 8,612 13,352 14,776 34,289
Schedule of non-capital losses	$ 2024 187 2025 199 2026 279 2027 236 2028 257 2029 205 2030 172 2031 338 2032 726 2033 384 2034 1,495 2035 3,774 2036 6,165 2037 10,836 2038 30,812 2039 52,910 108,975

Gross Revenue (Tables)

Gross Revenue (Tables)	12 Months Ended
	Jul. 31, 2019
Revenue [abstract]
Schedule of gross revenue	Year ended July 31, 2019 July 31, 2018 Gross Cannabis Revenue $ $ Retail 53,590 – Medical 5,288 4,934 Wholesale 378 – Total gross revenue from sale of goods 59,256 4,934

Correction of Errors (Tables)

Correction of Errors (Tables)	12 Months Ended
	Jul. 31, 2019
Correction Of Errors [Abstract]
Schedule of restatement of consolidated statement of financial position	July 31, 2019 Previously reported Correction Adjustments As restated ASSETS $ $ $ $ Inventory 86,271 - (2,417 ) 83,854 Current assets 314,553 - (2,417 ) 312,136 Total Assets 881,040 - (2,417 ) 878,623 LIABILITIES Deferred tax liability 20,396 (14,373 ) - 6,023 Total Liabilities 104,284 (14,373 ) - 89,911 SHAREHOLDER'S EQUITY Deficit (124,698 ) 14,373 (2,417 ) (112,742 ) Total shareholder's equity 776,756 14,373 (2,417 ) 788,712
Schedule of restatement of consolidated statement of loss and comprehensive loss	Fiscal year ended July 31, 2019 Previously reported Correction Adjustments As restated $ $ $ $ Impairment loss on inventory 16,918 - 2,417 19,335 Gross margin 26,925 - (2,417 ) 24,508 Loss from operations (84,557 ) - (2,417 ) (86,974 ) Net loss and comprehensive loss attributable to shareholders before tax recovery (85,404 ) - (2,417 ) (87,821 ) Tax recovery 3,840 14,373 - 18,213 Total net loss (81,564 ) 14,373 (2,417 ) (69,608 ) Total net loss per share, basic and diluted (0.38 ) 0.06 (0.01 ) (0.33 )
Schedule of restatement of consolidated statement of changes in shareholders equity	July 31, 2019 Previously reported Correction Adjustments As restated $ $ $ $ Total net loss (81,564 ) 14,373 (2,417 ) (69,608 ) Deficit as at July 31, 2019 (124,698 ) 14,373 (2,417 ) (112,742 ) Shareholder's equity as at July 31, 2019 776,756 14,373 (2,417 ) 788,712
Schedule of restatement of consolidated statements of cash flows	July 31, 2019 Previously reported Correction Adjustments As restated $ $ $ $ OPERATING ACTIVITIES Total net loss (81,564 ) 14,373 (2,417 ) (69,608 ) Tax recoveries (3,840 ) (14,373 ) - (18,213 ) Impairment loss on inventory 16,918 - 2,417 19,335 Total operating activities (124,706 ) - - (124,706 )

Basis of Presentation (Narrativ

Basis of Presentation (Narrative) (Details)	12 Months Ended
	Jul. 31, 2019
8980268 Canada Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Neal Up Brands Inc
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	60.00%

Schedule of major subsidiaries

Schedule of major subsidiaries (Details)	12 Months Ended
	Jul. 31, 2019
HEXO Operations Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Newstrike Brands Ltd.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
HEXO USA Inc.
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Keystone Isolation Technologies Inc. ("KIT")
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	60.00%

Significant Accounting Polici_4

Significant Accounting Policies, Accounting Standards and Interpretations (Narrative) (Details)	12 Months Ended
	Jul. 31, 2019
Minimum
Maturity Term For Short-Term Investments [Abstract]
Maturity term for short-term investments	3 months
Maximum
Maturity Term For Short-Term Investments [Abstract]
Maturity term for short-term investments	12 months

Schedule of terms and method us

Schedule of terms and method use to calculate amortization of tangible assets (Details)	12 Months Ended
	Jul. 31, 2019
Land
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Not amortized
Amortization term	No term
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 to 20 years
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	lease term
Furniture and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 years
Cultivation and production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 to 20 years
Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	5 years
Computers
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Straight line
Amortization term	3 years
Construction in progress
Disclosure of detailed information about property, plant and equipment [line items]
Amortization method	Not amortized
Amortization term	No term

Schedule of terms and method _2

Schedule of terms and method use to calculate amortization of intangible assets (Details)	12 Months Ended
	Jul. 31, 2019
Domain names
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	10 years
Health Canada licenses
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	20 years
Software
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	3 to 5 years
Patents
Disclosure of detailed information about intangible assets [line items]
Amortization method	Straight line
Useful life of finite life intangible assets	20 years

Cash, Cash Equivalents and Sh_3

Cash, Cash Equivalents and Short-Term Investments (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Categories of current financial assets [abstract]
Interest income	$ 5,187	[1]	$ 2,115
[1]	Restated

Schedule of cash, cash equivale

Schedule of cash, cash equivalents and short-term investments (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018	Jul. 31, 2017
Disclosure Of Short Term Investments [Line Items]
Cash and cash equivalents	$ 113,568	[1]	$ 99,042	$ 38,453
Short-term investments	25,937	[1]	145,747
Operating cash
Disclosure Of Short Term Investments [Line Items]
Cash and cash equivalents	5,993		66,438
High interest savings accounts
Disclosure Of Short Term Investments [Line Items]
Cash and cash equivalents	$ 107,575		32,604
High interest savings accounts | Minimum
Disclosure Of Short Term Investments [Line Items]
Interest rate	1.45%
High interest savings accounts | Maximum
Disclosure Of Short Term Investments [Line Items]
Interest rate	2.10%
Term deposits & GIC
Disclosure Of Short Term Investments [Line Items]
Interest rate	4.25%
Maturity date	maturity of 3 to 12 months
Short-term investments	$ 25,937		$ 145,747
Term deposits & GIC | Minimum
Disclosure Of Short Term Investments [Line Items]
Interest rate	2.85%
Term deposits & GIC | Maximum
Disclosure Of Short Term Investments [Line Items]
Interest rate	4.25%
[1]	Restated

Restricted Cash (Narrative) (De

Restricted Cash (Narrative) (Details) - CAD ($) $ in Thousands		Jul. 31, 2019	Jul. 31, 2018
Restricted Cash [Line Items]
Restricted cash and cash equivalents	[1]	$ 22,350
In escrow to facilitate a purchase agreement
Restricted Cash [Line Items]
Restricted cash and cash equivalents		3,433
Amount drawn down on pro rata basis		433
Remaining balance drawn down to retain 15% on future expected purchases		3,000
Restricted to secure the implementation of greenhouse infrastructure
Restricted Cash [Line Items]
Restricted cash and cash equivalents		3,141
Additional capital contribution held in trust
Restricted Cash [Line Items]
Restricted cash and cash equivalents		4,076
Remaining balance held in debt service reserve account
Restricted Cash [Line Items]
Restricted cash and cash equivalents		9,200
Neal Up Brands Inc
Restricted Cash [Line Items]
Balance amount of trust related the Company's joint venture		$ 2,500	$ 0
[1]	Restated

Schedule of commodity taxes rec

Schedule of commodity taxes recoverable and other receivables (Details) - CAD ($) $ in Thousands	Jul. 31, 2019		Jul. 31, 2018
Commodity Taxes Recoverable And Other Receivables [Abstract]
Commodity taxes recoverable	$ 14,415		$ 4,237
Accrued interest income	570		0
Other receivables	262		0
Total commodity taxes recoverable and other receivables	$ 15,247	[1]	$ 4,237
[1]	Restated

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019		Jul. 31, 2018
Classes Of Inventories [Line Items]
Inventory expensed to cost of goods sold		$ 18,565		$ 965
Stock based compensation expensed to costs of sales		936
Fair value adjustment on inventory sold		16,357	[1]	2,289
Inventory write-down	[1]	$ 19,335
Adjustment to net realizable value of inventory				$ 1,491
[1]	Restated

Schedule of inventories (Detail

Schedule of inventories (Details) - CAD ($) $ in Thousands	Jul. 31, 2019		Jul. 31, 2018
Classes Of Inventories [Line Items]
Dried cannabis	$ 48,345		$ 6,555
Oils	22,743		3,163
Hemp derived distillate	1,523
Purchased dried cannabis	8,087
Packaging and supplies	3,156		697
Total inventory	83,854	[1]	10,415
Capitalized cost
Classes Of Inventories [Line Items]
Dried cannabis	28,996		2,115
Oils	17,377		2,281
Hemp derived distillate	1,523
Purchased dried cannabis	8,087
Packaging and supplies	3,156		697
Total inventory	59,139		5,093
Biological asset fair value adjustment
Classes Of Inventories [Line Items]
Dried cannabis	19,349		4,440
Oils	5,366		882
Hemp derived distillate	0
Purchased dried cannabis	0
Packaging and supplies	0		0
Total inventory	$ 24,715		$ 5,322
[1]	Restated

Biological Assets (Narrative) (

Biological Assets (Narrative) (Details) $ in Thousands	Jul. 31, 2019CAD ($)kilogram	Jul. 31, 2018CAD ($)kilogram	Jul. 31, 2017CAD ($)
Disclosure of detailed information about biological assets [line items]
Biological assets	$ 7,371	$ 2,332	$ 1,504
Seeds | Level 3 Investments
Disclosure of detailed information about biological assets [line items]
Biological assets	2	6
Cannabis plants | Level 3 Investments
Disclosure of detailed information about biological assets [line items]
Biological assets	$ 8,279	$ 2,326
Cannabis plants | Current biological assets | Level 3 Investments
Disclosure of detailed information about biological assets [line items]
Expected biological assets yield | kilogram	19,218	4,374

Schedule of changes in the carr

Schedule of changes in the carrying value of biological assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Disclosure of detailed information about biological assets [abstract]
Carrying amount, beginning of period	$ 2,332	$ 1,504
Acquired through acquisition	3,291	0
Production costs capitalized	19,215	993
Net increase in fair value due to biological transformation less cost to sell	38,856	7,340
Transferred to inventory upon harvest	56,323	7,505
Carrying amount, end of period	$ 7,371	$ 2,332

Schedule of detailed informatio

Schedule of detailed information about biological assets (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2019CAD ($)CAD_per_DriedgramGram	Jul. 31, 2018CAD ($)CAD_per_DriedgramGram
Obtained through actual retail prices on a per strain basis
Average selling price input values per dried gram | CAD_per_Driedgram		4.66
Sensitivity analysis, impact of variance on selling price to valuation	$ 480	$ 329
Average selling price sensitivity analysis, variance used	5.00%	5.00%
Obtained through historical harvest cycle results on a per strain basis
Sensitivity analysis, impact of variance on average yield per plant to valuation	$ 344
Yield per plant sensitivity analysis, variance used	5.00%	5.00%
Obtained through the estimates of stage of completion within the harvest cycle
Average stage of completion within harvest cycle	29.00%	32.00%
Sensitivity analysis, impact of variance on average stage of growth per plant to valuation	$ 1,148	$ 320
Stage of growth sensitivity analysis, variance used	5.00%	5.00%
Obtained through the estimates of wastage within the cultivation and production cycle
Sensitivity analysis impact of variance on wastage expectation result in change in valuation	$ 302
Wastage sensitivity analysis variance used	5.00%	5.00%
Minimum
Obtained through actual retail prices on a per strain basis
Average selling price input values per dried gram | CAD_per_Driedgram	4.23
Obtained through historical harvest cycle results on a per strain basis
Average yield per plant | Gram	15	50
Obtained through the estimates of wastage within the cultivation and production cycle
Wastage dependent upon the stage within the harvest cycle	0.00%	0.00%
Maximum
Obtained through actual retail prices on a per strain basis
Average selling price input values per dried gram | CAD_per_Driedgram	5.01
Obtained through historical harvest cycle results on a per strain basis
Average yield per plant | Gram	123	235
Obtained through the estimates of wastage within the cultivation and production cycle
Wastage dependent upon the stage within the harvest cycle	30.00%	30.00%

Property, Plant and Equipment_2

Property, Plant and Equipment (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Disclosure of detailed information about property, plant and equipment [line items]
Property plant and equipment in accounts payable and accrued liabilities	$ 20,521		$ 3,920
Inventory capitalized depreciation costs	$ 4,825
Average annual interest rate	3.20%
Contractual commitments for remaining leasehold improvements	$ 33,455		40,471
Depreciation of property, plant and equipment	1,747	[1]	896
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Capitalized borrowing costs	$ 511		$ 994
[1]	Restated

Schedule of property, plant and

Schedule of property, plant and equipment (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	$ 54,333		$ 5,850
Additions from business acquisitions	46,003
Net Additions / (Deductions)	158,457		48,483
Adjustments	0		0
Ending balance	258,793	[1]	54,333
Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	55,715		6,336
Additions from business acquisitions	46,003
Net Additions / (Deductions)	165,029		49,379
Adjustments	0		0
Ending balance	266,747		55,715
Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,382		486
Additions from business acquisitions	0
Depreciation	6,572		896
Adjustments	0		0
Ending balance	7,954		1,382
Land
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,038		358
Additions from business acquisitions	4,301
Net Additions / (Deductions)	0		680
Adjustments	0		0
Ending balance	5,339		1,038
Land | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,038		358
Additions from business acquisitions	4,301
Net Additions / (Deductions)	0		680
Adjustments	0		0
Ending balance	5,339		1,038
Land | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	0		0
Additions from business acquisitions	0
Depreciation	0		0
Adjustments	0		0
Ending balance	0		0
Buildings
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	32,003		3,551
Additions from business acquisitions	18,855
Net Additions / (Deductions)	7,506		3,591
Adjustments	88,078		24,861
Ending balance	146,442		32,003
Buildings | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	32,536		3,745
Additions from business acquisitions	18,855
Net Additions / (Deductions)	11,365		3,930
Adjustments	88,078		24,861
Ending balance	150,834		32,536
Buildings | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	533		194
Additions from business acquisitions	0
Depreciation	3,859		339
Adjustments	0		0
Ending balance	4,392		533
Leasehold improvements
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	197		0
Additions from business acquisitions	0
Net Additions / (Deductions)	300		197
Adjustments	0		0
Ending balance	497		197
Leasehold improvements | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	206		0
Additions from business acquisitions	0
Net Additions / (Deductions)	421		206
Adjustments	0		0
Ending balance	627		206
Leasehold improvements | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	9		0
Additions from business acquisitions	0
Depreciation	121		9
Adjustments	0		0
Ending balance	130		9
Furniture and equipment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,134		735
Additions from business acquisitions	119
Net Additions / (Deductions)	3,991		1,038
Adjustments	650		(639)
Ending balance	5,894		1,134
Furniture and equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	1,661		900
Additions from business acquisitions	119
Net Additions / (Deductions)	4,576		1,233
Adjustments	0		(472)
Ending balance	6,356		1,661
Furniture and equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	527		165
Additions from business acquisitions	0
Depreciation	585		195
Adjustments	(650)		167
Ending balance	462		527
Cultivation and production equipment
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	3,962		357
Additions from business acquisitions	9,913
Net Additions / (Deductions)	26,588		2,952
Adjustments	(650)		653
Ending balance	39,813		3,962
Cultivation and production equipment | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	4,031		380
Additions from business acquisitions	9,913
Net Additions / (Deductions)	28,085		3,165
Adjustments	0		486
Ending balance	42,029		4,031
Cultivation and production equipment | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	69		23
Additions from business acquisitions	0
Depreciation	1,497		213
Adjustments	650		(167)
Ending balance	2,216		69
Vehicles
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	95		88
Additions from business acquisitions	0
Net Additions / (Deductions)	803		3
Adjustments	0		4
Ending balance	898		95
Vehicles | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	151		114
Additions from business acquisitions	0
Net Additions / (Deductions)	880		33
Adjustments	0		4
Ending balance	1,031		151
Vehicles | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	56		26
Additions from business acquisitions	0
Depreciation	77		30
Adjustments	0		0
Ending balance	133		56
Computers
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	471		156
Additions from business acquisitions	529
Net Additions / (Deductions)	1,360		315
Adjustments	0		0
Ending balance	2,360		471
Computers | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	659		234
Additions from business acquisitions	529
Net Additions / (Deductions)	1,793		425
Adjustments	0		0
Ending balance	2,981		659
Computers | Accumulated amortization
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	188		78
Additions from business acquisitions	0
Depreciation	433		110
Adjustments	0		0
Ending balance	621		188
Construction in progress
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	15,433		605
Additions from business acquisitions	12,286
Net Additions / (Deductions)	117,909		39,707
Adjustments	(88,078)		(24,879)
Ending balance	57,550		15,433
Construction in progress | Cost
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	15,433		605
Additions from business acquisitions	12,286
Net Additions / (Deductions)	117,909		39,707
Adjustments	(88,078)		(24,879)
Ending balance	$ 57,550		$ 15,433
[1]	Restated

Intangible Assets and Other L_3

Intangible Assets and Other Longer-Term Assets (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Changes in intangible assets other than goodwill [abstract]
Amount of managerial software intangible assets not yet available for use	$ 121		$ 258
Intangible assets in accounts payable and accrued liabilities	422		266
Capitalized transaction costs	212
Other longer term investment	100
Research and development expense	$ 2,822	[1]
[1]	Restated

Schedule of intangible assets a

Schedule of intangible assets and other longer-term assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 4,044	$ 2,763
Additions from business acquisitions	122,340
Net Additions / (Deductions)	1,210	1,281
Disposals/adjustments	(312)	0
Ending balance	127,282	4,044
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	5,242	3,196
Additions from business acquisitions	122,340
Net Additions / (Deductions)	2,977	2,046
Disposals/adjustments	(312)	0
Ending balance	130,247	5,242
Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,198	433
Additions from business acquisitions	0
Net Additions / (Deductions)		765
Amortization	1,767
Disposals/adjustments	0	0
Ending balance	2,965	1,198
Cultivating and processing license
Disclosure of detailed information about intangible assets [line items]
Beginning balance	2,142	2,268
Additions from business acquisitions	113,888
Net Additions / (Deductions)	(1,198)	(126)
Disposals/adjustments	0	0
Ending balance	114,832	2,142
Cultivating and processing license | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	2,545	2,545
Additions from business acquisitions	113,888
Net Additions / (Deductions)	0	0
Disposals/adjustments	0	0
Ending balance	116,433	2,545
Cultivating and processing license | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	403	277
Additions from business acquisitions	0
Amortization	1,198	126
Disposals/adjustments	0	0
Ending balance	1,601	403
Brand
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Additions from business acquisitions	8,440
Net Additions / (Deductions)	0
Disposals/adjustments	0
Ending balance	8,440	0
Brand | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Additions from business acquisitions	8,440
Net Additions / (Deductions)	0
Disposals/adjustments	0
Ending balance	8,440	0
Software
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,014	495
Additions from business acquisitions	12
Net Additions / (Deductions)	1,263	519
Disposals/adjustments	0	0
Ending balance	2,289	1,014
Software | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,800	651
Additions from business acquisitions	12
Net Additions / (Deductions)	1,746	1,149
Disposals/adjustments	0	0
Ending balance	3,558	1,800
Software | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	786	156
Additions from business acquisitions	0
Amortization	483	630
Disposals/adjustments	0	0
Ending balance	1,269	786
Domain names
Disclosure of detailed information about intangible assets [line items]
Beginning balance	576	0
Additions from business acquisitions	0
Net Additions / (Deductions)	(57)	576
Disposals/adjustments	0	0
Ending balance	519	576
Domain names | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	585	0
Additions from business acquisitions	0
Net Additions / (Deductions)	0	585
Disposals/adjustments	0	0
Ending balance	585	585
Domain names | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	9	0
Additions from business acquisitions	0
Amortization	57	9
Disposals/adjustments	0	0
Ending balance	66	9
Patents
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Additions from business acquisitions	0
Net Additions / (Deductions)	1,202
Disposals/adjustments	0
Ending balance	1,202	0
Patents | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Additions from business acquisitions	0
Net Additions / (Deductions)	1,231
Disposals/adjustments	0
Ending balance	1,231	0
Patents | Accumulated amortization
Disclosure of detailed information about intangible assets [line items]
Beginning balance	0
Additions from business acquisitions	0
Amortization	29
Disposals/adjustments	0
Ending balance	29	0
Other longer term assets and capitalized transaction costs
Disclosure of detailed information about intangible assets [line items]
Beginning balance	312	0
Additions from business acquisitions	0
Net Additions / (Deductions)	0	312
Disposals/adjustments	(312)	0
Ending balance	0	312
Other longer term assets and capitalized transaction costs | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	312	0
Additions from business acquisitions	0
Net Additions / (Deductions)	0	312
Disposals/adjustments	(312)	0
Ending balance	$ 0	$ 312

Schedule of changes in expected

Schedule of changes in expected amortization expense (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2019CAD ($)
2019
Disclosure Of Intangible Assets And Other Longer Term Assets [Line Items]
(Decrease) increase in amortization expense	$ (87)
2020
Disclosure Of Intangible Assets And Other Longer Term Assets [Line Items]
(Decrease) increase in amortization expense	(119)
2021
Disclosure Of Intangible Assets And Other Longer Term Assets [Line Items]
(Decrease) increase in amortization expense	(100)
2022
Disclosure Of Intangible Assets And Other Longer Term Assets [Line Items]
(Decrease) increase in amortization expense	(3)
Later
Disclosure Of Intangible Assets And Other Longer Term Assets [Line Items]
(Decrease) increase in amortization expense

Business Acquisition (Narrative

Business Acquisition (Narrative) (Detail)	1 Months Ended	12 Months Ended
	May 24, 2019CAD ($)Year$ / shares	Jul. 31, 2019CAD ($)Year		Jul. 31, 2018CAD ($)Year
Disclosure of detailed information about business combination [line items]
Expected life of options (years) | Year				7
Expected volatility, share options granted				65.00%
Net revenue		$ 47,541,000	[1]	$ 4,934,000
Net loss		$ (69,608,000)	[1]	$ (23,350,000)
Minimum
Disclosure of detailed information about business combination [line items]
Risk free interest rate of replacement options		1.54%		2.06%
Expected life of options (years) | Year		5
Expected volatility, share options granted		64.00%
Exercise price of options granted		$ 0.75		$ 1.37
Maximum
Disclosure of detailed information about business combination [line items]
Risk free interest rate of replacement options		2.42%		2.37%
Expected life of options (years) | Year		7
Expected volatility, share options granted		76.00%
Exercise price of options granted		$ 8.95		$ 5.14
Newstrike Brands Limited
Disclosure of detailed information about business combination [line items]
Net revenue	$ 2,770,000
Net loss	$ (13,699,000)
Percentage of voting equity interests acquired	100.00%
Exchange ratio	0.06332
Increase in net revenue based on management estimates If each acquisition had occurred		9,287,000
Increase in net loss based on management estimates If each acquisition had occurred		$ 19,096,000
Non-capitalized transaction expenses	$ 3,958,000
Newstrike Brands Limited | Neal Brothers Inc.
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired	60.00%
Newstrike Brands Limited | Warrants
Disclosure of detailed information about business combination [line items]
Volatility rate of warrants	75.00%
Stock price of warrants | $ / shares	$ 9.11
Newstrike Brands Limited | Warrants | Minimum
Disclosure of detailed information about business combination [line items]
Risk free rate of warrants	1.48%
Expected life of warrants	8 months 22 days
Exercise price of warrants | $ / shares	$ 11.84
Newstrike Brands Limited | Warrants | Maximum
Disclosure of detailed information about business combination [line items]
Risk free rate of warrants	1.57%
Expected life of warrants	4 years 26 days
Exercise price of warrants | $ / shares	$ 27.64
Newstrike Brands Limited | Replacement Options
Disclosure of detailed information about business combination [line items]
Expected volatility, share options granted	75.00%
Stock price of options | $ / shares	$ 9.11
Newstrike Brands Limited | Replacement Options | Minimum
Disclosure of detailed information about business combination [line items]
Risk free interest rate of replacement options	1.48%
Expected life of options (years) | Year	1.2
Exercise price of options granted	$ 6
Newstrike Brands Limited | Replacement Options | Maximum
Disclosure of detailed information about business combination [line items]
Risk free interest rate of replacement options	1.57%
Expected life of options (years) | Year	4.7
Exercise price of options granted	$ 17.37
[1]	Restated

Schedule of business acquisitio

Schedule of business acquisition (Details) $ / shares in Units, $ in Thousands		Jul. 31, 2019CAD ($)	May 24, 2019CAD ($)Share$ / sharesshares
Long-term assets
Goodwill	[1]	$ 111,877
Newstrike Brands Limited
Disclosure of detailed information about business combination [line items]
Number of shares issued | Share			35,394,041
Par value of shares issued | $ / shares			$ 9.11
Amount of shares issued			$ 322,439
Number of Warrants outstanding | shares			7,196,164
Amount of Warrants outstanding			$ 12,229
Number of Replacement options issued | shares			2,002,365
Amount of Replacement options issued			$ 7,134
Total fair value of consideration			341,802
Current assets
Cash and cash equivalents			49,366
Accounts receivable			1,204
Other receivables			4,585
Inventory			22,359
Biological assets			3,291
Long-term assets
Property, plant and equipment			46,003
Investments			14,492
Convertible debenture receivable			1,220
Prepaid expenses			1,631
Prepaid expense and license			1,526
Software			10
Cultivation and processing license			113,888
Brand			8,440
Goodwill			111,877
Total assets			379,892
Current liabilities
Accounts payable and accrued liabilities			12,849
Payment received in advance			5
Long-term liabilities
Deferred tax liabilities			24,236
Total liabilities			37,090
Non-controlling interest			1,000
Total net assets acquired			341,802
Net accounts receivables acquired
Trade receivables			5,789
Expected uncollectible receivables			0
Net accounts receivables acquired			$ 5,789
[1]	Restated

Convertible Debentures - 2017 S

Convertible Debentures - 2017 Secured Convertible Debentures - (Narrative) (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands	1 Months Ended		3 Months Ended														12 Months Ended
	Jun. 25, 2018Share	Jan. 30, 2018CAD ($)$ / shares	Jul. 31, 2019CAD ($)SharePrice_per_Unit$ / shares	Jul. 31, 2019CAD ($)Price_per_Unit$ / shares	Apr. 30, 2019CAD ($)Share$ / shares	Apr. 30, 2019$ / shares	Jan. 31, 2019CAD ($)Share$ / shares	Jan. 31, 2019$ / shares	Oct. 31, 2018CAD ($)Share$ / shares	Oct. 31, 2018$ / shares	Jul. 31, 2018CAD ($)Share$ / shares	Jul. 31, 2018CAD ($)$ / shares	Apr. 30, 2018CAD ($)Share$ / shares	Apr. 30, 2018$ / shares	Oct. 31, 2017CAD ($)Share$ / shares	Oct. 31, 2017$ / shares	Jul. 31, 2019CAD ($)SharePrice_per_Unit$ / shares		Jul. 31, 2019USD ($)Share$ / shares	Jul. 31, 2018CAD ($)Share$ / shares	Jul. 31, 2019USD ($)Price_per_Unit	Jul. 31, 2017CAD ($)
Statements Line Items
Number of warrants issued | Share																	11,500,000		11,500,000	37,413,681
Weighted average exercise price of warrants issued | $ / shares		$ 5.60															$ 6			$ 4.34
Fair value of warrant liability			$ 493	$ 493							$ 3,130	$ 3,130					$ 493			$ 3,130	$ 375	$ 1,356
Weighted average share price, warrants issued | $ / shares		$ 3.93
Expected life of warrants issued		1 year
Expected dividends, warrants issued		$ 0
Expected volatility, warrants issued		65.00%
Expected risk-free interest rate, warrants issued		1.25%
Finance costs																				4,792
Accreted interest																				1,368
Conversion of convertible debenture amount																				$ 76,153
Number of warrants exercised | Share	5,261,043		8,053,544		3,661,761		682,678		3,137,746		13,214,883		2,475		481,896		15,535,729		15,535,729	31,919,572
Proceeds from warrants exercised			$ 47,396		$ 8,425		$ 1,307		$ 5,589		$ 38,601		$ 4,423		$ 406		$ 69,259
Exercise price of warrants exercised | (per share)				$ 0.76		$ 0.76		$ 0.76		$ 0.76		$ 0.76		$ 0.76	$ 0.75	$ 0.70			$ 0.76
Exercise of warrants																	56,146			$ 70,225
Total gains (losses) on financial assets at fair value through profit or loss																	$ (3,730)	[1]		(5,091)
Minimum
Statements Line Items
Exercise price of warrants exercised | $ / shares			$ 0.75		$ 0.75		$ 0.75		$ 0.75		$ 0.75		$ 0.75				$ 0.75
Maximum
Statements Line Items
Exercise price of warrants exercised | $ / shares			$ 5.60		$ 5.60		$ 5.60		$ 5.60		$ 5.60		$ 5.60				$ 5.60
2017 Secured Convertible Debentures
Statements Line Items
Number of warrants exercised | Share																	863,693		863,693
Proceeds from warrants exercised																	$ 863		$ 656
Exercise price of warrants exercised | $ / shares																			$ 0.76
Value of warrants exercised																	6,367		$ 4,819
Exercise of warrants																	$ 6,367
2017 Secured Convertible Debentures | Warrant Liability
Statements Line Items
Expected life of warrants issued																	12 months		12 months
Expected dividends, warrants issued																	$ 0
Expected volatility, warrants issued																	75.00%		75.00%
Total gains (losses) on financial assets at fair value through profit or loss																	$ 3,730			$ 5,091
2017 Secured Convertible Debentures | Remaining warrant liability
Statements Line Items
Weighted average exercise price of warrants issued | $ / shares																			$ 4.24
Expected life of warrants issued																	12 months		12 months
Expected dividends, warrants issued																	$ 0
Expected volatility, warrants issued																	74.00%		74.00%
Expected risk-free interest rate, warrants issued																	1.61%		1.61%
Foreign exchange rate (USD/CAD) | Price_per_Unit			1.3148	1.3148													1.3148				1.3148
[1]	Restated

Convertible Debentures - 2017 U

Convertible Debentures - 2017 Unsecured Convertible Debentures 8% - (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Statements Line Items
Accreted interest		$ 1,368
2017 Unsecured Convertible Debentures 8%
Statements Line Items
Interest rate	8.00%
Interest capitalized to property, plant and equipment		922
Accreted interest		$ 814

Convertible Debentures - 2018 U

Convertible Debentures - 2018 Unsecured Convertible Debentures 7% - (Narrative) (Details) $ / shares in Units, $ in Thousands, $ in Thousands	Jan. 15, 2018CAD ($)$ / sharesshares	Dec. 13, 2017$ / shares	Jan. 30, 2018CAD ($)$ / shares	Nov. 24, 2017CAD ($)Share$ / shares	Jul. 31, 2019CAD ($)Share$ / shares		Jul. 31, 2018CAD ($)Share$ / shares	Jul. 31, 2019USD ($)	Jul. 31, 2017CAD ($)
Statements Line Items
Number of warrants issued | Share					11,500,000		37,413,681
Weighted average exercise price of warrants issued | $ / shares			$ 5.60		$ 6		$ 4.34
Fair value liability					$ 493		$ 3,130	$ 375	$ 1,356
Weighted average share price, warrants issued | $ / shares			$ 3.93
Expected life of warrants issued			1 year
Expected dividends, warrants issued			$ 0
Expected volatility, warrants issued			65.00%
Expected risk-free interest rate, warrants issued			1.25%
Finance costs							4,792
Conversion feature, net of issuance costs							6,777
Conversion of 7% unsecured convertible debentures							54,746
Interest expense					$ 469	[1]	1,529
Accretion							$ 1,368
2018 Unsecured Convertible Debentures 7%
Statements Line Items
Notes and debentures issued				$ 69,000
Interest rate				7.00%
Conversion price | $ / shares				$ 2.20
Weighted average trading price required to trigger forced conversion | $ / shares				$ 3.15
Period of time for trade price to exceed threshold price to trigger automatic conversion				10 days
Number of warrants issued | Share				15,663,000
Description of number of warrants issued to debenture holders				227 for every $1,000 unit
Weighted average exercise price of warrants issued | $ / shares				$ 3
Closing trading price required to trigger expiration of warrants | $ / shares				$ 4.50
Period of time for trade price to exceed threshold price to trigger expiration of warrants				10 days
Fair value liability				$ 58,187
Discount rate for fair value financial liabilities				14.00%
Residual proceeds of convertible debentures				$ 10,813
Placement agent fee				3,450
Additional financing cost				476
Volume weighted average price | $ / shares		$ 3.32
Unit of principal amount of 7.0% debenture	$ 1,000
Stock issued for conversion per unit of convertible securities | shares	454.54
Accrued and unpaid interest per unit of principal amount | $ / shares	$ 2.92
Additional stock issued for conversion of convertible securities, accrued and unpaid interest | shares	1.33
Total stock issued for conversion of convertible securities and accrued and unpaid interest, per unit of principal | shares	455.87
Carrying value of the debentures	$ 54,700
Interest payable paid through shares	46
Conversion feature, net of issuance costs	6,809
Conversion of 7% unsecured convertible debentures	$ 61,555
2018 Unsecured Convertible Debentures 7% | Warrant Liability
Statements Line Items
Residual proceeds of convertible debentures				3,530
Value of warrants issued				$ 8,648
Weighted average share price, warrants issued | $ / shares				$ 2.62
Expected life of warrants issued				1 year
Expected dividends, warrants issued				$ 0
Expected volatility, warrants issued				65.00%
Expected risk-free interest rate, warrants issued				1.25%
2018 Unsecured Convertible Debentures 7% | Conversion Feature Liability
Statements Line Items
Fair value liability				$ 17,843
Residual proceeds of convertible debentures				$ 7,283
Weighted average share price, warrants issued | $ / shares				$ 2.62
Expected life of warrants issued				3 months
Expected dividends, warrants issued				$ 0
Expected volatility, warrants issued				65.00%
Expected risk-free interest rate, warrants issued				1.25%
2018 Unsecured Convertible Debentures 7% | Broker Warrants
Statements Line Items
Number of warrants issued | Share				1,568
Weighted average exercise price of warrants issued | $ / shares				$ 3
Value of warrants issued				$ 866
Weighted average share price, warrants issued | $ / shares				$ 2.62
Expected life of warrants issued				1 year
Expected dividends, warrants issued				$ 0
Expected volatility, warrants issued				65.00%
Expected risk-free interest rate, warrants issued				1.25%
[1]	Restated

Schedule of convertible debentu

Schedule of convertible debentures (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2018CAD ($)
Disclosure Of Convertible Debentures [Line Items]
Beginning balance	$ 20,639
Gross proceeds	69,000
Issuance costs	(4,792)
Warrants, net of issuance costs	(3,285)
Conversion feature, net of issuance costs	(6,777)
Accretion	1,368
Conversion of debenture	(76,153)
Ending balance	0
2017 unsecured convertible debentures 8%
Disclosure Of Convertible Debentures [Line Items]
Beginning balance	20,639
Gross proceeds	0
Issuance costs	0
Warrants, net of issuance costs	0
Conversion feature, net of issuance costs	0
Accretion	814
Conversion of debenture	(21,453)
Ending balance	0
2018 unsecured convertible debentures 7%
Disclosure Of Convertible Debentures [Line Items]
Beginning balance	0
Gross proceeds	69,000
Issuance costs	(4,792)
Warrants, net of issuance costs	(3,285)
Conversion feature, net of issuance costs	(6,777)
Accretion	554
Conversion of debenture	(54,700)
Ending balance	$ 0

Schedule of warrant liability a

Schedule of warrant liability activity (Details) $ in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2019CAD ($)	Jul. 31, 2019USD ($)	Jul. 31, 2018CAD ($)
Debt instruments held [abstract]
Opening balance	$ 3,130		$ 1,356
Granted	0		0
Expired	0		0
Exercised	(6,367)		(3,317)
Revaluation due to foreign exchange	3,730		5,091
Closing balance	$ 493	$ 375	$ 3,130

Share Capital (Narrative) (Deta

Share Capital (Narrative) (Details)	Oct. 04, 2018CAD ($)Share$ / sharesshares	May 24, 2019shares	Jan. 30, 2019CAD ($)$ / sharesshares	Jun. 25, 2018Share	Jan. 30, 2018CAD ($)Share$ / shares	Nov. 24, 2017Share	Jul. 31, 2019CAD ($)Share$ / sharesshares	Jul. 31, 2019Share$ / sharesshares	Apr. 30, 2019CAD ($)Share$ / sharesshares	Apr. 30, 2019$ / shares	Jan. 31, 2019CAD ($)Share$ / sharesshares	Jan. 31, 2019$ / shares	Oct. 31, 2018CAD ($)Share$ / sharesshares	Oct. 31, 2018$ / shares	Jul. 31, 2018CAD ($)Share$ / sharesshares	Jul. 31, 2018Share$ / shares	Apr. 30, 2018CAD ($)Share$ / sharesshares	Apr. 30, 2018$ / shares	Jan. 31, 2018CAD ($)Share$ / sharesshares	Jan. 31, 2018$ / shares	Oct. 31, 2017CAD ($)Share$ / sharesshares	Oct. 31, 2017$ / shares	Jul. 31, 2019CAD ($)Share$ / sharesshares		Jul. 31, 2019Share$ / sharesshares	Jul. 31, 2018CAD ($)Share$ / shares	Jul. 31, 2017Share
Number of warrants exercised | Share				5,261,043			8,053,544		3,661,761		682,678		3,137,746		13,214,883		2,475				481,896		15,535,729			31,919,572
Exercise price of warrants exercised | (per share)								$ 0.76		$ 0.76		$ 0.76		$ 0.76		$ 0.76		$ 0.76			$ 0.75	$ 0.70			$ 0.76
Proceeds from warrants exercised							$ 47,396,000		$ 8,425,000		$ 1,307,000		$ 5,589,000		$ 38,601,000		$ 4,423,000				$ 406,000		$ 69,259,000
Number of common shares issued from warrant exercise | shares							8,053,544		3,661,761		682,678		3,137,746		13,214,883		2,475				481,896		15,535,729
Units issued in period | Share					37,375,000
Units issued in period, price per unit | $ / shares					$ 4
Proceeds from issuance of units					$ 149,500,000
Weighted average exercise price of warrants issued | $ / shares					$ 5.60																		$ 6			$ 4.34
Weighted average share price, warrants issued | $ / shares					$ 3.93
Number of warrants issued | Share																							11,500,000			37,413,681
Value of warrants issued, value per warrant					$ 0.56
Number of warrants expired | Share																							531			62,728
Expected life of warrants issued					1 year
Expected dividends, warrants issued					$ 0
Expected volatility, warrants issued					65.00%
Expected risk-free interest rate, warrants issued					1.25%
Cash share issue costs					$ 6,380,000
Underwriters commissions					5,980,000
Underwriters expenses					10,000
Underwriters legal fees					97,000
Additional cash issuance costs					311,000
Residual value of common shares issued					7,342,000
Share issuance costs allocated to warrants					$ 523,000
Share issuance costs																							$ 3,827,000			$ 7,144,000
Number of common shares issued in closing of offering | shares			7,700,000
Share issue price of common shares issued in closing of offering | $ / shares			$ 6.50
Proceeds from common shares issued in closing of offering			$ 50,050,000
Number of common shares issued in over-allotment option pool | shares			1,155,000
Share issue price of common shares issued in over-allotment option pool | $ / shares			$ 6.50
Proceeds from common shares issued in over-allotment option pool			$ 7,508,000
Proceeds from issuing shares			$ 57,558,000																							$ 149,500,000
Number of common shares issued | shares			8,855,000
Accumulated underwriting and legal fees			$ 3,827,000
Net proceeds from issuing shares			$ 53,731,000
Number of common shares outstanding | shares							256,981,753	256,981,753															256,981,753		256,981,753
Number of outstanding warrants | Share							29,585,408	29,585,408							26,425,504	26,425,504							29,585,408		29,585,408	26,425,504	20,994,123
Maximum term of options granted for share based payment arrangement																							10 years
Maximum number of common shares reserved for issuance for options | shares							25,698,175	25,698,175															25,698,175		25,698,175
Number of share options issued and outstanding | shares							17,376,615	17,376,615															17,376,615		17,376,615
Stock-based compensation																							$ 28,008,000	[1]		$ 4,997,000
Amount of stock based compensation allocated to inventory																							$ 1,724,000
Equity associated with 8% convertible debentures
Number of common shares issued from warrant exercise | shares																			7,799,960
Conversion of debt, shares issued | shares																			15,687,500
Conversion of debt, interest rate of converted instrument																			8.00%
Conversion of debt, shares issued for accrued interest | shares																			166,387
Equity associated with 7% unsecured convertible debentures
Number of common shares issued from warrant exercise | shares																			2,922,393
Conversion of debt, shares issued | shares																			31,363,252
Conversion of debt, interest rate of converted instrument																			7.00%
Conversion of debt, shares issued for accrued interest | shares																			20,829
Convertible debentures
Number of warrants exercised | Share																			5,025,627
Exercise price of warrants exercised | (per share)																			$ 0.75	$ 0.70
Proceeds from warrants exercised																			$ 30,937,000
Number of common shares issued from warrant exercise | shares																			5,021,940
Underwriters warrants
Weighted average exercise price of warrants issued | $ / shares					$ 4
Weighted average share price, warrants issued | $ / shares					$ 3.93
Number of warrants issued in exchange for services | Share					1,495
Value of warrants issued					$ 1,486,000
Value of warrants issued, value per warrant					$ 0.99
Expected life of warrants issued					1 year
Expected dividends, warrants issued					$ 0
Expected volatility, warrants issued					65.00%
Expected risk-free interest rate, warrants issued					1.25%
Broker compensation warrants
Number of warrants exercised | Share																							1,916,527
Compensation warrants originally issued to certain investment banks on November 24, 2017
Number of warrants exercised | Share				1,505,453
Number of warrants issued | Share						1,568,181
Number of warrants expired | Share				62,728
Minimum
Exercise price of warrants exercised | $ / shares							$ 0.75		$ 0.75		$ 0.75		$ 0.75		$ 0.75		$ 0.75						$ 0.75
Maximum
Exercise price of warrants exercised | $ / shares							$ 5.60		$ 5.60		$ 5.60		$ 5.60		$ 5.60		$ 5.60						$ 5.60
Newstrike Brands Limited
Number of common shares issued | shares		35,394,041
Transaction with joint venture partner Molson Coors
Exercise price of warrants exercised | $ / shares	$ 6
Number of common shares issued from warrant exercise | shares	1
Weighted average share price, warrants issued | $ / shares	$ 8.45
Weighted average fair value of warrants at grant date, value per warrant	$ 3.69
Number of warrants issued | Share	11,500,000
Value of warrants issued, value per warrant	$ 6
Expected life of warrants issued	1 year 6 months
Expected dividends, warrants issued	$ 0
Expected volatility, warrants issued	65.00%
Expected risk-free interest rate, warrants issued	0.75%
[1]	Restated

Schedule of warrants outstandin

Schedule of warrants outstanding (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Jul. 31, 2019CAD ($)Share$ / shares	Jul. 31, 2019$ / shares	Jul. 31, 2018Share	Jul. 31, 2017Share
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	29,585,408		26,425,504	20,994,123
Net book value | $	$ 60,925
2018 Equity financing Exercise price of $5.60 expiring January 30, 2020
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	10,512,208
Net book value | $	$ 5,673
Warrants exercise price | $ / shares	$ 5.60
Warrants expiration date	Jan. 30, 2020
February 2018 financing warrants exercise price of $27.64 expiring February 16, 2020
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	4,413,498
Net book value | $	$ 1,331
Warrants exercise price | $ / shares	$ 27.64
Warrants expiration date	Feb. 16, 2020
June 2019 financing warrants exercise price of $15.79 expiring June 19, 2023
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	2,184,540
Net book value | $	$ 9,998
Warrants exercise price | $ / shares	$ 15.79
Warrants expiration date	Jun. 19, 2023
Broker/consultant warrants exercise price of $20.85 expiring February 16, 2020
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	264,809
Net book value | $	$ 160
Warrants exercise price | $ / shares	$ 20.85
Warrants expiration date	Feb. 16, 2020
Broker/consultant warrants exercise price of $11.84 expiring June 19, 2020
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	262,021
Net book value | $	$ 610
Warrants exercise price | $ / shares	$ 11.84
Warrants expiration date	Jun. 19, 2020
Broker/consultant warrants Exercise price of $0.75 expiring November 3, 2021
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	175,618
Net book value | $	$ 78
Warrants exercise price | $ / shares	$ 0.75
Warrants expiration date	Nov. 3, 2021
Broker/consultant warrants Exercise price of $0.75 expiring March 14, 2022
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	94,282
Net book value | $	$ 66
Warrants exercise price | $ / shares	$ 0.75
Warrants expiration date	Mar. 14, 2022
Broker/consultant warrants Exercise price of $15.79 expiring June 19, 2023
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	61
Net book value | $	$ 1
Warrants exercise price | $ / shares	$ 15.79
Warrants expiration date	Jun. 19, 2023
Inner Spirit warrants Exercise price of $15.63 expiring July 21, 2020
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	71,235
Net book value | $	$ 129
Warrants exercise price | $ / shares	$ 15.63
Warrants expiration date	Jul. 21, 2020
Joint Venture Molson warrants Exercise price of $6.00 expiring October 4, 2021
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	11,500,000
Net book value | $	$ 42,386
Warrants exercise price | $ / shares	$ 6
Warrants expiration date	Oct. 4, 2021
All Warrants Except 2017 Secured Convertible Debenture Warrants
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	29,478,272
Net book value | $	$ 60,432
2017 secured convertible debenture warrants exercise price of USD$0.76 expiring November 14, 2019
Warrants Exercised [Line Items]
Number of outstanding warrants | Share	107,136
Net book value | $	$ 493
Warrants exercise price | $ / shares		$ 0.76
Warrants expiration date	Nov. 14, 2019

Schedule of warrant activity (D

Schedule of warrant activity (Details)	1 Months Ended		3 Months Ended							12 Months Ended
	Jun. 25, 2018Share	Jan. 30, 2018$ / shares	Jul. 31, 2019Share$ / shares	Apr. 30, 2019Share	Jan. 31, 2019Share	Oct. 31, 2018Share$ / shares	Jul. 31, 2018Share$ / shares	Apr. 30, 2018Share	Oct. 31, 2017Share$ / shares	Jul. 31, 2019Share$ / shares	Jul. 31, 2018Share$ / shares
Share Capital [Abstract]
Outstanding, beginning of period | Share						26,425,504			20,994,123	26,425,504	20,994,123
Outstanding, beginning of period, weighted average exercise price | $ / shares						$ 4.35			$ 1.31	$ 4.35	$ 1.31
Expired during period | Share										(531)	(62,728)
Expired during period, weighted average exercise price | $ / shares										$ 0	$ 3
Acquired and reissued through acquisition | Share										7,196,164	0
Acquired and reissued through acquisition, weighted average exercise price | $ / shares										$ 23.10	$ 0
Issued during period | Share										11,500,000	37,413,681
Warrants issued during period, weighted average exercise price | $ / shares		$ 5.60								$ 6	$ 4.34
Exercised during period | Share	(5,261,043)		(8,053,544)	(3,661,761)	(682,678)	(3,137,746)	(13,214,883)	(2,475)	(481,896)	(15,535,729)	(31,919,572)
Exercised during period, weighted average exercise price | $ / shares										$ 3.61	$ 2.33
Outstanding, end of period | Share			29,585,408				26,425,504			29,585,408	26,425,504
Outstanding, end of period, weighted average exercise price | $ / shares			$ 9.95				$ 4.35			$ 9.95	$ 4.35

Schedule of stock options grant

Schedule of stock options granted (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)Share	Jul. 31, 2018CAD ($)Share
Stock option grant date September 8, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		September 8, 2017
Exercise price | $		$ 1.37
Vesting period		10 years
Stock option grant date September 8, 2017 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		650,000
Stock option grant date September 8, 2017 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		1,000
Stock option grant date November 6, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		November 6, 2017
Exercise price | $		$ 2.48
Vesting period		10 years
Stock option grant date November 6, 2017 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		125,000
Stock option grant date November 6, 2017 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		3,000
Stock option grant date December 4, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		December 4, 2017
Exercise price | $		$ 2.69
Vesting period		10 years
Stock option grant date December 4, 2017 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		1,750,000
Stock option grant date December 4, 2017 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		20,000
Stock option grant date January 29, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		January 29, 2018
Exercise price | $		$ 4.24
Vesting period		10 years
Stock option grant date January 29, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date January 29, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		261,000
Stock option grant date March 12, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		March 12, 2018
Exercise price | $		$ 3.89
Vesting period		10 years
Stock option grant date March 12, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		325,000
Stock option grant date March 12, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date April 16, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		April 16, 2018
Exercise price | $		$ 4.27
Vesting period		10 years
Stock option grant date April 16, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		845,000
Stock option grant date April 16, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		61,500
Stock option grant date June 8, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		June 8, 2018
Exercise price | $		$ 5.14
Vesting period		10 years
Stock option grant date June 8, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		0
Stock option grant date June 8, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		441,000
Stock option grant date July 11, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		July 11, 2018
Exercise price | $		$ 4.89
Vesting period		10 years
Stock option grant date July 11, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		4,325,000
Stock option grant date July 11, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted		1,366,500
Stock option grant date September 17, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	September 17, 2018
Exercise price | $	$ 7.93
Vesting period	10 years
Stock option grant date September 17, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	650,000
Stock option grant date September 17, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	523,500
Stock option grant date November 22, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	November 22, 2018
Exercise price | $	$ 5.92
Vesting period	10 years
Stock option grant date November 22, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	0
Stock option grant date November 22, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	440,000
Stock option grant date December 17, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	December 17, 2018
Exercise price | $	$ 5.09
Vesting period	10 years
Stock option grant date December 17, 2018 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	74,000
Stock option grant date December 17, 2018 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	227,500
Stock option grant date December 17, 2018 | Director
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	54,000
Vesting period	6-months
Stock option grant date February 19, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	February 19, 2019
Exercise price | $	$ 7.13
Vesting period	10 years
Stock option grant date February 19, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	615,000
Stock option grant date February 19, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	626,000
Stock option grant date February 21, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	February 21, 2019
Exercise price | $	$ 7.46
Vesting period	10 years
Stock option grant date February 21, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	3,333,333
Stock option grant date February 21, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	0
Stock option grant date March 20, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	March 20, 2019
Exercise price | $	$ 8.50
Vesting period	10 years
Stock option grant date March 20, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	325,000
Stock option grant date March 20, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	1,077,500
Stock option grant date April 17, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	April 17, 2019
Exercise price | $	$ 8.24
Vesting period	10 years
Stock option grant date April 17, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	0
Stock option grant date April 17, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	1,132,500
Stock option grant date July 18, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	July 18, 2019
Exercise price | $	$ 6.54
Vesting period	10 years
Stock option grant date July 18, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	650,000
Stock option grant date July 18, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	2,768,785
Stock option grant date July 26, 2019
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	July 26, 2019
Exercise price | $	$ 5.88
Vesting period	10 years
Stock option grant date July 26, 2019 | Executive and directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	250,000
Stock option grant date July 26, 2019 | Non-executive employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted	0

Schedule of stock option activi

Schedule of stock option activity (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)Share	Jul. 31, 2018CAD ($)Share
Share Capital [Abstract]
Options issued, Opening balance | Share	14,388,066	5,748,169
Weighted average exercise price, Opening balance | $	$ 3.02	$ 0.68
Options issued, Granted | Share	12,693,118	10,174,000
Weighted average exercise price, Granted | $	$ 7.27	$ 4.16
Options Issued, Acquired and reissued through acquisition | Share	2,002,365	0
Weighted average exercise price, acquired and reissued through acquisition | $	$ 9.49	$ 0
Options issued, Forfeited | Share	(1,226,763)	(626,830)
Weighted average exercise price, Forfeited | $	$ 6.33	$ 3.44
Options issued, Exercised | Share	(3,567,867)	(907,273)
Weighted average exercise price, Exercised | $	$ 1.20	$ 0.65
Options issued, Closing balance | Share	24,288,919	14,388,066
Weighted average exercise price, Closing balance | $	$ 5.87	$ 3.02

Schedule of stock options outst

Schedule of stock options outstanding (Details)	Jul. 31, 2019YearShare	Jul. 31, 2018Share	Jul. 31, 2017Share
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	24,288,919	14,388,066	5,748,169
Weighted average remaining contractual life (years) | Year	8.49
Number exercisable | Share	6,379,908
Weighted average remaining contractual life (years) | Year	6.48
Exercise price 0.58
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	372,900
Weighted average remaining contractual life (years) | Year	0.08
Number exercisable | Share	363,000
Weighted average remaining contractual life (years) | Year	0.30
Exercise price 0.75
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	1,228,750
Weighted average remaining contractual life (years) | Year	0.34
Number exercisable | Share	1,013,750
Weighted average remaining contractual life (years) | Year	1.07
Exercise price 1.27
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	522,620
Weighted average remaining contractual life (years) | Year	0.16
Number exercisable | Share	322,053
Weighted average remaining contractual life (years) | Year	0.37
Exercise price 3.15
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	4,748
Weighted average remaining contractual life (years) | Year	0
Number exercisable | Share	4,748
Weighted average remaining contractual life (years) | Year	0
Exercise Price 6.00
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	891,833
Weighted average remaining contractual life (years) | Year	0.04
Number exercisable | Share	891,833
Weighted average remaining contractual life (years) | Year	0.14
Exercise price 1.37
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	352,866
Weighted average remaining contractual life (years) | Year	0.12
Number exercisable | Share	82,304
Weighted average remaining contractual life (years) | Year	0.10
Exercise price 2.48
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	86,332
Weighted average remaining contractual life (years) | Year	0.03
Number exercisable | Share	22,342
Weighted average remaining contractual life (years) | Year	0.03
Exercise price 2.69
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	853,333
Weighted average remaining contractual life (years) | Year	0.29
Number exercisable | Share	313,335
Weighted average remaining contractual life (years) | Year	0.41
Exercise price 4.24
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	258,000
Weighted average remaining contractual life (years) | Year	0.09
Number exercisable | Share	122,519
Weighted average remaining contractual life (years) | Year	0.16
Exercise Price 17.37
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	253,270
Weighted average remaining contractual life (years) | Year	0.04
Number exercisable | Share	253,270
Weighted average remaining contractual life (years) | Year	0.14
Exercise price 3.89
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	325,000
Weighted average remaining contractual life (years) | Year	0.12
Number exercisable | Share	135,418
Weighted average remaining contractual life (years) | Year	0.18
Exercise price 16.58
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	31,659
Weighted average remaining contractual life (years) | Year	0
Number exercisable | Share	15,828
Weighted average remaining contractual life (years) | Year	0
Exercise price 16.74
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	56,985
Weighted average remaining contractual life (years) | Year	0
Number exercisable | Share	28,488
Weighted average remaining contractual life (years) | Year	0.01
Exercise price 4.27
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	879,002
Weighted average remaining contractual life (years) | Year	0.32
Number exercisable | Share	366,852
Weighted average remaining contractual life (years) | Year	0.50
Exercise price 16.10
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	63,319
Weighted average remaining contractual life (years) | Year	0
Number exercisable | Share	63,319
Weighted average remaining contractual life (years) | Year	0
Exercise price 4.89
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	5,513,497
Weighted average remaining contractual life (years) | Year	2.03
Number exercisable | Share	2,046,567
Weighted average remaining contractual life (years) | Year	2.87
Exercise price 5.14
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	107,666
Weighted average remaining contractual life (years) | Year	0.04
Number exercisable | Share	35,680
Weighted average remaining contractual life (years) | Year	0.05
Exercise price 10.42
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	162,295
Weighted average remaining contractual life (years) | Year	0.01
Number exercisable | Share	138,549
Weighted average remaining contractual life (years) | Year	0.04
Exercise price 10.42
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	142,467
Weighted average remaining contractual life (years) | Year	0.01
Number exercisable | Share	71,230
Weighted average remaining contractual life (years) | Year	0.02
Exercise price 11.84
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	44,322
Weighted average remaining contractual life (years) | Year	0
Number exercisable | Share	11,079
Weighted average remaining contractual life (years) | Year	0
Exercise price 7.93
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	1,058,500
Weighted average remaining contractual life (years) | Year	0.40
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 8.21
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	94,979
Weighted average remaining contractual life (years) | Year	0.01
Number exercisable | Share	23,744
Weighted average remaining contractual life (years) | Year	0.01
Exercise price 5.92
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	310,000
Weighted average remaining contractual life (years) | Year	0.12
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 5.09
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	276,500
Weighted average remaining contractual life (years) | Year	0.11
Number exercisable | Share	54,000
Weighted average remaining contractual life (years) | Year	0.08
Exercise price 6.94
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	94,979
Weighted average remaining contractual life (years) | Year	0.02
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 8.84
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	94,979
Weighted average remaining contractual life (years) | Year	0.02
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 7.13
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	1,136,000
Weighted average remaining contractual life (years) | Year	0.45
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 7.46
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	3,333,333
Weighted average remaining contractual life (years) | Year	1.31
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 8.50
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	1,222,500
Weighted average remaining contractual life (years) | Year	0.49
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise Price 8.24
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	857,500
Weighted average remaining contractual life (years) | Year	0.34
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 6.54
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	3,408,785
Weighted average remaining contractual life (years) | Year	1.40
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0
Exercise price 5.88
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Number outstanding | Share	250,000
Weighted average remaining contractual life (years) | Year	0.10
Number exercisable | Share	0
Weighted average remaining contractual life (years) | Year	0

Schedule of fair value of stock

Schedule of fair value of stock options granted (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)Year	Jul. 31, 2018CAD ($)Year
Disclosure of range of exercise prices of outstanding share options [line items]
Expected life of options (years) | Year		7
Expected annualized volatility		65.00%
Minimum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 0.75	$ 1.37
Stock price	$ 5.09	$ 1.37
Risk-free interest rate	1.54%	2.06%
Expected life of options (years) | Year	5
Expected annualized volatility	64.00%
Maximum
Disclosure of range of exercise prices of outstanding share options [line items]
Exercise price	$ 8.95	$ 5.14
Stock price	$ 8.50	$ 5.14
Risk-free interest rate	2.42%	2.37%
Expected life of options (years) | Year	7
Expected annualized volatility	76.00%

Schedule of anti-dilutive secur

Schedule of anti-dilutive securities excluded from computation of diluted earnings per share (Details) - shares	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	53,874,327	40,813,570
Options
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	24,288,919	14,388,066
Warrants issued with $0.75 units
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	0	3,234,960
2015 Secured convertible debentures warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	0	1,318,332
2016 Unsecured convertible debenture warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	0	100,002
2017 Secured convertible debenture warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	107,136	928,542
2018 equity warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	10,512,208	18,570,500
2018 February 2018 financing warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	4,413,498	0
2019 June financing warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	2,184,540	0
Joint venture and Inner Spirit issued warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	11,571,235	0
Convertible debenture broker/finder warrants
Earnings per share [line items]
Antidilutive securities excluded from computation of diluted earnings per share	796,791	2,273,168

Convertible Debentures Receiv_2

Convertible Debentures Receivable (Narrative) (Details) - CAD ($) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 13, 2019	Jul. 26, 2018	Jul. 31, 2019		Jul. 31, 2018	May 24, 2019
Disclosure Of Convertible Note Receivable [Line Items]
Current convertible note receivable			$ 13,354	[1]	$ 10,000
Fire and Flower ("FF")
Disclosure Of Convertible Note Receivable [Line Items]
Payments for convertible note receivable	$ 800	$ 10,000
Convertible debenture interest rate	0.00%	8.00%
Description of convertible debenture maturity	November 30, 2019	July 31, 2020
Description of conversion of debt to equity	conversion feature to convert the debenture into common shares of F&F at $0.80 as defined within the agreement. The debentures may be partially or converted in-full into common shares at the maturity date at the holder's option	conversion feature to convert the debenture into common shares of F&F at the lower of $1.15 and the share price as defined within the agreement. The Company obtained the debenture as a part of a strategic investment into the private retail cannabis market. The debentures may be converted into common shares or a loan on July 31, 2020, which bears interest at 12%, at the holders option
Share price			$ 1.33
Current convertible note receivable			$ 12,024		10,000
Accrued unpaid interest			397
Unrealized revaluation gain on convertible debenture			$ 1,627
Newstrike Brands Limited
Disclosure Of Convertible Note Receivable [Line Items]
Convertible debenture receivable						$ 1,220
Share price			$ 1.33
Current convertible note receivable			$ 1,330
Unrealized revaluation gain on convertible debenture			$ 110
[1]	Restated

Term Loan (Narrative) (Details)

Term Loan (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Feb. 15, 2019	Feb. 14, 2019	Jul. 31, 2019
Term loan
Disclosure of detailed information about borrowings [line items]
Proceeds from Term Loan		$ 35,000	$ 35,000
Borrowing costs incurred		$ 1,347
Due within 12 months			3,500
Carrying value of term loan, net			33,374
Total interest expense			252
Interest costs capitalised			511
Accretion of deferred financing costs			387
Minimum cash balance maintained			$ 15,000
Canadian Imperial Bank Of Commerce And Bank Of Montreal [Member]
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing	$ 65,000
Expected averate rate of interest	mid-to-high 5% per annum range
Maximum borrowing capacity	$ 135,000
Minimum repayment of outstanding balance in percentage.	minimum 2.5% of the outstanding balance each quarter
Canadian Imperial Bank Of Commerce And Bank Of Montreal [Member] | Term loan
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing	$ 50,000
Loans maturity	mature in 2022
Canadian Imperial Bank Of Commerce And Bank Of Montreal [Member] | Revolving loan
Disclosure of detailed information about borrowings [line items]
Amount of secured debt financing	$ 15,000
Loans maturity	mature in 2022

Schedule of term loan (Details)

Schedule of term loan (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2019CAD ($)
Deferred financing costs
Current	$ 3,117	[1]
Long term	30,257	[1]
Term loan
Term Loan
Additions Current	0
Additions Long term	35,000
Adjustments Current	3,500
Adjustments Long term	(3,500)
Repayments Current	(87)
Repayments Long term	(788)
Current	3,413
Long term	30,712
Deferred financing costs
Additions Current	(296)
Additions Long term	(1,347)
Adjustments Current	0
Adjustments Long term	296
Realized expense Current	0
Realized expense Long term	596
Current	3,117
Long term	$ 30,257
[1]	Restated

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Disclosure of risk management strategy related to hedge accounting [line items]
Short-term investments	$ 25,937	[1]	$ 145,747
Trade and other current payables	45,581	[1]	8,995
Interest Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Short-term investments	517
Long term loan	$ 33,374
Immaterial increase or decrease in interest rate	5.00%
Price Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Long term loan	$ 493
Percentage of increase or decrease in the fair value of financial assets	10.00%
Amount of increase or decrease in comprehensive loss due to 10% of increase or decrease in the fair value of these financial assets	$ 340
Credit Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Expected credit loss	37		$ 94
Maximum exposure to credit risk	$ 194,902
Economic Dependence Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Percentage of sales recorded from three crown corporations	81.00%
Percentage of trade receivables from three crown corporations	79.00%
Liquidity Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Cash and cash equivalents and short-term investments	$ 139,505
Trade and other current payables	$ 52,685
[1]	Restated

Schedule of price risk exposure

Schedule of price risk exposure (Details) - Price Risk $ in Thousands	Jul. 31, 2019CAD ($)
Disclosure of risk management strategy related to hedge accounting [line items]
Financial assets	$ 16,756
Financial liabilities	(493)
Total exposure	$ 16,263

Schedule of aging of trade rece

Schedule of aging of trade receivables (Details) - CAD ($) $ in Thousands	Jul. 31, 2019		Jul. 31, 2018
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	$ 19,693	[1]	$ 644
Credit Risk
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	19,693		644
Credit Risk | 0-30 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	14,102		262
Credit Risk | 31-60 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	1,826		188
Credit Risk | 61-90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	166		91
Credit Risk | Over 90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Aging of trade receivables	$ 3,599		$ 103
[1]	Restated

Schedule of ECL by aging group

Schedule of ECL by aging group (Details) - Credit Risk - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Disclosure of risk management strategy related to hedge accounting [line items]
Expected Credit Loss	$ 37	$ 94
0-30 days
Disclosure of risk management strategy related to hedge accounting [line items]
Expected Credit Loss	3	0
31-60 days
Disclosure of risk management strategy related to hedge accounting [line items]
Expected Credit Loss	7	0
61-90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Expected Credit Loss	3	0
Over 90 days
Disclosure of risk management strategy related to hedge accounting [line items]
Expected Credit Loss	$ 24	$ 94

Schedule of operating expenses

Schedule of operating expenses by nature (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Expenses by nature [abstract]
Stock-based compensation	$ 28,008	[1]	$ 4,997
Marketing and promotion	22,308		2,447
Salaries and benefits	25,349		6,992
Consulting	11,176		3,659
Professional fees	8,258		1,761
Facilities	5,697		919
General and administrative	4,462		1,442
Travel	2,710		488
Amortization of intangible assets	1,767	[1]	765
Depreciation of property, plant and equipment	1,747	[1]	896
Total	$ 111,482	[1]	$ 24,367
[1]	Restated

Schedule of operating expense_2

Schedule of operating expenses by nature - stock based compensation (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Expenses by nature [abstract]
General and administrative related stock -based compensation	$ 26,322
Marketing and promotion related stock based compensation	1,686
Total operating expense related stock-based compensation	28,008	[1]	$ 4,997
Stock based compensation capitalized to inventory	1,724
Total stock based compensation	$ 29,732
[1]	Restated

Schedule of operating expense_3

Schedule of operating expenses by nature - payroll related wages and benefits (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Expenses by nature [abstract]
General and administrative related wages and benefits	$ 17,975
Marketing and promotion related wages and benefits	6,162
Research and development related wages and benefits	1,212
Total operating expense related wages and benefits	25,349	$ 6,992
Wages and benefits capitalized through cost of sales	10,905
Total wages and benefits in the period	$ 36,254

Investment in Associate and J_3

Investment in Associate and Joint Ventures (Narrative) (Details) $ / shares in Units, € in Thousands, $ in Thousands, ft² in Millions		Oct. 04, 2018CAD ($)$ / sharesshares	Oct. 31, 2018CAD ($)ft²	Jan. 30, 2018$ / shares	Jul. 31, 2019CAD ($)$ / shares		Jul. 31, 2018CAD ($)$ / shares	Jul. 31, 2019USD ($)	Jul. 31, 2019EUR (€)	Jul. 31, 2018USD ($)	Jul. 31, 2017CAD ($)
Disclosure of joint ventures [line items]
Capitalized transaction costs					$ 212
Interest income					5,187	[1]	$ 2,115
Cash consideration of investment	[1]				$ 13,427
Warrants issued during period, weighted average exercise price | $ / shares				$ 5.60	$ 6		$ 4.34
Truss - Investment in Associate
Disclosure of joint ventures [line items]
Proportion of ownership interest in joint venture		42.50%
Number of shares held | shares		42,500
Capitalized fair value of warrant consideration		$ 42,386
Capitalized transaction costs					$ 721		$ 0
Share of net loss					(2,796)		0
Cash consideration of investment					11,476		0
Carrying value					$ 51,786		0				$ 0
Truss - Investment in Associate | Molson Coors Canada (the "Partner")
Disclosure of joint ventures [line items]
Proportion of ownership interest in joint venture		57.50%
Number of shares held | shares		57,500
Number of warrants granted | shares		11,500,000
Period of warrants granted		3 years
Warrants issued during period, weighted average exercise price | $ / shares		$ 6
Belleville Complex Inc | Joint Ventures
Disclosure of joint ventures [line items]
Proportion of ownership interest in joint venture			25.00%
Proportion of ownership interest in joint venture held by partners			75.00%
Area of property | ft²			1.5
Interest rate			4.00%
Tenant period			20 years
Interest income			$ 454
Carrying value
HEXOMed | Joint Ventures
Disclosure of joint ventures [line items]
Proportion of ownership interest in joint venture held by partners					33.34%
Capitalized transaction costs					$ 125		0
Share of net loss					(168)		0
Cash consideration of investment					1,106		0
Carrying value					$ 1,063		$ 0				$ 0
Total cash contribution | €									€ 250
Additional cash contribution | €									€ 500
Percentage increase in interest					51.00%
[1]	Restated

Schedule of investment in assoc

Schedule of investment in associate and joint ventures - statement of financial position (Details ) - CAD ($) $ in Thousands	Jul. 31, 2019		Jul. 31, 2018	Jul. 31, 2017
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	$ 113,568	[1]	$ 99,042	$ 38,453
Current assets	312,136	[1]	276,621
Current liabilities	52,685	[1]	$ 12,125
Truss - Investment in Associate
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	14,318
Current assets	5,701
Non-current assets	7,880
Current liabilities	7,477
Non-current liabilities	0
Belleville Complex Inc | Joint Ventures
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	278
Current assets	2,604
Non-current assets	19,906
Current liabilities	1,155
Non-current liabilities	21,909
HEXOMed | Joint Ventures
Disclosure Of Associate And Joint Ventures [Line Items]
Cash and cash equivalents	542
Current assets	59
Non-current assets	22
Current liabilities	26
Non-current liabilities	$ 0
[1]	Restated

Schedule of investment in ass_2

Schedule of investment in associate and joint ventures - statement of comprehensive loss (Details) - CAD ($) $ in Thousands		7 Months Ended	11 Months Ended		12 Months Ended
		Jul. 31, 2019	Jul. 31, 2019	Jul. 31, 2019	Jul. 31, 2019		Jul. 31, 2018
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue					$ 47,541	[1]	$ 4,934
Operating expenses excluding depreciation and amortization					(111,482)	[1]	(24,367)
Loss from operations					(86,974)	[1]	$ (17,966)
Income tax expenses	[1]				$ (18,213)
Truss - Investment in Associate
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue				$ 0
Operating expenses excluding depreciation and amortization				(6,579)
Depreciation and amortization				0
Other expenses				0
Loss from operations				(6,579)
Income tax expenses				0
Total comprehensive loss				$ (6,579)
Belleville Complex Inc | Joint Ventures
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue			$ 4,018
Operating expenses excluding depreciation and amortization			(3,716)
Depreciation and amortization			(578)
Other expenses			0
Loss from operations			(276)
Income tax expenses			0
Total comprehensive loss			$ (276)
HEXOMed | Joint Ventures
Disclosure Of Associate And Joint Ventures [Line Items]
Revenue		$ 0
Operating expenses excluding depreciation and amortization		0
Depreciation and amortization		0
Other expenses		(503)
Loss from operations		(503)
Income tax expenses		0
Total comprehensive loss		$ (503)
[1]	Restated

Schedule of investment in ass_3

Schedule of investment in associate and joint ventures (Details ) - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019	Jul. 31, 2018
Disclosure Of Associate And Joint Ventures [Line Items]
Cash consideration of investment	[1]	$ 13,427
Capitalized transaction costs		212
Truss - Investment in Associate
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance		0	$ 0
Cash consideration of investment		11,476	0
Fair value of warrant consideration		42,386	0
Capitalized transaction costs		721	0
Share of net loss		(2,796)	0
Ending Balance		51,786	0
HEXOMed | Joint Ventures
Disclosure Of Associate And Joint Ventures [Line Items]
Opening Balance		0	0
Cash consideration of investment		1,106	0
Capitalized transaction costs		125	0
Share of net loss		(168)	0
Ending Balance		$ 1,063	$ 0
[1]	Restated

Long-term Investments (Narrativ

Long-term Investments (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended			12 Months Ended
	May 24, 2019CAD ($)$ / sharesshares	Feb. 22, 2019CAD ($)shares	Nov. 30, 2018CAD ($)Receipt	Jul. 31, 2019CAD ($)$ / sharesshares	Jul. 31, 2018CAD ($)	Jul. 25, 2019CAD ($)	Feb. 22, 2019USD ($)
Disclosure Of Long Term Investment [Line Items]
Fair value of investments				$ 14,277,000
Losses on disposals of investments					$ 650,000
Fire & Flower Inc. common share purchase warrants
Disclosure Of Long Term Investment [Line Items]
Number of subscription | Receipt			1,980,000
Proceeds from subscription receipts			$ 2,970,000
Subscription receipts convert to common shares ratio			1
Cash injection net of fees						$ 2,493,000
Losses on disposals of investments				477,000
Segra International Corp
Disclosure Of Long Term Investment [Line Items]
Fair value of investments				300,000	100,000
Gain (loss) on investments				$ 200,000
Percentage of variance to underlying preferred share price				5.00%
Number of shares held | shares				400,000
Initial investment per share				$ 0.25
Fair value of investment per share				$ 0.75
Newstrike
Disclosure Of Long Term Investment [Line Items]
Market price per common shares | $ / shares	$ 9.11
Percentage of voting equity interests acquired	100.00%
Newstrike | Fire & Flower Inc. common share purchase warrants
Disclosure Of Long Term Investment [Line Items]
Subscription receipts convert to common shares ratio	1
Fair value of investments	$ 243,000
Number of common share purchase warrants obtained | shares	1,000,000
Fair value of warrants	$ 505,000
Losses on disposals of investments	$ 243,000
Market price of warrants | $ / shares	$ 1.33
Expected life of warrants	8 months 12 days
Dividends on warrants
Volatility rate of warrants	100.00%
Risk free rate of warrants	1.46%
Newstrike | Inner Spirit common shares
Disclosure Of Long Term Investment [Line Items]
Fair value of investments	$ 2,850,000
Gain (loss) on investments	$ 150,000
Number of common shares obtained | shares	15,000,000
Market price per common shares | $ / shares				$ 0.20
Newstrike | Inner Spirit common share purchase warrants
Disclosure Of Long Term Investment [Line Items]
Subscription receipts convert to common shares ratio	1
Number of common share purchase warrants obtained | shares	7,500,000
Gain (loss) on investments	$ (11,000)
Fair value of warrants	$ 414,000
Market price of warrants | $ / shares	$ 0.20
Expected life of warrants	1 year
Dividends on warrants
Volatility rate of warrants	100.00%
Risk free rate of warrants	1.48%
Newstrike | Greentank Technologies
Disclosure Of Long Term Investment [Line Items]
Fair value of investments		$ 6,723,000
Gain (loss) on investments				$ 149,000
Number of preferred shares acquired | shares		1,953,125
Cash consideration		$ 6,622,000					$ 5,000
Percentage of variance to underlying preferred share price				5.00%
Change in investments fair value due to underlying preferred share price				$ 331,000
Newstrike | Neal Brothers Inc.
Disclosure Of Long Term Investment [Line Items]
Fair value of investments	$ 4,000,000
Percentage of voting equity interests acquired	19.90%
Cash consideration	$ 5,604,000
Percentage of variance to underlying preferred share price				5.00%
Change in investments fair value due to underlying preferred share price				$ 200,000

Schedule of long-term investmen

Schedule of long-term investments (Details) - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019	Jul. 31, 2018
Disclosure Of Long Term Investment [Line Items]
Long-term investments, ending balance	[1]	$ 14,277
Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		100
Investment		17,462
Divesture/Transfer		2,755
Subtotal		14,807
Change in fair value		(530)
Long-term investments, ending balance		14,277	$ 100
Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Long-term investments, ending balance			0
Fire & Flower Inc. common shares | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Investment		2,970
Divesture/Transfer		(2,493)
Subtotal		477
Change in fair value		(477)
Long-term investments, ending balance		0	0
Fire & Flower Inc. common shares | Level 1 Investments | Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Long-term investments, ending balance			0
Fire & Flower Inc. common share purchase warrants | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Investment		505
Divesture/Transfer		(262)
Subtotal		243
Change in fair value		(243)
Long-term investments, ending balance		0	0
Fire & Flower Inc. common share purchase warrants | Level 1 Investments | Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Long-term investments, ending balance			0
Inner Spirit common shares | Level 1 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Investment		2,850
Divesture/Transfer		0
Subtotal		2,850
Change in fair value		150
Long-term investments, ending balance		3,000	0
Inner Spirit common shares | Level 1 Investments | Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Long-term investments, ending balance			0
Inner Spirit common share purchase warrants | Level 2 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Investment		414
Divesture/Transfer		0
Subtotal		414
Change in fair value		(11)
Long-term investments, ending balance		403	0
Inner Spirit common share purchase warrants | Level 2 Investments | Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Long-term investments, ending balance			0
Greentank Technologies | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Investment		6,723
Divesture/Transfer		0
Subtotal		6,723
Change in fair value		(149)
Long-term investments, ending balance		6,574	0
Greentank Technologies | Level 3 Investments | Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Long-term investments, ending balance			0
Neal Brothers Inc. | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Investment		4,000
Divesture/Transfer		0
Subtotal		4,000
Change in fair value		0
Long-term investments, ending balance		4,000	0
Neal Brothers Inc. | Level 3 Investments | Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		0
Long-term investments, ending balance			0
Segra International Corp
Disclosure Of Long Term Investment [Line Items]
Change in fair value		200
Segra International Corp | Level 3 Investments | Fair value
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		100
Investment		0
Divesture/Transfer		0
Subtotal		100
Change in fair value		200
Long-term investments, ending balance		300	100
Segra International Corp | Level 3 Investments | Cost
Disclosure Of Long Term Investment [Line Items]
Long-term investments, beginning balance		$ 0
Long-term investments, ending balance			$ 0
[1]	Restated

Related Party Disclosure (Narra

Related Party Disclosure (Narrative) (Details)	Sep. 07, 2018CAD ($)	Jul. 11, 2018CAD ($)Shareshares	Mar. 12, 2018CAD ($)Share	Dec. 04, 2017CAD ($)Shareshares	Nov. 06, 2017CAD ($)Share	Sep. 08, 2017CAD ($)Share	Jul. 26, 2019CAD ($)Share	Jul. 18, 2019CAD ($)Share	Mar. 20, 2019CAD ($)Share	Feb. 21, 2019CAD ($)Share	Feb. 19, 2019CAD ($)Share	Dec. 17, 2018CAD ($)Shareshares	Sep. 17, 2018CAD ($)Share	Apr. 16, 2018CAD ($)Share	Jul. 31, 2019CAD ($)Share	Jul. 31, 2018CAD ($)Share
Disclosure of transactions between related parties [line items]
Percentage of ownership of common shares by key management personnel															6.15%	8.77%
Number of stock options granted | Share															12,693,118	10,174,000
Exercise price															$ 7.27	$ 4.16
Description of granted stock options vesting period															Unless otherwise stated the below granted stock options will vest on the one-year anniversary of the date of grant and the balance will vest quarterly over two years thereafter.
Executives
Disclosure of transactions between related parties [line items]
Number of stock options granted | Share						650,000	250,000	650,000	325,000		615,000	74,000	650,000
Exercise price						$ 1.37	$ 5.88	$ 6.54	$ 8.50		$ 7.13	$ 5.09	$ 7.93
Number of stock option vested | shares												54,000
Terms of vesting period												6 months
CEO
Disclosure of transactions between related parties [line items]
Number of stock options granted | Share										3,333,333
Exercise price										$ 7.46
Description of granted stock options vesting period										Additional to the standard vesting terms as defined in Note 11, is an achievement condition in which vesting may only occur once a volume weighted average trading price of $10 or greater is achieved for a 20-day period prior to a vesting date. All unvested options will carry over and vest if the condition is met at a future vesting date.
Directors and executives
Disclosure of transactions between related parties [line items]
Number of stock options granted | Share		4,325,000	325,000	1,750,000										845,000
Exercise price		$ 4.89	$ 3.89	$ 2.69										$ 4.27
Number of stock option vested | shares		350,000		75,000
Director
Disclosure of transactions between related parties [line items]
Number of stock options granted | Share					125,000
Exercise price					$ 2.48
Belleville Complex Inc | Joint Ventures
Disclosure of transactions between related parties [line items]
Cash advances and loans made to related parties	$ 20,279,000

Schedule of compensation provid

Schedule of compensation provided to key management (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Disclosure of transactions between related parties [abstract]
Salary and/or consulting fees	$ 3,550	$ 1,969
Bonus compensation	481	275
Stock-based compensation	16,235	3,836
Total	$ 20,266	$ 6,080

Capital Management (Narrative)

Capital Management (Narrative) (Details) - CAD ($) $ in Thousands	Jul. 31, 2019		Jul. 31, 2018	Jul. 31, 2017
Disclosure Of Capital Management [Abstract]
Shareholders' equity	$ 788,712	[1]	$ 322,873	$ 32,439
[1]	Restated

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details) - CAD ($) $ in Thousands	1 Months Ended
	Jun. 28, 2018	Jul. 31, 2019
Belleville Complex Inc
Commitments And Contingencies [Line Items]
Amount of commitments balance		$ 99,652
Additional lease commitments		$ 2,089
Letter of Credit
Commitments And Contingencies [Line Items]
Maximum limit under agreement	$ 3,141
Expiry period of letter of credit	1 year
Surety Bond
Commitments And Contingencies [Line Items]
Maximum limit under agreement	$ 2,000
Percentage of premium of bond	0.10%

Schedule of future minimum paym

Schedule of future minimum payments under contractual financial obligations (Details) $ in Thousands	Jul. 31, 2019CAD ($)
Commitments And Contingencies [Line Items]
Annual minimum payments payable	$ 192,230
2020
Commitments And Contingencies [Line Items]
Annual minimum payments payable	93,647
2021
Commitments And Contingencies [Line Items]
Annual minimum payments payable	7,332
2022
Commitments And Contingencies [Line Items]
Annual minimum payments payable	5,804
2023
Commitments And Contingencies [Line Items]
Annual minimum payments payable	5,259
2024
Commitments And Contingencies [Line Items]
Annual minimum payments payable	4,970
Thereafter
Commitments And Contingencies [Line Items]
Annual minimum payments payable	$ 75,218

Schedule of annual minimum paym

Schedule of annual minimum payments and commitments held by investment in associate and joint ventures (Details) $ in Thousands	Jul. 31, 2019CAD ($)
Commitments And Contingencies [Line Items]
Annual minimum payments and commitments held by its investment in associate and joint ventures	$ 28,835
2020
Commitments And Contingencies [Line Items]
Annual minimum payments and commitments held by its investment in associate and joint ventures	26,962
2021
Commitments And Contingencies [Line Items]
Annual minimum payments and commitments held by its investment in associate and joint ventures	1,794
2022
Commitments And Contingencies [Line Items]
Annual minimum payments and commitments held by its investment in associate and joint ventures	26
2023
Commitments And Contingencies [Line Items]
Annual minimum payments and commitments held by its investment in associate and joint ventures	26
2024
Commitments And Contingencies [Line Items]
Annual minimum payments and commitments held by its investment in associate and joint ventures	$ 27

Schedule of carrying value of f

Schedule of carrying value of financial instruments (Details) - CAD ($) $ in Thousands	Jul. 31, 2019		Jul. 31, 2018	Jul. 31, 2017
Assets
Cash and cash equivalents	$ 113,568	[1]	$ 99,042	$ 38,453
Restricted cash	22,350
Short-term investments	25,937	[1]	145,747
Trade receivables	19,693	[1]	644
Commodity taxes recoverable and other receivables	15,247		4,237
Convertible debenture receivable	13,354	[1]	10,000
Long term investments	14,277
Liabilities
Accounts payable and accrued liabilities	45,581	[1]	8,995
Warrant liability	493	[1]	3,130
Deferred rent liability	946
Term loan	33,374
Amortized cost of financial assets
Assets
Cash and cash equivalents	0		0
Restricted cash	0
Short-term investments	0		0
Trade receivables	19,693		644
Commodity taxes recoverable and other receivables	15,247		4,237
Convertible debenture receivable	0
Long term investments	0
Financial assets designated as FVTPL
Assets
Cash and cash equivalents	113,568		99,042
Restricted cash	22,350
Short-term investments	25,937		145,747
Trade receivables	0
Commodity taxes recoverable and other receivables	0
Convertible debenture receivable	13,354		10,000
Long term investments	14,277
Amortized cost of financial liabilities
Liabilities
Accounts payable and accrued liabilities	45,581		8,995
Warrant liability	0		0
Deferred rent liability	946
Term loan	33,374
Financial liabilities designated as FVTPL
Liabilities
Accounts payable and accrued liabilities	0		0
Warrant liability	493		$ 3,130
Deferred rent liability	0
Term loan	$ 0
[1]	Restated

Ancillary Revenue (Narrative) (

Ancillary Revenue (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Disclosure Of Ancillary Revenue [Abstract]
Realized net revenues from management fees	$ 199	[1]
[1]	Restated

License and Prepaid Royalty -_3

License and Prepaid Royalty - HIP (Narrative) (Details) $ in Thousands		1 Months Ended	12 Months Ended
		May 24, 2019CAD ($)Shareshares	Jul. 31, 2019CAD ($)
License And Prepaid Royalty [Line Items]
Amortization of intangible assets	[1]		$ 117
Newstrike
License And Prepaid Royalty [Line Items]
Number of shares issued | Share		35,394,041
Newstrike | Hip Agreement
License And Prepaid Royalty [Line Items]
Term of royalty agreement		5 years
Renewal term of royalty agreement		2 years
Number of shares issued | Share		3,000,000
Initial fair value of shares issued		$ 2,655
Percentage of revenue		2.50%
Number of shares issued for future royalties payable | shares		1,000,000
Fair value of intangible assets			1,409
Newstrike | Hip Agreement | Licences
License And Prepaid Royalty [Line Items]
Fair value of intangible assets		$ 926	867
Amortization of intangible assets			$ 59
Useful life of finite life intangible assets			five-year term
Newstrike | Hip Agreement | Prepaid royalty
License And Prepaid Royalty [Line Items]
Fair value of intangible assets		$ 600	$ 542
Amortization of intangible assets			$ 58
[1]	Restated

Schedule of license and prepaid

Schedule of license and prepaid royalty - HIP (Details) - Newstrike - Hip Agreement - CAD ($) $ in Thousands	Jul. 31, 2019	May 24, 2019
License And Prepaid Royalty [Line Items]
Fair value of intangible assets	$ 1,409
Licences
License And Prepaid Royalty [Line Items]
Fair value of intangible assets	867	$ 926
Prepaid royalty
License And Prepaid Royalty [Line Items]
Fair value of intangible assets	$ 542	$ 600

Schedule of non-controlling int

Schedule of non-controlling interest (Details) - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019		Jul. 31, 2018
Disclosure of subsidiaries [line items]
Current assets		$ 312,136	[1]	$ 276,621
Current liabilities		52,685	[1]	12,125
Non-controlling interests	[1]	1,000
Neal Up Brands Inc
Disclosure of subsidiaries [line items]
Current assets		2,500		0
Non-current assets		0		0
Current liabilities		0		0
Non-current liabilities		0		0
Net assets		$ 2,500		$ 0
Non-controlling interest (%)		40.00%		0.00%
Non-controlling interests		$ 1,000		$ 0
[1]	Restated

Schedule of components of incom

Schedule of components of income tax expense (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income taxes paid (refund) [abstract]
Current tax for the year	$ 0	$ 0
Adjustments of previous years	0	0
Total	$ 0	$ 0

Schedule of deferred income tax

Schedule of deferred income tax expense (recovery) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Income taxes paid (refund) [abstract]
Origination and reversal of temporary differences	$ (13,007)	$ (6,780)
Difference between statutory tax rate and deferred tax rate	172	(7)
Change in temporary difference for which no deferred tax assets are recorded	(5,377)	6,787
Deferred income tax recovery	$ (18,213)	$ 0

Schedule of income tax rate rec

Schedule of income tax rate reconciliation (Details) - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019	Jul. 31, 2018
Income taxes paid (refund) [abstract]
Expected tax rate		26.64%	26.90%
Earnings before income taxes		$ (87,281)	$ (23,350)
Expected tax benefit resulting from loss		(23,252)	(6,281)
Adjustments for the following items: [abstract]
Tax rate differences		172	(7)
Permanent differences		9,973	3,095
Change in temporary differences for which no tax assets are recorded		(5,770)	2,401
True up and other		664	$ 792
Income Tax Expense	[1]	$ 18,213
[1]	Restated

Schedule of reconciliation of d

Schedule of reconciliation of deferred tax assets and liabilities (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	$ 0	$ 0
Recognized in income	18,212	0
Recognized in goodwill	(24,236)
Recognized in Equity/OCI		0
Ending balance	(6,023)	0
Taxable temporary differences
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(117)	0
Recognized in income	7,195	(117)
Recognized in goodwill	(200)
Recognized in Equity/OCI		0
Ending balance	6,858	(117)
Biological assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(458)	0
Recognized in income	(764)	(458)
Recognized in goodwill	(292)
Recognized in Equity/OCI		0
Ending balance	(1,514)	(458)
Inventory
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	(1,432)	0
Recognized in income	(930)	(1,432)
Recognized in goodwill	(559)
Recognized in Equity/OCI		0
Ending balance	(2,920)	(1,432)
Loss carryforward
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	2,007	0
Recognized in income	14,058	2,007
Recognized in goodwill	7,304
Recognized in Equity/OCI		0
Ending balance	23,369	2,007
Share issue costs
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	0
Recognized in income	(1,003)
Recognized in goodwill	1,724
Ending balance	721	0
Intangible assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	0
Recognized in income	(344)
Recognized in goodwill	(32,193)
Ending balance	(32,537)	0
Revaluation of financial instruments - Equity
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	0	(813)
Recognized in income		0
Recognized in Equity/OCI		813
Ending balance		0
Deferred tax assets
Reconciliation of changes in deferred tax liability (asset) [abstract]
Opening balance	$ 0	813
Recognized in income		0
Recognized in Equity/OCI		(813)
Ending balance		$ 0

Schedule of deductible temporar

Schedule of deductible temporary differences and unused tax losses (Details) - CAD ($) $ in Thousands	Jul. 31, 2019	Jul. 31, 2018
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	$ 14,776	$ 34,289
Loss carryforward
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	5,898	20,672
Research and development expenditures
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	266	266
Fixed Assets
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	0	0
Share issue costs
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences and unused tax losses for which no deferred tax assets have been recognized	$ 8,612	$ 13,352

Schedule of non-capital losses

Schedule of non-capital losses (Details) $ in Thousands	Jul. 31, 2019CAD ($)
Income taxes paid (refund) [abstract]
2024	$ 187
2025	199
2026	279
2027	236
2028	257
2029	205
2030	172
2031	338
2032	726
2033	384
2034	1,495
2035	3,774
2036	6,165
2037	10,836
2038	30,812
2039	52,910
Total	$ 108,975

Loss on Investment (Narrative)

Loss on Investment (Narrative) (Details) $ in Thousands	12 Months Ended
	Jul. 31, 2018CAD ($)
Disclosure Of Loss On Investment [Abstract]
Loss on investment	$ 650

Gross Revenue (Narrative) (Deta

Gross Revenue (Narrative) (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Revenue [abstract]
Sales returns and recoveries	$ 6,718

Schedule of gross revenue (Deta

Schedule of gross revenue (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018
Schedule Of Gross Revenue [Line Items]
Gross revenue from sale of goods	$ 59,256	[1]	$ 4,934
Retail
Schedule Of Gross Revenue [Line Items]
Gross revenue from sale of goods	53,590		0
Medical
Schedule Of Gross Revenue [Line Items]
Gross revenue from sale of goods	5,288		4,934
Wholesale
Schedule Of Gross Revenue [Line Items]
Gross revenue from sale of goods	$ 378		$ 0
[1]	Restated

Segmented Information (Narrativ

Segmented Information (Narrative) (Details)	12 Months Ended
	Jul. 31, 2019Segment
Disclosure of operating segments [abstract]
Number of operating segment	1

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - CAD ($) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
		Oct. 23, 2019	Sep. 24, 2019	Jul. 31, 2019	Aug. 02, 2019	Aug. 01, 2019
Disclosure of non-adjusting events after reporting period [line items]
Cash consideration of investment	[1]			$ 13,427
Subsequent events
Disclosure of non-adjusting events after reporting period [line items]
Letter of credit					$ 2,581	$ 3,142
Subsequent events | HEXO MED
Disclosure of non-adjusting events after reporting period [line items]
Proportion of ownership holding			51.00%	33.30%
Cash consideration of investment			$ 729
Subsequent events | 8.0% unsecured debentures
Disclosure of non-adjusting events after reporting period [line items]
Notes and debentures issued		$ 70,001
Borrowings, interest rate		8.00%
Conversion price		$ 3.16
Weighted average trading price required to trigger forced conversion		$ 7.50
Period of time for trade price to exceed threshold price to trigger automatic conversion		15 days
Number of days notice for whole or in part debentures repurchase		30 days
Percentage of principal convertible debentures for change of control		115.00%
Percentage of principal convertible debentures outstanding for change of control tendered for redemption		90.00%
[1]	Restated

Correction of Errors (Narrative

Correction of Errors (Narrative) (Details) - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019		Jul. 31, 2018
Correction Of Errors [Line Items]
Deferred tax liability	[1]	$ 6,023
Deficit		(112,742)	[1]	$ (43,134)
Net loss		(69,608)	[1]	$ (23,350)
Impairment loss on inventory	[1]	19,335
Correction
Correction Of Errors [Line Items]
Deferred tax liability		(14,373)
Deficit		14,373
Net loss		14,373
Impairment loss on inventory		0
Adjustments
Correction Of Errors [Line Items]
Deferred tax liability		0
Deficit		(2,417)
Net loss		(2,417)
Impairment loss on inventory		$ 2,417
[1]	Restated

Schedule of restatement of cons

Schedule of restatement of consolidated statement of financial position (Details) - CAD ($) $ in Thousands		Jul. 31, 2019		Jul. 31, 2018	Jul. 31, 2017
ASSETS
Inventory		$ 83,854	[1]	$ 10,415
Current assets		312,136	[1]	276,621
Total Assets		878,623	[1]	334,998
LIABILITIES
Deferred tax liability	[1]	6,023
Total Liabilities		89,911	[1]	12,125
SHAREHOLDER'S EQUITY
Deficit		(112,742)	[1]	(43,134)
Total shareholder's equity		788,712	[1]	$ 322,873	$ 32,439
Previously reported
ASSETS
Inventory		86,271
Current assets		314,553
Total Assets		881,040
LIABILITIES
Deferred tax liability		20,396
Total Liabilities		104,284
SHAREHOLDER'S EQUITY
Deficit		(124,698)
Total shareholder's equity		776,756
Correction
ASSETS
Inventory		0
Current assets		0
Total Assets		0
LIABILITIES
Deferred tax liability		(14,373)
Total Liabilities		(14,373)
SHAREHOLDER'S EQUITY
Deficit		14,373
Total shareholder's equity		14,373
Adjustments
ASSETS
Inventory		(2,417)
Current assets		(2,417)
Total Assets		(2,417)
LIABILITIES
Deferred tax liability		0
Total Liabilities		0
SHAREHOLDER'S EQUITY
Deficit		(2,417)
Total shareholder's equity		$ (2,417)
[1]	Restated

Schedule of restatement of co_2

Schedule of restatement of consolidated statement of loss and comprehensive loss (Details) - CAD ($) $ / shares in Units, $ in Thousands		12 Months Ended
		Jul. 31, 2019		Jul. 31, 2018
Correction Of Errors [Line Items]
Impairment loss on inventory	[1]	$ 19,335
Gross margin		24,508	[1]	$ 6,400
Loss from operations		(86,974)	[1]	(17,966)
Net loss and comprehensive loss attributable to shareholders before tax recovery		(87,821)	[1]	(23,350)
Tax recovery	[1]	18,213
Total net loss		$ (69,608)	[1]	$ (23,350)
Total net loss per share, basic and diluted (in dollars per share)		$ (0.33)	[1]	$ (0.17)
Previously reported
Correction Of Errors [Line Items]
Impairment loss on inventory		$ 16,918
Gross margin		26,925
Loss from operations		(84,557)
Net loss and comprehensive loss attributable to shareholders before tax recovery		(85,404)
Tax recovery		3,840
Total net loss		$ (81,564)
Total net loss per share, basic and diluted (in dollars per share)		$ (0.38)
Correction
Correction Of Errors [Line Items]
Impairment loss on inventory		$ 0
Gross margin		0
Loss from operations		0
Net loss and comprehensive loss attributable to shareholders before tax recovery		0
Tax recovery		14,373
Total net loss		$ 14,373
Total net loss per share, basic and diluted (in dollars per share)		$ 0.06
Adjustments
Correction Of Errors [Line Items]
Impairment loss on inventory		$ 2,417
Gross margin		(2,417)
Loss from operations		(2,417)
Net loss and comprehensive loss attributable to shareholders before tax recovery		(2,417)
Tax recovery		0
Total net loss		$ (2,417)
Total net loss per share, basic and diluted (in dollars per share)		$ (0.01)
[1]	Restated

Schedule of restatement of co_3

Schedule of restatement of consolidated statement of changes in shareholders equity (Details) - CAD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018	Jul. 31, 2017
Correction Of Errors [Line Items]
Total net loss	$ (69,608)	[1]	$ (23,350)
Deficit	(112,742)	[1]	(43,134)
Shareholder's equity	788,712	[1]	$ 322,873	$ 32,439
Previously reported
Correction Of Errors [Line Items]
Total net loss	(81,564)
Deficit	(124,698)
Shareholder's equity	776,756
Correction
Correction Of Errors [Line Items]
Total net loss	14,373
Deficit	14,373
Shareholder's equity	14,373
Adjustments
Correction Of Errors [Line Items]
Total net loss	(2,417)
Deficit	(2,417)
Shareholder's equity	$ (2,417)
[1]	Restated

Schedule of restatement of co_4

Schedule of restatement of consolidated statements of cash flows (Details) - CAD ($) $ in Thousands		12 Months Ended
		Jul. 31, 2019		Jul. 31, 2018
OPERATING ACTIVITIES
Total net loss		$ (69,608)	[1]	$ (23,350)
Tax recoveries	[1]	(18,213)
Impairment loss on inventory	[1]	19,335
Total operating activities		(124,706)	[1]	$ (22,185)
Previously reported
OPERATING ACTIVITIES
Total net loss		(81,564)
Tax recoveries		(3,840)
Impairment loss on inventory		16,918
Total operating activities		(124,706)
Correction
OPERATING ACTIVITIES
Total net loss		14,373
Tax recoveries		(14,373)
Impairment loss on inventory		0
Total operating activities		0
Adjustments
OPERATING ACTIVITIES
Total net loss		(2,417)
Tax recoveries		0
Impairment loss on inventory		2,417
Total operating activities		$ 0
[1]	Restated